Socioeconomic inequalities in colorectal cancer survival in England and Japan by Saito, M
LSHTM Research Online
Saito, M; (2019) Socioeconomic inequalities in colorectal cancer survival in England
and Japan. PhD thesis, London School of Hygiene & Tropical Medicine. DOI:
https://doi.org/10.17037/PUBS.04654954
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4654954/
DOI: https://doi.org/10.17037/PUBS.04654954
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
1 
 
 
 
 
Socioeconomic inequalities in  
colorectal cancer survival 
in England and Japan 
 
Mari Saito 
 
 
Thesis submitted in accordance with the requirements for the degree 
of  
Doctor of Philosophy 
of the 
University of London  
May 2019 
 
Department of Non-Communicable Disease Epidemiology 
 
Faculty of Epidemiology and Population Health 
 
LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE 
 
 
 
No funding received 
 
Research group affiliation: Cancer Survival Group  
2 
 
Declaration 
I, Mari Saito, confirm that the work presented in this thesis is my own. Where information has 
been derived from other sources, I confirm that this has been indicated in the thesis. 
Signed: 
 
Date: 
09 May 2019  
3 
 
Abstract 
Large improvements in cancer survival have been seen in the last two decades due to 
improvement in early diagnosis and treatment. However, inequalities in cancer survival remain, 
not only between but also within countries; survival varies by gender, age, ethnicity and 
socioeconomic status. Notably, socioeconomic inequalities in cancer survival were observed in 
England and part of Japan, despite healthcare systems based on universal health coverage. 
Particularly, colorectal cancer (CRC) has a wide range of variability in its survival by 
deprivation. For example, 3 to 10% difference in 1-year net survival for CRC between the least 
and the most deprived has been reported in both countries. However, the mechanisms of 
socioeconomic inequalities in cancer survival are still not fully understood. 
I examined whether socioeconomic inequalities in CRC treatment and survival existed in 
current data, and explored factors associated with the inequalities by investigating data from 
whole England and Osaka University Hospital in Japan. 
Firstly, I examined socioeconomic disparities in receipt of major surgery for the primary lesion 
and the postoperative mortality. Secondly, I examined the socioeconomic gap in CRC survival 
using flexible parametric models. Lastly, I proceeded to mediation analysis, a novel technique, 
to investigate the mechanism of survival inequalities. 
In England, socioeconomic inequalities in survival existed for both colon and rectal cancer in 
the stages of potential for cure. There were socioeconomic inequalities in receipt of surgery for 
rectal cancer, and in postoperative mortality for colon cancer in England. In Japan, no 
socioeconomic inequalities existed in receipt of major surgery and survival. 
Results of mediation analyses revealed that, in England, reducing emergency presentation for 
both colon and rectal cancer and improving postoperative care for colon cancer may reduce the 
survival inequalities. In Japan, further investigation with a larger population is needed to 
determine the survival inequalities and understand its mechanism.
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Chapter 1: Introduction 
1.1 Global burden of cancer 
Worldwide, cancer is a leading cause of death; in 2018, new cancer cases were estimated to be 
18.1 million [1]. The disease has accounted for an estimated 9.5 million deaths in 2018, with the 
most common cancer sites of the deaths being lung, colorectal, stomach, liver and breast [1]. 
Significant improvements in cancer survival have been seen in the last two decades. This has 
been due to improvements in early diagnosis and treatment. However, inequalities in cancer 
survival remain, not only between but also within countries; survival varies by gender, age, 
ethnicity and socioeconomic status (SES). Notably, socioeconomic inequalities in cancer 
survival have been observed in England and a part of Japan, despite the national healthcare 
systems based on universal health coverage (UHC). In particular, colorectal cancer (CRC) has a 
wide range of variability in its survival by SES. For example, 3 to 10% difference in the one-
year net survival for CRC has been reported between the least and the most deprived groups in 
both countries [2, 3]. 
Determinants of cancer survival include tumour (stage), patient (age, comorbidities and 
awareness [4]) and healthcare system factors (prompt access to specialist investigations, 
diagnostic assessment and stage-appropriate treatment) [5]. Previous research has examined 
factors such as perceived barriers to timely presentation [6] and the role of primary care in 
ensuring timely access to diagnosis [7]. However, the mechanism of how cancer care affects 
inequalities in cancer survival is not fully understood. 
In this thesis, I examine whether the socioeconomic inequalities in survival exist in the current 
data and explore which factors could explain these inequalities by investigating data from 
England and Japan. Both countries have well-established UHCs, but England has a history of 
investigating socioeconomic inequalities, while Japan has only begun to examine them. I use the 
example of CRC since it is one of the five most common cancers affecting males and females in 
both countries.  
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1.2 Socioeconomic inequalities in cancer survival in countries with 
universal health coverage 
1.2.1 Universal health coverage 
Universal health coverage aims to offer quality healthcare services to all people according to 
their need, removing both financial and non-financial barriers as far as possible [8]. Non-
financial barriers can mean acceptable healthcare services, for example in terms of quality of 
care delivered or distance to these services [8, 9]. 
Universal health coverage has three dimensions: the breadth, depth and height of coverage. The 
breadth means the proportion of the population covered, the depth the range of quality services 
covered, and the height the proportion of healthcare costs covered [10]. 
Although the extent of each dimension covered is different by UHC countries, basically, UHC 
should ensure financial protection and equity of access to healthcare. However, even in 
countries achieving UHC, socioeconomic inequalities in cancer care have been reported [11]. 
1.2.2 Socioeconomic inequalities and terminology 
Kawachi et al. (2002) defined SES as an individual’s social and economic position related to 
others and consists of education, income and occupation [12]. Deprivation can be defined in two 
ways: absolute and relative [12-14]. Absolute deprivation is the inability to satisfy basic human 
needs (food and shelter) [12]. Relative deprivation is the deprivation relative to the standards in 
a society [12]. Socioeconomic inequalities in health partly reflect the consequence of relative 
deprivation [12]. 
Strictly speaking, the term socioeconomic ‘inequalities’ in survival means variations in survival 
among patients with different socioeconomic backgrounds. Inequalities do not involve any 
moral judgement [12]. On the other hand, ‘inequity’ implies inequalities which are unfair, 
unnecessary, systematic and socially produced, so avoidable (amenable) [9, 12, 15]. 
Equity in healthcare can be seen in two ways. Firstly, horizontal equity is ‘equal treatment for 
equal need’. The principle is that people with the same level of need should be assured of equal 
19 
 
access, use or expenditure [9]. Secondly, vertical equity means ‘unequal treatment for unequal 
need’. 
In this thesis, I defined that the need is the ‘capacity to benefit from treatment’. Thus, the CRC 
patients, at the same stage and the same general condition should be offered equal treatment, 
irrespective of their socioeconomic circumstances. I assess how much of the effect of SES on 
survival could be explained by socioeconomic inequalities in healthcare access.  
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1.2.3 Study rationale: why focusing on healthcare system to tackle health 
inequalities? 
Inequalities in health can result from various causes. The Lalonde Report in 1974 suggested a 
conceptual model for the determinants of health [16]. In the ‘health field’ concept, health is 
determined by genetic predispositions, behaviour and lifestyle, environment, and healthcare 
systems. Subsequently, Whitehead and Dahlgren reported a framework for broader health 
determinants. Solving health inequalities not only requires improving access to essential 
facilities and services (i.e. healthcare systems), strengthening individuals and communities (to 
be able to make healthier choices) and encouraging macroeconomic and cultural changes, but it 
also requires equal distribution of these factors [17]. Healthcare systems are considered as 
‘down-stream factors’, and other factors are considered as ‘up-stream factors’. For cancer, as 
shown in Figure 1.1, other than healthcare system factors, a patient’s health-seeking behaviour 
may have an impact on the timeliness of diagnosis. Lifestyle (e.g. smoking, obesity), age, 
comorbidities and genetic predispositions can also be potentially associated with survival 
inequalities. 
Figure 1.1 Health field concept for colorectal cancer 
Bullet points indicate examples in CRC. Modification from source: Lalonde, Whitehead and Dahlgren [16, 17]. 
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When we consider an association between SES and cancer care, socioeconomic differences in 
access to cancer care can be influenced by multiple factors. As shown in Figure 1.2, SES is 
primarily defined by education, occupation and income, but is also influenced by country 
affluence. A country’s affluence influences capacity in healthcare resources and the primary and 
secondary prevention of CRC, such as lifestyle change and screening [18]. Insufficient 
healthcare resources can be one reason for people from different SES groups compete to receive 
cancer care. The competition may force patients to take responsibility for receiving a timely and 
appropriate diagnosis by themselves. The corresponding capacity to deal with this situation 
depends more on up-stream factors such as the ability to perceive, seek and engage [19]. Worse 
stage distribution may be observed in deprived groups as a consequence, and the competition 
may continue for receiving treatment. Accordingly, the final outcome, cancer survival can result 
in an unequal manner. 
Figure 1.2 Association between socioeconomic status, access to cancer care and survival 
Modification from source: Alberto, 2013 [20]. 
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Concentration index and Lorenz curve are used to show the existence and distribution of equity 
in healthcare access or health outcomes. However, these indices neither show how inequity in 
healthcare access is translated into a final health outcome nor the mechanism of how inequities 
in a health outcome is generated. Nolte and McKee (2004) suggested the concept of ‘amenable 
mortality’ as an indicator assessing healthcare quality [21, 22]. Some studies have explored the 
association between inputs (health expenditure) and mortality [5, 23]. However, the relationship 
is difficult to interpret because of reverse causality [24]. 
Debates have raged on whether healthcare impacts on health outcomes [22]. So far, studies 
exploring mechanisms on how socioeconomic inequalities impact on cancer survival are sparse 
[25]. Cancer care requires high resource inputs and sophisticated coordination of care by 
multiple levels of healthcare factors [5, 26]. Survival is one of the key measures to assess the 
quality of cancer care in a country, and it reflects the progress of how people are treated [5]. 
Thus, evaluating the role of treatment on the effects of SES on survival is essential to tackle 
inequalities [26].  
23 
 
1.3 Colorectal cancer in England and Japan 
I describe here the epidemiology of CRC, as well as the characteristics of the population and 
healthcare system in England and Japan. Next, I detail the diagnosis, treatment and patient 
pathway for CRC patients to highlight where socioeconomic inequalities in CRC survival may 
arise in each country. 
1.3.1 Epidemiology 
Colorectal cancer was estimated to be the third commonest diagnosed cancer in the world in 
2018 [1]. Of cancer deaths worldwide, CRC accounted for 9.2%, with approximately 880,792 
estimated deaths in 2018 [1]. CRC is also a growing public health burden in both England and 
Japan. England had 34,952 new CRC cases (age-standardised incidence rate 84.4 in males and 
55.4 in females per 100,000 population), which made it the fourth most prevalent cancer in 
2016 [27]. The total number of deaths from CRC in England was 13,417 in 2016, which 
accounted for 10% of all cancer deaths [28]. Japan had 158,127 new CRC cases (excluding 
carcinoma in situ, age-standardised incidence rate 77.5 in males and 47.3 in females per 100,000 
population) in 2016, which was the third commonest cancer diagnosed in male and the second 
in female [29]. The total number of CRC deaths in Japan was 50,681 in Japan in 2017, which 
was the second largest cause of cancer deaths of all neoplasms [30]. 
Both countries have suffered socioeconomic inequalities in CRC survival. In England in 2006, 
the deprivation gap (i.e. a simple difference in survival estimates between the most and the least 
deprived groups) in one-year survival from colon and rectal cancer was approximately 7% in 
males and 10.6% in females [3]. In Osaka Prefecture, Japan in 2001–2004, the deprivation gap 
in one-year net survival from CRC was 6.3% in males and 2.9% in females [2].  
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1.3.2 Population characteristics 
England has an estimated population of 55.6 million (84% of the total population, 66.0 million 
in the United Kingdom [UK]), with 18% aged 65 years and over [31]. In 2016, life expectancy 
at birth in the UK was 81.0 [32]. The large gap in life expectancy between different local areas 
in England has been reported continuously [33, 34]. The Gini coefficient (income inequality) 
was 0.35 in the UK in 2016 [35]. The poverty rate (a ratio of the number of people whose 
income is under poverty line: defined as half the median of the household income in the total 
population) was 0.11 in 2016 [36]. In 2017, cancer was the most common cause of death at 
28%, followed by cardiovascular diseases (heart diseases and strokes at 25%) in England and 
Wales [37]. Expenditure spent on cancer was £6.7 billion (United States [US]$ 9.6 billion) in 
2012–2013 [38]. 
Japan has an estimated population of 126.8 million in 2017, with 27% aged 65 years and over. 
Japan’s life expectancy at birth was 84.0 years in 2016 [32]. Cancer was the leading cause of 
death at 30%, followed by heart disease (16%) and cerebrovascular disease (11%) in 2010 [39]. 
Of the total health expenditure at ¥ (Japanese Yen) 42 trillion (US$ 383 billion), 10.1% was 
spent on cancer care in 2016 [40]. The Osaka Prefecture, which is the site of this study in Japan, 
sits on the west side of the main island. The prefecture had an estimated population of 8.8 
million in 2017, being the third most populated prefecture in Japan [41]. Japan has a relatively 
homogenous ethnic composition; however, health inequalities have begun to be reported, 
alongside a rising relative poverty rate since the economic recession in the 1990s [42, 43]. The 
Gini coefficient was 0.34 [35], and the poverty rate was 0.16 in 2015 [36]. The number of 
people in Osaka Prefecture, who receive public assistance because of their income falling below 
the minimum living standard, is by far the highest among the 47 prefectures in Japan. 
Approximately 54‰ (permil, per 1,000 inhabitants) and 33‰ of the population in Osaka City 
and Osaka Prefecture, respectively, received the assistance, whereas at the national level, this 
figure was 16.9‰ in 2016 [44]. Population characteristics and cancer risk factors in England 
and Japan are shown in Table 1.1. 
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Table 1.1 Population characteristics and cancer risk factors in England and Japan 
Abbreviations: GDP, Gross domestic product; UK, United Kingdom; US $, United States dollars. *Figures of the 
UK. All figures for Japan are of Japan as a country but not of Osaka Prefecture unless stated. 
Data source: Ministry of Health, Labour and Welfare (Japan), National Audit Office (UK), OECD data (Japan, UK), 
Office for National Statistics (UK), Osaka Prefectural Government (Japan) and The World Bank Data (Japan, UK). 
1.3.3 Governance of healthcare system and cancer policy 
The healthcare in both countries is publicly funded (tax-based in England and social health 
insurance in Japan); however, provision of care is public-based in England and private-based in 
Japan with more of self-regulation by providers. The National Health Service (NHS) in England 
maintains a free-of-charge principle in the public healthcare system; thus, patients have equal 
access to cancer care in terms of direct costs. On the other hand, irrespective of public or private 
care, patients in Japan pay co-payment depending on their insurance plans, but it is at a 
relatively low cost at 10–30% of their total health expenditure. To save catastrophic payment, a 
threshold of monthly co-payment is set, depending on age and income. For extremely poor 
households, a public assistance system exists with exemption from co-payment [45]. 
In England, cancer care is provided within networks of hospitals, each organised as what are 
termed Trusts, semi-autonomous organisations within the NHS. While this system enables the 
care of some rare cancers to be centralised, common cancers such as CRC are managed in most 
general hospitals, where care is based on the national guidelines and subject to a variety of 
national regulators that monitor aspects of care such as quality. All hospitals providing cancer 
 
England Japan 
Land area (km2) 242 thousand (UK) 337.9 thousand (Japan) 
 
132.9 thousand (England) 1899 (Osaka Prefecture) 
Estimated total population (2017) 66.0 million (UK) 126.8 million (Japan) 
 
55.6 million (England) 8.8 million (Osaka Prefecture) 
Aged 65 or more (2017) 18.2%* 27.0% 
Country of birth different from the country of 
residence (2017) 
14%* 2.0% 
Poverty rate ratio 0.111 (2016)* 0.157 (2015) 
Life expectancy at birth (years, 2016) 81.0* 84.0 
Total health expenditure (% GDP, 2015) 9.9* 10.9 
Health spending per capita (US $, 2016) 3833* 4513 
Expenditure spent on cancer service (US $) £6.7 billion (US $9.6 billion) 
(England, 2012–2013) 
¥4.2 billion (US $38.3 billion) 
(2016) 
Gini coefficient 0.35 (2016)* 0.34 (2015) 
Smoking prevalence (2016) 22.3%* 22.1% 
Obesity in adults (measured, 2016) 26.2%* 4.2% 
Total alcohol consumption 
(litters per capita, 2016) 
11.5* 8.0 
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care should have multidisciplinary teams (MDTs), bringing together an appropriate combination 
of specialists. However, despite this framework, which should facilitate equitable treatment in 
theory, inequities persist [46]. 
In Japan, the Ministry of Health, Labour and Welfare (MHLW) initiated an accreditation system 
for what it termed Designated Cancer Hospitals (DCHs) in 2001; however, CRC is also treated 
in non-DCHs [47]. In 2016, 80% of all CRC cases in Osaka Prefecture were treated in DCHs in 
Osaka (data not shown). Hospitals are so designated if they fulfil certain requirements, 
including the presence of MDTs, sufficient volumes of cancer surgery or chemotherapy, and the 
employment of specialists in a range of aspects of cancer care. In 2019, there are 392 DCHs in 
Japan, and Osaka Prefecture had one prefectural and 16 regional DCHs in 2018 [48, 49]. 
However, even in DCHs, wide variations in surgical volumes and the use of chemotherapy or 
radiotherapy have been reported [50, 51]. 
1.3.4 Provider reimbursement and incentives 
In both countries, individual doctors, who work in secondary care are paid by salary, whereas 
doctors working at the primary care level are paid by different systems. Eighty percent of 
primary care doctors, so-called general practitioners (GPs) in England, are paid mainly by 
capitation, but also with a combination of fee-for-service (FFS) and pay-for-performance (P4P) 
[52]. P4P incentives are used in primary care to achieve targeted performances set by the 
Quality and Outcomes Framework (e.g. immunisation uptake) [52, 53]. Regarding cancer, P4P 
incentives are used for the uptake of cervical cancer screening [54], but not for the early 
detection of CRC. 
In Japan, historically, there is little distinction between doctors working in primary care and 
hospitals. Japan does not have physicians that correspond precisely with the GPs in England 
[55]. The speciality of ‘general internal medicine’ is relatively minor in Japan, and most doctors 
have another sub-speciality, such as gastroenterology. There are no performance or waiting time 
targets set for the doctors working at the primary care level; we may call them primary care 
physicians (PCPs), and they are paid by FFS for the outpatient services. The benefit for cancer 
diagnosis is that there is no disincentive for doctors to conduct diagnostic tests. Rather, PCPs 
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profit more if they test more, making the overall system vulnerable to market failure (supplier-
induced demand). 
Since the function of primary and secondary care duplicates in the general healthcare system in 
Japan, MHLW promotes distinct role-sharing and coordination in cancer care. For DCHs in 
Japan, the government provides subsidies for hospitals to achieve requirements for the 
accreditation. Both clinics and DCHs are incentivised when they provide coordinated cancer 
care (e.g. referrals from and follow-up at PCPs). An additional fee is set for patients who are 
treated in these accredited DCHs. 
1.3.5 Resources and workforce 
While resources are controlled by the government in England, they are not centrally controlled 
in Japan. England has a higher density of doctors per population; however, the proportion of 
CRC specialists is assumed to be higher in Japan due to the nature of speciality composition.  
Regarding medical technology resources, the total number of CT scans in Japan was by far the 
highest among all the Organisation for Economic Co-operation and Development (OECD) 
countries (107 per 1,000,000 inhabitants in Japan, 9 per 1,000,000 inhabitants in the UK in 
2014) [56]. In Japan, colonoscopy is widely available at both the primary and secondary 
healthcare levels [57] (Table 1.2). Geographical variations (by prefectures or medical area) in 
terms of density of medical resources or number of colonoscopies conducted have not been 
studied and are not known. 
In England, the NHS Cancer Plan (2000) and the NHS Improvement Plan (2004) proposed the 
increases in equipment procurement [58, 59]. The Plan in 2000 also stated to increase the 
number of specialists (e.g. gastroenterologists and radiotherapists). A significant increase in the 
cancer workforce was reported in the Cancer Reform Strategy in 2007 [60]. However, the 
density in secondary care facilities, such as medical devices and hospital beds, is still much 
lower than that of Japan and other European countries (MRI with 51.7 per 1,000,000 inhabitants 
in Japan, 7.2 per 1,000,000 inhabitants in the UK in 2014, hospital beds with 13.1 per 1,000 
inhabitants in Japan, 3.6 per 1,000 inhabitants in the UK in 2016) [56, 61, 62] (Table 1.2). 
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In Japan, the problem of quality differences among DCHs is compounded by the geographical 
maldistribution of doctors [63]. Inequalities in overall healthcare access have not been solved in 
Japan; persistent shortages of doctors occur in rural areas where doctors have no additional 
monetary incentives. 
Table 1.2 Medical resources by England and Japan 
Source: ‡ OECD data [56, 61, 62, 69], § Ministry of Health, Labour and Welfare (Japan) [57]. ǁ Rounded to the 
nearest 1000. # MDCT (multi-detector CT); ## other CT (single-detector CT. Excluding PET CT). † Derived by 
dividing the annual figure in the reference by 12 (months).  
 UK Japan 
Number of doctors per 1,000‡ (2016) 2.78 2.43 
Number of nurses per 1,000‡ (2016) 7.88 11.34 
Hospital beds per 1,000‡ (2017) 2.5 13.1 
Length of hospital stay‡ 
(acute care in days, 2017) 
5.9 16.2 
Number of hospitals (2017) 
 
1,920 (estimate)‡ 
7,361 (GP practices in England) 
[64] 
8,412 (hospitals)‡ 
101,471(clinics)§ 
Number of hospitals per 1,000,000‡ (2017) 29.06 (estimate) 66.39 
Adult ICU beds per 100,000 (2005) 3.5 [65] 4.3 [65-67] 
Number of institutions with colonoscopy 
Upper: hospitals (number of beds≥20), 
lower: clinics (number of beds<20) (Japan)§ 
 
484 [68] 
 
4,091 
6,647 
Total number of colonoscopies  
conducted/monthǁ 
Upper: hospitals, lower: clinics (Japan)§ 
 
119,000 [68]† 
 
258,000 
137,000 
Number of CT scans per 1,000,000‡ (2014) 9 107 
Number of MRI per 1,000,000‡ (2014) 7.2 51.7 
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1.3.6 Screening, diagnosis and treatment 
Change in bowel habit, blood in faeces and abdominal pain are the main three symptoms in 
CRC. These symptoms are very common and non-specific, making a decision to provide 
diagnostic tests for CRC sometimes challenging especially at early stages. 
Diagnostic tests used are faecal occult blood testing (FOBT), barium enema and endoscopy 
(flexible sigmoidoscopy and colonoscopy). National screening programmes for CRC are 
available in both England and Japan. FOBT, flexible sigmoidoscopy, colonoscopy, computed 
tomography (CT) colonography and barium enemas are the main tests used for the screening 
worldwide. The choice of screening tests varies by countries [70], depending on sensitivity, 
specificity and cost-effectiveness. For symptomatic patients, endoscopy is the initial diagnostic 
procedure. 
In England, biannual Guaiac-based FOBT (gFOBT) was introduced as a population-based 
screening programme in 2006, i.e. before the study period covered in this thesis in England 
(2010 to 2013). The screening is performed at approximately 100 local screening centres for the 
eligible population (age 60–74, from 2010 onwards) [71]. Participants with an abnormal test 
result are arranged to attend specialist screening practitioner (SPP) clinics for colonoscopy [71]. 
In 1993, a pilot study commenced using flexible sigmoidoscopy; this procedure was only 
introduced in 2013 for screening in aged 55, in addition to gFOBT [72], and therefore cannot 
affect the analysis and results of the present study in England. In 2012–2015, the screening 
uptake was 57.9% among the target population in England [73, 74]. 
In Japan, annual iFOBT (immunochemical faecal occult blood test, same as FIT: faecal 
immunochemical test) has been performed on 40 years old and over (no upper limit for the 
eligible age), since 1992, i.e. covering the study period in Japan (2012 to 2015) in this thesis. 
Apart from the population screening, opportunistic screening (iFOBT, barium or flexible 
sigmoidoscopy) is also offered to applicants. Among the population aged 40 to 69 in Japan, the 
screening uptake (including opportunistic screening) was 29.8% in 2013 [75]. 
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Histopathological assessment by endoscopic biopsy is needed for the definitive diagnosis of the 
primary tumour. Metastasis to other organs (particularly liver and lungs for CRC) are assessed 
by imaging (CT scan). Although sensitivity is around 60 to 70% depending on the type of CT 
[76], lymph node metastasis is also assessed by the routine use of multi-detector CT (MDCT) in 
Japan [77]. Endorectal ultrasound (ERUS) for early T stage or MRI (magnetic resonance 
imaging) for intermediate/advanced T stage is used to identify the depth of invasion in rectal 
cancer, which has a higher local recurrence risk than colon cancer. 
Treatment decisions depend mostly on the clinical stage, but age, comorbidities and 
performance status are also taken into consideration. In Japan, for purely localised tumours 
(cTis and carcinoma with slight submucosal invasion), endoscopic resection, such as endoscopic 
mucosal resection (EMR) or endoscopic submucosal dissection (ESD) without node dissection, 
is the first choice of treatment [78-81]. 
Tumour resection, by major surgery, is performed with curative intent for CRC clinically 
diagnosed as T1 (submucosal cancer) and over. In the past, APER (abdominoperineal excision 
of rectum) with permanent stoma was performed for rectal cancer. Although APER is the only 
option for rectal cancer which is located very close to the anal canal, as surgical techniques 
improve, APER became less preferable compared with anterior resection (AR) combined with 
anastomosis (connection of the intestine by staplers). In emergency or aged cases, Hartmann’s 
operation is performed; the operation resects cancer without removing the distal rectal stump; 
thus, it is less invasive. 
For stage II (high risk) and III patients, adjuvant (postoperative) chemotherapy is added to the 
R0 (no residual) resection. Combination chemotherapy of FOLFOX (folinic acid, 5-FU and 
oxaliplatin) or capecitabine monotherapy are the recommended options in England [82]. In 
Japan, in addition to these regimens, the use of 5-FU plus folinic acid, UFT (tegafur-uracil) plus 
folinic acid, capecitabine plus oxaliplatin, or S-1 (tegafur gimeracil oteracil) are covered by 
insurance; the chemotherapy is recommended to start within four to eight weeks after curative 
resection, with in principle a duration of six months in Japan [80, 81]. Chemotherapy may also 
be performed for stage IV patients with unresectable tumour aiming to prolong their survival if 
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the patient has a good performance status, or for some cases, even aiming cure. If a patient with 
stage IV shows a substantial tumour size reduction after 12 to 16 weeks of the chemotherapy, an 
operation could be offered (called ‘conversion therapy’) [83, 84]. Biologic targeted agents (e.g. 
bevacizumab, panitumumab, cetuximab and regorafenib) have been developed in recent years; 
however, the indication of the use is only for stage IV patients, depending on individual’s 
molecular pathological types. 
Radiotherapy is performed for either curative or palliative intent. In European countries, 
neoadjuvant (preoperative) radiotherapy, either chemoradiotherapy (CRT) or short-course 
preoperative radiotherapy (SCPRT), is recommended for the locally advanced rectal cancer 
(>cT3b) to reduce recurrence at the local site [85-87]. In Japan, neoadjuvant radiotherapy is 
rarely used. Instead, aiming an improvement in overall survival and a reduction in local 
recurrence, lateral lymph node dissection is performed for lower rectal cancer of which the 
lower margin locates below the peritoneal reflection [78-80]. Pathologically proven T3 (pT3 
invading deeper than subserosa or more) or node extension (N positive) are the indications for 
adjuvant radiotherapy [80]. Although local recurrence is decreased by adjuvant radiotherapy, 
there is no evidence that this therapy improves survival [88].  
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1.3.7 Patient pathways for CRC patients 
Patient pathway is mapped in Figure 1.3 to outline provision of cancer care in England and 
Japan. The map identifies steps in the care that might influence survival in each context, from 
the recognition of symptoms to the end of the initial definitive treatment. Screening was 
removed from the patient pathway map because, for the study period, it is considered as 
secondary preventative measure: less than 10% of all CRC cases were detected through 
screening in England [89], while in Japan, this proportion was likely to be low too because of 
the relatively small screening uptake [90]. 
Ten principal events were identified in the care process (in the centre) that are common to the 
pathways in both countries, starting from consultation with a primary care doctor through the 
end of the first definitive treatment. Each event is connected by a path, drawn as an arrow A to J 
in the centre of the figure. The left-hand side of the figure describes those elements and 
processes that are specific to England, while the right-hand side describes those specific to 
Japan. In the following sections, I describe the CRC patient journey from the steps of 
presentation, diagnosis to treatment. 
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Figure 1.3 Patient pathways for colorectal cancer patients in England and Japan 
 
3
3
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Presentation 
In the NHS, patients with symptoms typically consult their GP first before they can access more 
specialised services (Figure 1.3, box 1). The only exceptions are emergencies, such as intestinal 
bleeding or obstruction, when patients access the hospital emergency department directly (box 0 
to box 11 on the left side). In England, 85% of all-site cancer cases are diagnosed with 
symptoms, and 26% of the CRC cases are diagnosed after an emergency admission [7, 89, 91]. 
The GP will assess the patient’s history and physical signs and, possibly, undertake basic blood 
tests such as a full blood count. Then the GP decides whether to refer the patient on for further 
diagnostic tests (e.g. endoscopy) and specialist consultations. Those with suspected cancer 
should have a consultation of a cancer specialist with a maximum two-week-wait (2WW) from 
the GP’s referral (‘fast-track’ or urgent referral) if they have certain red flag symptoms or signs 
(Figure 1.3, path C). 
Borderless access and free movement among any medical institutions are the essential 
characteristics of the healthcare system in Japan [55]. Patients can directly access a specialist 
either in a clinic at primary care level (Figure 1.3 path A) or most hospitals. The majority of 
patients use a clinic as the first contact. 
Diagnosis 
In England, all colonoscopies are conducted at the secondary care level in principle. There is 
evidence of variations in the use of colonoscopy and flexible sigmoidoscopy across CCGs [46]. 
In Japan, there is evidence of socioeconomic differences in the utilisation of outpatient services, 
and delays in obtaining care among older people due to co-payment (barrier at Figure 1.3, path 
A) [42, 92-94]. However, the horizontal inequity and delays in the elderly population did not 
differentiate the speciality of healthcare (PCP or specialist service); thus, it is not known 
whether those figures influence the rates of emergency presentation (Figure 1.3, box 0 to box 11 
on the right side), timeliness of diagnosis, or the place for cancer treatment. 
Although co-payment is necessary, patients have access to diagnostic tests including endoscopy 
performed by gastroenterology specialists at both primary and secondary care levels (box 1 to 
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box 1a on the right side and box 4, two grid pattern areas in Figure 1.3). However, the capacity 
of colonoscopies is not investigated nationwide [95]. 
Treatment 
In England, at the planning phase (Figure 1.3, box 7), NICE (National Institute for Health and 
Care Excellence) (2004) used to recommend all newly diagnosed CRC patients to be cared by 
MDT [96, 97]. 
In Japan, MDT meetings are not necessary for all cases but are usually held only for the patients 
who are out of indication for treatment recommended in the guidelines. In DCHs, radiotherapy 
is available at the same institution where surgical treatment is provided. A specialised colorectal 
surgeon would contact a radiotherapist directly when radiotherapy is needed. For lower rectal 
cancer in Japan, neoadjuvant radiotherapy is rarely used; the first definitive treatment for most 
of the advanced cases is surgical resection with lateral lymph node dissection (Figure 1.3, path 
H) [78-80, 98]. Usually, in contrast to England, the CRC specialist surgeon who operated (box 
8b) is fully responsible for the postoperative care (including urgent re-operation), planning of 
the adjuvant therapy and follow-up (path I and J).  
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1.3.8 Potential steps on the patient pathway where inequalities may rise 
Potential measures that may reflect barriers in the pathway are listed to the right of Figure 1.3. 
Apart from patients’ health-seeking behaviour or preferences, late-stage presentation, delays in 
diagnosis or emergency presentation may partly originate from barriers in primary care. Delays 
in treatment, differences in place of treatment (e.g. reference cancer care centre or non-cancer 
hospitals, high-volume hospital or low-volume hospital, hospital with specialist or non-
specialist) or receipt of treatment may mean barriers in secondary care. 
1.3.9 Receipt of treatment as a measure of healthcare access 
Over the last decades, various indicators have been developed to assess cancer care. What 
elements ‘quality of care’ consists of depends firstly on the cancer site. In the specific context of 
CRC, early detection, accurate diagnosis and staging, prompt and stage-appropriate treatment, 
management of complications after surgery, regular follow-up by specialist and palliative care 
may imply good quality of care [5]; however, it does not necessarily mean that all these 
elements contribute to better survival. 
According to Donabedian model, quality indicators can be categorised into three groups: 
structure, process and outcome measures [99]. Achieving a longer survival is a self-explanatory 
outcome goal, and receipt of treatment (i.e. process measure), particularly surgical treatment, 
remains a crucial step to survive for CRC patients. Receipt of surgical treatment can also be a 
composite measure of accessibility of care, as shown in the patient pathway. 
Additional measures have also been suggested for assessing the quality of the provided care or 
postoperative management [100]. Regarding quality of surgery, one example of quality 
indicators is the number of lymph nodes yield [100, 101]. For postoperative management, some 
indicators incorporate postoperative complications such as anastomotic leakage [102], 
reoperation [103], failure to rescue [104, 105] and short-term postoperative mortality [106-108]. 
Postoperative complications and failure to rescue can be challenging to capture within 
population-level datasets because of, for example, inaccuracy of coding and missing data [109, 
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110], whereas data on postoperative mortality are generally more reliable, as individual vital 
status is usually available at national level. 
My focus here is to gather evidence on the differential access to care by SES and how such 
inequalities in access to care may influence the survival of CRC. In this thesis, I employ receipt 
of surgery for the primary lesion as a measure of access to CRC care, and postoperative 30-day 
mortality as the quality indicator of surgery as well as the short-term outcome measure. Because 
the detailed information is not available in the population-level database as described above, 
building indicators to assess the quality of care is beyond the aim of this thesis.  
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1.4 Aims and objectives 
Based on the patient pathway presented in Figure 1.3, this thesis focuses on the receipt of 
treatment (intermediate outcome) to explain inequalities in survival. 
1.4.1 Aims 
This study aims to understand the mechanisms by which the socioeconomic inequalities in CRC 
survival can be explained by patient, tumour and treatment factors. 
1.4.2 Objectives 
1. To examine whether socioeconomic inequalities in CRC care exist in each country of 
England and Japan, in recent years (England: 2010–2013, Japan: 2012–2015). 
2. To examine whether socioeconomic inequalities in CRC survival exist in each country 
of England and Japan, in recent years (England: 2010–2013, Japan: 2012–2015). 
3. To estimate how much of the socioeconomic inequalities in CRC survival are affected 
by socioeconomic inequalities in receipt of treatment. 
1.5 Thesis structure 
Chapter 2 reviews the literature on inequalities in receipt of treatment in UHC countries. 
Chapter 3 explains the data materials used in Chapters 4 and 5, and the methodology used in 
Chapter 4.5. 
Chapter 4 and Chapter 5 explore the socioeconomic inequalities in CRC care and survival in 
England and Osaka, Japan. 
Chapter 6 concludes the thesis with implications for future research. 
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Chapter 2: Literature review 
2.1 Inequalities in receipt of treatment in UHC countries 
2.1.1 Introduction and methods 
This literature review aims to explore evidence on the socioeconomic inequalities in access or 
utilisation of CRC care, especially focusing on the receipt of treatment in UHC countries. 
Socioeconomic inequalities in cancer survival can be caused by patient, tumour (stage) or 
healthcare system factors [111]. Reports have suggested evidence for socioeconomic 
inequalities in survival in countries with UHC [3, 112, 113]; however, how cancer care is 
accessed or utilised by different SES groups, the consequences of the differential treatment in 
relation to the survival inequalities, are poorly understood. As described in Chapter 1.2.1, in 
theory, in countries with UHC, equity of access to the acceptable quality of care should be 
ensured. Therefore, differential cancer care should not be observed by SES. 
OECD high-income countries with public health coverage were defined as UHC countries and 
included in the review [114, 115]; therefore, the United States, where private health coverage 
has been dominant (54%), was excluded from this review. 
In this thesis, I defined that cancer care refers to diagnosis and treatment but not the first and 
second prevention measures such as screening. Of the cancer care defined and the potential care 
measures identified in Figure 1.3, I further confined this review to the receipt of treatment 
(surgery, chemotherapy or radiotherapy) or type of treatment to explore evidence on the 
socioeconomic inequalities in access or utilisation of cancer care at the secondary care level. 
Measures of treatment receipt that do not necessarily affect survival (e.g. receipt of palliative 
care, stoma reversal, use of outpatient service or length of hospitalisation) were excluded. 
‘Socioeconomic status’ contains complex concepts; for this review, I defined disadvantaged 
groups as those with low incomes, in low occupation classes, or categorised as deprived groups 
defined by a multiple index. Reports defining disparities by age, sex, ethnicity, race, educational 
years, marital status, insurance status, geographical distance or rurality were therefore excluded. 
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Epidemiological research papers published between 1st January 2000 and 31st June 2019 were 
reviewed in PubMed, Ovid system (Embase, Global Health, Econlit, Social Policy and Practice) 
and Web of Science. Research papers, which were identified in the references of the original 
articles reviewed, were also manually assessed and added. Reports published in the 1990s or 
earlier were excluded as CRC treatment had changed dramatically since the 1990s. Non-English 
documents, non-Japanese documents, conference abstracts, review papers (e.g. literature review 
and meta-analysis), letters and qualitative reports were also excluded. Search strategies 
comprised the follows and are further detailed in Table 2.1. 
The aim of this review is to assess differential receipt of treatment; therefore, regarding 
socioeconomic variations in mode of presentation and outcomes (both postoperative mortality 
and survival from diagnosis), the articles that do not report disparities in treatment receipt, were 
excluded from this review, even if variations in presentation or mortality/survival are used as 
final outcomes. 
1. (bowel OR colon* OR rectum or rectal OR colorectal) AND (adenocarcinoma OR 
cancer) (as title) 
2. socioeconomic OR socio-economic OR deprivation OR income (as keyword) 
3. inequalit* OR inequit* OR differen* OR variation OR disparit* (as title) 
4. inequalit* OR inequit* OR disparit* (as keyword) 
5. treatment OR management OR care OR operation OR surgery OR resection OR 
specialty OR specialist OR time OR delay OR therapy OR chemotherapy OR 
radiotherapy OR chemoradiotherapy (as keyword)  
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Table 2.1 Search strategies in three search engines 
Pubmed ((bowel[Title] OR colon*[Title] OR rectum[Title] OR 
rectal[Title] OR colorectal[Title]) AND (adenocarcinoma[Title] 
OR cancer[Title])) AND ((inequalit*[Title] OR inequit*[Title] 
OR differen*[Title] OR variation[Title] OR disparit*[Title]) OR 
(inequalit*[Abstract] OR inequit*[Abstract] OR 
disparit*[Abstract])) AND (socioeconomic OR socio-economic 
OR deprivation OR income) AND (treatment OR management 
OR care OR operation OR surgery OR resection OR specialty OR 
specialist OR time OR delay OR therapy OR chemotherapy OR 
radiotherapy OR chemoradiotherapy) 
Ovid system 
Embase 
Global Health 
Econlit 
Social Policy and Practice 
1 (bowel or colon* or rectum or rectal or colorectal).m_titl. 
2 (adenocarcinoma or cancer).m_titl. 
3 1 and 2 
4 (socioeconomic or socio-economic or deprivation or 
income).mp. [mp=ab, ti, ot, bt, hw, id, cc, tx, ct, sh, tn, dm, mf, 
dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy, pt] 
5 (inequalit* or inequit* or differen* or variation or 
disparit*).m_titl. 
6 (inequalit* or inequit* or disparit*).mp. [mp=ab, ti, ot, bt, hw, 
id, cc, tx, ct, sh, tn, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, 
ui, sy, pt] 
7 (treatment or management or care or operation or surgery or 
resection or specialty or specialist or time or delay or therapy or 
chemotherapy or radiotherapy or chemoradiotherapy).mp. 
[mp=ab, ti, ot, bt, hw, id, cc, tx, ct, sh, tn, dm, mf, dv, kw, fx, dq, 
nm, kf, ox, px, rx, an, ui, sy, pt] 
8 5 or 6 
9 3 and 4 and 8 and 7 
10 limit 9 to yr="2000 -Current" 
11 remove duplicates from 10 
12 (America* or United States or USA).m_titl. 
13 11 not 12 
Web of Science #1 TI=(bowel OR colon* OR rectum OR rectal OR colorectal) 
AND TI=(adenocarcinoma OR cancer) 
#2 ALL=(inequalit* OR inequit* OR disparit*) 
#3 TI=(inequalit* OR inequit* OR differen* OR variation OR 
disparit*) 
#4 ALL=(socioeconomic OR socio-economic OR deprivation OR 
income) 
#5 ALL=(treatment OR management OR care OR operation OR 
surgery OR resection OR specialty OR specialist OR time OR 
delay OR therapy OR chemotherapy OR radiotherapy OR 
chemoradiotherapy) 
#6 #1 AND (#2 OR #3) AND #4 AND #5 
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The quality of studies was then assessed by using Newcastle-Ottawa Scale (NOS) for non-
randomized studies (cohort or case-control studies) (Table 2.2) [116]. The scale assesses three 
main components: for cohort studies, (i) selection, (ii) comparability of cohorts and (iii) 
assessment of outcome: for case-control studies, (i) selection, (ii) comparability of cases and 
controls and (iii) ascertainment of exposure. Each outcome in a study was assessed and allotted 
a star if the study design or description fulfils a requirement in each of the nine questions. The 
maximum total a study can obtain is nine stars. Regarding the comparability, I assigned one star 
if a study outcome is derived controlling for stage. I also allotted an additional star if a study 
outcome is derived controlling for comorbidities or ASA (American Society of 
Anesthesiologists) grade. 
The aim of this literature review is to summarise the available evidence on socioeconomic 
inequalities in access to cancer care for my analyses in the later chapters, but not to develop or 
assess quality indicators for cancer care. As the definitions and measurement of outcomes vary 
among studies, the outcomes were not pooled and this review is thus descriptive. 
Table 2.2 Newcastle-Ottawa Scale for cohort or case-control studies 
Cohort studies 
Selection 
(4 stars) 
1. Representativeness of cohort members: truly or somewhat representative of the 
community 
2. Selection of non-exposed cohort members: coming from the same community 
as the exposed members 
3. Ascertainment of exposure: secure record (e.g. surgical records) or structured 
interview 
4. Demonstration that outcome was not known at the start of study: yes or no 
Comparability 
(2 stars) 
1. a) Outcome controlled for stage 
b) Outcome controlled for comorbidities or ASA grade 
Outcome 
(3 stars) 
1. Assessment of outcome: independent blind assessment or record linkage 
2. Adequate length of follow-up for observing outcome to occur: yes or no 
3. Adequacy of follow-up: complete follow-up or small proportion of lost to 
follow-up (less than 30%) or description of the lost to follow-up 
Total 9 stars 
Case-control studies 
Selection 
(4 stars) 
1. Adequacy of case definition: yes (ICD codes, record linkage, self-reports) or 
no (no description) 
2. Representativeness of cases: obviously representative 
3. Selection of controls: community controls 
4. Definition of controls: no history of endpoint/disease 
Comparability 
(2 stars) 
1. a) Outcome controlled for stage 
b) Outcome controlled for comorbidities or ASA grade 
Exposure 
(3 stars) 
1. Ascertainment of exposure: secure record or structured interview (blind to 
case or control status) 
2. Same method of ascertainment for case and control: yes or no 
3. Non-response rate: same rate for both groups 
Total 9 stars 
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2.1.2 Results 
PubMed identified 427 articles. Ovid system (Embase, Global Health, Econlit, Social Policy 
and Practice) and Web of Science identified 922 and 477 articles, respectively. After removing 
duplications and irrelevant studies by screening titles and abstracts, 101 full-text articles were 
assessed for the eligibility. From the initially identified articles, further 28 articles were deemed 
as relevant (Figure 2.1). 
A total of 60 articles from seven UHC countries were identified as having descriptions on 
socioeconomic variations in receipt of treatment. The UK reported the most, followed by 
France. From other European countries, the Netherlands and Sweden reported some 
socioeconomic variations in cancer care. From Asia, one article from Korea reported 
socioeconomic variations. There was no article reporting disparities in receipt of treatment from 
Japan. 
Figure 2.1 Flow diagram for literature review  
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Description on variations in receipt of treatment was categorised into eight groups: 
socioeconomic variations in mode of presentation, place of treatment, time to treatment, receipt 
of any treatment, receipt of surgical treatment, type of surgical treatment, receipt of 
chemotherapy and receipt of radiotherapy. The identified studies are listed by group in Table 
2.3. 
Of the 60 studies, nine studies had reported socioeconomic differences in mode of presentations, 
and 26 had assessed the postoperative mortality or long-term survival, in addition to the report 
of differential receipt of treatment. Eight studies assessed differences in places of treatment (e.g. 
referral cancer care centres or not, high-volume or low-volume hospitals). Fifteen studies 
reported time to treatment by SES. Six studies reported on receipt of any treatment, 14 on 
receipt of surgery, 18 on type of surgery, 20 on receipt of chemotherapy, and ten on receipt of 
radiotherapy. 
Treatment and survival can be determined by stage, comorbidities, urgency of presentation or 
operation and speciality/volume of surgeon or hospital [111, 117]. Thus, I extracted information 
on whether an analysis was adjusted for those factors. For all outcomes, important factors, 
which were adjusted in each multivariable model, are shown in italics after adjusted odds ratios 
(ORs) or hazard ratios (HRs). 
Results of the quality assessment of the studies by NOS for cohort or case-control studies are 
shown in Table 2.14.  
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Mode of presentation or surgery 
In addition to the variations in receipt of treatment, nine studies reported socioeconomic 
disparities in mode of presentations (Table 2.4). In most studies, the unadjusted odds of 
emergency presentation were higher in the most deprived group than the least deprived group. 
Because mode of presentation was not the final outcome in the reviewed studies, all studies 
except two [118, 119] did not control for stage and comorbidities (Table 2.4 and Table 2.14). 
For these two studies, the adjusted odds of emergency presentation did not differ by SES. The 
definition of emergency presentation varied also by country. All three studies, which reported 
urgency of treatment, was from England, comparing elective versus emergency surgery [120-
122]. The OR of receiving emergency treatment in the most deprived group varied between 1.15 
and 1.30 in these three studies. 
Place and time to treatment 
In the eight studies on place of treatment, the OR of the most deprived group being treated in a 
reference cancer care centre or a high-volume hospital ranged from 0.32 to 1.22 (Table 2.5). 
Regarding the time to treatment, although there were 15 studies, there was mixed evidence for 
deprived groups with longer time to treatment. Not only the definitions for starting dates, but 
outcomes varied among the studies (Table 2.6). 
Regarding the quality of the studies, studies reporting place of treatment pointed generally 
higher than seven stars in NOS. On the contrary, two studies on time to treatment [123, 124] 
were poor in the description of selection of the study population (Table 2.14). 
Receipt of any treatment, surgery and type of surgery 
Of the six studies on the receipt of any treatment, two studies from England [125, 126] found 
that deprived groups were less likely to receive treatment than the least deprived group (Table 
2.7). In other studies, socioeconomic trends favouring affluent patients were less clear. 
Receipt of surgery was reported to be generally low in deprived patients. The OR of receiving 
surgery in the most deprived group varied between 0.52 and 1.13 (Table 2.8). In most studies 
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reporting the receipt of surgery, disease stage was controlled. Three studies adjusted for the 
mode of presentation [118, 127, 128] and one study adjusted for the urgency of operation [120]. 
Four studies assessed socioeconomic variation in receipt of liver resection for stage IV CRC. 
Three studies specified liver-limited metastasis to synchronous cancer [128-130], whereas one 
[131] did not. 
Of the 18 studies on the type of surgery, there were two studies on curative vs palliative surgery, 
one on total vs partial pelvic exenteration, nine on non-restorative surgery, two on laparoscopic 
surgery, six on the number of lymph node yields and two on the speciality of a surgeon (Table 
2.9). Generally, deprived patients were likely to receive non-restorative surgery, such as APER, 
rather than restorative surgery such as AR. Laparoscopic surgery was also less received by the 
deprived group. Lymph node yield 12 or more was relatively equally achieved among different 
SES groups. Access to a specialised surgeon was also consistent among the SES groups. 
Almost all studies scored eight or nine stars in quality assessment by NOS regarding receipt of 
surgery. When type of surgery was the outcome, some studies scored seven or lower stars 
because not controlling for stage or comorbidities (Table 2.14). 
Receipt of chemotherapy 
Of the 20 studies, four studies specified the study population to patients with stage IV [125, 
132-134] (Table 2.10). Other studies, except for one [135], specified the use to adjuvant therapy 
or controlled stage information. One study evaluated access to KRAS testing [132]. Access to 
adjuvant chemotherapy was generally low for the deprived groups; the OR of receiving 
chemotherapy in the most deprived group ranged from 0.31 to 0.99. 
Regarding the quality of the studies, most studies scored seven or higher stars in NOS; however, 
some studies were unclear in terms of follow-up period to observe receipt of chemotherapy 
(Table 2.14, no star for the question Outcome 2. for cohort studies). 
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Receipt of radiotherapy 
Ten studies on the receipt of radiotherapy mostly focused on neoadjuvant therapy use for rectal 
cancer patients (Table 2.11). The OR in receiving radiotherapy varied between 0.62 and 1.39. 
One study from Sweden reported strong evidence for socioeconomic inequalities in the use of 
radiotherapy, even stratified by several factors [136]. All studies scored seven or higher stars in 
NOS (Table 2.14). 
Postoperative mortality and long-term survival 
Table 2.12 represents those studies which reported postoperative mortality or survival. Table 
2.13 shows survival reports of which the entry is the diagnosis. Nine studies measured 
postoperative short-term mortality (Table 2.12). Eight studies extended the analysis to overall 
(i.e. all-cause) survival, of which the end point was more than one year from the entry. Three 
studies [137-139] assessed cancer-specific survival, one [140] assessed relative survival, and 
two [120, 141] assessed net survival. Most studies adjusted disease stage or showed results by 
stratified stage. ASA grades were adjusted in two studies [120, 122]. Comorbidities were 
adjusted in four studies [138, 139, 142, 143], and the urgency of presentation or surgery 
(emergency or elective) were adjusted in six studies [120, 122, 137, 141-143]. In all studies, the 
odds of postoperative short-term death in the most deprived group exceeded one. 
Eleven studies measured long-term survival since diagnosis (Table 2.13). Even after adjusting 
for the effects of stage and treatment factors, the hazard of death in the most deprived group was 
generally higher than that of the least deprived group; the HR ranged between 0.83 and 1.54. 
Quality of study was high (8 or 9 stars in NOS) in all studies except one [121] (Table 2.14).
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Table 2.3 Literature identified for variations in cancer care by socioeconomic status  
Cancer care Australia Canada France Netherlands Sweden UK Korea 
Emergency 
presentation 
 Helewa, 2013 [119] Rollet, 2018 [118]   Raine (E), 2010 [144] 
Borowski (E), 2016 [145] 
Hole (S), 2002 [137] 
Oliphant (S), 2013 [141] 
Bharathan (E), 2011 [120] 
Harris (E), 2009 [121] 
Smith (E), 2006 [122] 
 
Place of treatment Kelsall, 2008 [146] 
Field, 2015 [147] 
 Blais, 2006 [148] 
Dejardin, 2005 [149] 
  Pitchforth (S), 2002 [150] 
Vallance (E), 2017 [151] 
Borowski (E), 2016 [145] 
Kim, 2010 
[152] 
Time to treatment Jorgensena, 2014 [142] Porter, 2005 [124] 
Bardell, 2006 [153] 
Lima, 2011 [139] 
Rayson, 2012 [154] 
Maddison, 2012 [155] 
Johnston, 2004 [156] 
Helewa, 2013 [119] 
Moriceau, 2015 [157] van der Geest, 2013 
[158] 
 Neal (E), 2005 [123] 
Campbell (S), 2002 [159] 
Chamberlain (E), 2015 [133] 
Lejeune (E), 2010 [126] 
Redaniel (E), 2014 [140] 
 
Any treatment Jorgensena, 2014 [142] 
Beckman, 2014 [160] 
Maddison, 2012 [155] Rollet, 2018 [118]   Crawford (E), 2012 [125] 
Lejeune (E), 2010 [126] 
 
Surgical treatment Beckman, 2014 [160] 
Hall, 2005 [127] 
 Rollet, 2018 [118] t Lam-Boer, 2015 
[129] 
Olsson, 2010 
[161] 
Noren, 2016 [130] 
Campbell (S), 2002 [159] 
Hayes (E), 2019 [162] 
Jones (E), 2008 [163] 
Paterson (S), 2014 [135] 
Harris (E), 2009 [121] 
Bharathan (E), 2011 [120] 
Morris (E), 2010 [131] 
Vallance (E), 2018 [128] 
 
Type of surgical 
treatment, others 
 Del Paggio, 2017 [138] Dolet, 2019 [164] 
Lamy, 2018 [132] 
Rollet, 2018 [118] 
Dik, 2014 [143] Olsson, 2010 
[161] 
Hole (S), 2002 [137] 
Oliphant (S), 2013 [141] 
Harris (E), 2009 [121] 
Paterson (S), 2014 [135] 
Morris (E), 2008 [165] 
Raine (E), 2010 [144] 
Smith (E), 2006 [122] 
Tilney (E), 2008 [166] 
Tilney (E), 2009 [167] 
Byrne (E), 2018 [168] 
Radwan (W), 2016 [169] 
Wrigley (E), 2003 [170] 
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Table 2.3 continued 
Cancer care Australia Canada France Netherlands Sweden UK 
Chemotherapy Jorgensenb, 2014 [171] 
Kelsall, 2008 [146] 
Beckman, 2014 [160] 
Lima, 2011 [139] 
Rayson, 2012 [154] 
Dejardin, 2008 [172] 
Lamy, 2018 [132] 
Rollet, 2018 [118] 
van der Geest, 2013 [158] 
Lemmens, 2005 [173] 
Meulenbeld, 2008 [134] 
van Steenbergen, 2010 [174] 
 Campbell (S), 2002 [159] 
Hayes (E), 2019 [162] 
Hole (S), 2002 [137] 
Jones (E), 2008 [163] 
Paterson (S), 2014 [135] 
Pitchforth (S), 2002 [150] 
Chamberlain (E), 2015 [133] 
Crawford (E),2012 [125] 
Radiotherapy Jorgensenb, 2014 [171] 
Kelsall, 2008 [146] 
Beckman, 2014 [160] 
Maddison, 2012 [155]  Vulto, 2007 [175] Olsson, 2011 
[136] 
Campbell (S), 2002 [159] 
Jones (E), 2008 [163] 
Paterson (S), 2014 [135] 
Radwan (W), 2016 [169] 
Perioperative 
death 
Jorgensena, 2014 [142] Lima, 2011 [139] 
Del Paggio, 2017 [138] 
 Dik, 2014 [143] Noren, 2016 [130] Oliphant (S), 2013 [141] 
Harris (E), 2009 [121] 
Hole (S), 2002 [137] 
Bharathan (E), 2011 [120] 
Smith (E), 2006 [122] 
Tilney (E), 2008 [166] 
Tilney (E), 2009 [167] 
Radwan (W), 2016 [169] 
Redaniel (E), 2014 [140] 
Survival Kelsall, 2008 [146] 
Hall, 2005 [127] 
Field, 2015 [147] 
Helewa, 1013 [119] Dejardin, 2008 [172] Meulenbeld, 2008 [134] 
Lemmens, 2005 [173] 
t Lam-Boer, 2015 [129] 
 Harris (E), 2009 [121] 
Wrigley (E), 2003 [170] 
Lejeune (E), 2010 [126] 
Vallance (E), 2018 [128] 
Abbreviations: E, England; S, Scotland; UK, United Kingdom; W, Wales.  
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Table 2.4 Description of socioeconomic variations in mode of presentation 
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios or days (95% CI) in the most deprived 
group unless specified (reference: least deprived group) 
Rollet [118] 
(France, 2018) 
European 
Deprivation Index 
(EDI) 
C, stage II, III, IV, 2005–2010 Emergency admission (with occlusion, sub-
occlusion or perforation) 
Adjusted OR 1.22 (0.92, 1.61) #St, Cm 
Raine [144] 
(England, 2010) 
Index of Multiple 
Deprivation (IMD) 
CR, no stage information, 1999–
2006 
Emergency admission (vs elective) Adjusted OR 1.52 (1.47, 1.56) 
Helewa* [119] 
(Canada, 2013) 
Income CR, AJCC stage I–IV, 2004–2006 Urgent presentation (presented to 
emergency department and had surgeon 
consultation within 2 weeks of major 
surgery date) 
Adjusted OR 0.83 (0.52, 1.30) #St, Cm 
Borowski [145] 
(England, 2016) 
IMD CR, stage I–IV, 2009–2014 Emergency presentation (vs other referral 
routes) 
OR 1.70 (p=0.048, chi square test for trend) 
Hole* [137] 
(Scotland, 2002) 
Carstairs index CR, Duke's stage A–D, 1991–1994 Emergency presentation (vs elective) OR 0.99 (p=0.80, chi square test for trend) 
Oliphant* [141] 
(Scotland, 2013) 
Scottish Index of 
Multiple Deprivation 
(SIMD) score 
CR who underwent surgery, Duke's 
stage A–D, 2001–2004 
Emergency presentation (vs elective) OR 1.21 (p=0.033, chi square test for trend) 
Bharathan [120] 
(England, 2011) 
IMD CR, Duke's stage A–D, 1998–2002 Urgency of treatment (non-elective) OR 1.15 (p=0.014, chi square test for trend) 
Harris* [121] 
(England, 2009) 
IMD R, stage I–IV, 2001–2004 Emergency surgery OR 1.30 (p=1.00, Fisher's exact test) 
Smith [122] 
(England, 2006) 
Townsend score CR who underwent surgery, Duke's 
stage A–D, 2001–2002 
Emergency surgery (vs elective) OR 1.24 (p=0.003, chi square test for trend) 
Abbreviations: 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; C, colon cancer; CR, colorectal cancer; OR, odds ratio; SES, socioeconomic status. 
* has analysis on mortality or survival. # shows important factors adjusted in each multivariable model. Cm, comorbidities; St, stage.  
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Table 2.5 Description of socioeconomic variations in place of treatment 
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios or days (95% CI) in the most deprived 
group unless specified (reference: least deprived group) 
Blais [148] 
(France, 2006) 
Annual income CR, Duke's stage A–D, 1981–2000 Care centre type for surgery (treatment in 
reference care centre) 
1981–1990: adjusted OR 1.22 (0.87, 1.69), 1991–2000: 
adjusted OR 1.00 (0.75, 1.33) #St, Sx 
Dejardin [149] 
(France, 2005) 
Occupation CR, Duke's stage A–D, 1995 Management in reference cancer site Social class not associated with management in reference 
cancer site (social class not included in the multivariable 
model) 
Kelsall* [146] 
(Australia, 2008) 
Socio-Economic 
Indexes for Areas 
(SEIFA) 
CR, AJCC stage I–IV, 1990–1994 Use of high-volume hospital OR 0.68 
Kim [152] 
(Korea, 2010) 
Income C, no stage information, 2002–2005 Colectomy at high-volume hospitals High-volume hospital use: adjusted OR 0.59 (0.53, 0.66), low-
volume hospital use: adjusted OR 1.54 (1.38, 1.72) #Cm, EmPr 
Pitchforth [150] 
(Scotland,2002) 
Carstairs index CR, Duke's stage C who were 
admitted to a non-cancer hospital, 
1992–1996 
Referral on to the next cancer hospitals OR 0.60 (p=0.014) 
Field* [147] Index of Relative 
Socioeconomic 
Advantage and 
Disadvantage 
(IRSAD) score 
CR, AJCC stage IV, 2009–2014 Use of private or public hospital OR 0.32 (p<0.001, chi square test for trend) 
Vallance [151] 
(England, 2017) 
IMD CR, stage IV who had liver only 
metastasis at diagnosis and 
underwent bowel resection, 2010–
2013 
Use of spoke or hub hospital Hub hospital use: OR 0.60 (p<0.001, chi square test for trend) 
Borowski [145] 
(England, 2016) 
IMD CR, stage I–IV, 2009–2014 Volume of hospital referred from 
emergency referral 
High-volume hospital use: OR 1.05, low-volume hospital use: 
OR 1.08 (p=0.95, chi square test for trend) 
Abbreviations: 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; C, colon cancer; CR, colorectal cancer; OR, odds ratio; R, rectal cancer; SES, socioeconomic status. 
* has analysis on mortality or survival. # shows important factors adjusted in each multivariable model. Cm, comorbidities; EmPr, mode of presentation/admission (emergency or not); St, stage; Sx, 
use/type of surgery.  
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Table 2.6 Description of socioeconomic variations in time to treatment  
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios or days (95% CI) in the most deprived 
group unless specified (reference: least deprived group) 
Maddison [155] 
(Canada, 2012) 
Income C (stage III), R (stage II or III), 
2001–2005 
Waiting time within clinical benchmark (14 days 
from radiation oncology referral to consultation 
in rectal cancer) 
Adjusted OR 0.78 (0.38, 1.61) #Cm 
Moriceau [157] 
(France, 2016) 
EDI CR, all TNM stage, 2013 Time to diagnosis Adjusted HR 0.97 (0.50, 1.90) #St 
   
Time to treatment Adjusted HR 1.17 (0.60, 2.29) #St 
Neal [123] 
(England, 2005) 
Occupation CR, no stage information, 2002 Total delay Social class not associated with the outcome (social class not 
included in the multivariable model)    
Patient and primary care delays (pre-hospital 
delay) 
Social class not associated with the outcome (social class not 
included in the multivariable model)    
Referral delays Social class not associated with the outcome (social class not 
included in the multivariable model)    
Secondary care delay F(7)=2.247, p=0.028 in generalised linear model 
Porter [124] 
(Canada, 2005) 
Annual income CR, stage I–IV, 2001 Time from symptoms to first medical doctor 
(days) 
Median days (IQR): 36 (11, 72) in the most deprived group, 
20 (9, 61) in the least deprived group (p=0.34) 
   Time from first medical doctor to diagnosis 
(days) 
Median days (IQR): 87 (40, 177) in the most deprived group, 
60 (30, 155) in the least deprived group (p=0.20) 
   Time from diagnosis to surgery (days) Median days (IQR): 24 (14, 46) in the most deprived group, 
15 (9, 40) in the least deprived group (p=0.25) 
Bardell [153] 
(Canada, 2006) 
Median household 
income 
CR, no stage information, 
1984–2000 
Waiting time from diagnosis to admission for 
surgery (days) 
Adjusted mean waiting time 28.2 (27.2, 29.3) days in the 
least deprived group, 28.8 (27.7, 30.0) days in the most 
deprived group #Sp 
   Surgery within 2 weeks of diagnosis Adjusted OR 1.09 (1.00, 1.18) #Sp 
Campbell [159] 
(Scotland, 2002) 
Carstairs index CR, Duke's stage A–D, 1995–
1996 
Time from first referral to first treatment 
(surgery, chemotherapy or radiotherapy) 
Adjusted HR 1.24 (0.93, 1.67) #St, EmPr 
Chamberlain [133] 
(England, 2015) 
IMD CR, stage IV, 2011–2013 Time to treatment Adjusted HR 1.20 (0.92, 1.59) 
Jorgensen a* [142] 
(Australia, 2014) 
SEIFA CR, all stages who underwent 
surgery, 2007–2008 
Treatment within 31 days of decision SES not associated with the outcome (SES not included in the 
multivariable model) #St, Cm (C), St (R) 
   Treatment within 62 days of referral SES not associated with the outcome (SES not included in the 
multivariable model) #St, EmPr (C), St (R) 
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Table 2.6 continued 
  
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios or days (95% CI) in the most deprived 
group unless specified (reference: least deprived group) 
Paterson [135] 
(Scotland, 2014) 
SIMD CR, Duke's stage A–D, 2003–
2009 
62-day target met OR 1.02 (p=0.18, chi square test for trend) 
Lejeune* [126] 
(England, 2010) 
Townsend index CR, AJCC stage I–IV, 1997–2000 Time to treatment (treatment within first week) Adjusted OR 0.78 (0.72, 0.84) #St 
   Time to treatment (treatment within first month) Adjusted OR 0.84 (0.78, 0.90) #St 
   Time to treatment (treatment within 2-3 
months) 
Adjusted OR 0.91 (0.85, 0.98) #St 
   Time to treatment (treatment within4-6 months) Adjusted OR 1.07 (0.96, 1.18) #St 
Johnston [156] 
(Canada, 2004) 
Median household 
income 
CR, all stages who received 
radiotherapy within 1 year of 
diagnosis, 1992–2000 
Time from diagnosis to first consult with 
radiation oncologist (T1) 
Adjusted HR 1.06 (0.98, 1.13) per $10000 increase in median 
household income (continuous) #St 
   Time from first consult with radiation oncologist 
to first radiotherapy (T2) 
Adjusted HR 0.99 (0.92, 1.06) per $10000 increase in median 
household income (continuous) #St 
   Time from diagnosis to first radiotherapy (T1+T2) Adjusted HR 1.04 (0.97, 1.12) per $10000 increase in median 
household income (continuous) #St 
Lima* [139] 
(Canada, 2011) 
Median annual 
household income 
C, stage III, 2000–2005 Adjuvant chemotherapy within 12 weeks from 
surgery 
OR 0.65 
van der Geest [158] 
(Netherlands, 2013) 
SES based on the 
Netherlands 
Institute for Social 
Research 
C, stage III, 2006–2008 Delay of adjuvant chemotherapy Adjusted OR 0.32 (0.13, 0.76) #EmSx 
 
5
3
 
54 
 
Table 2.6 continued 
Abbreviations: 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; C, colon cancer; CR, colorectal cancer; EDI, European Deprivation Index; HR, hazard ratio; IMD, Index 
of Multiple Deprivation; IQR, interquartile range; OR, odds ratio; R, rectal cancer; SEIFA, Socio-Economic Indexes for Areas; SES, socioeconomic status; SIMD, Scottish Index of Multiple 
Deprivation score. * has analysis on mortality or survival. # shows important factors adjusted in each multivariable model. Cm, comorbidities; EmPr, mode of presentation/admission (emergency or 
not); EmSx, urgency of surgery (elective or emergency); Sp, speciality/type of surgeon/hospital or surgical/hospital volume; St, stage.  
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios or days (95% CI) in the most deprived 
group unless specified (reference: least deprived group) 
Maddison [155] 
(Canada, 2012) 
Income C (stage III) and R (stage II or 
III), 2001–2005 
Waiting time within clinical benchmark (14-day 
from radiation oncology referral to consultation 
in rectal cancer) 
Adjusted OR 0.78 (0.38, 1.61) #Cm 
Rayson [154] 
(Canada, 2012) 
Quebec Model 
(social and material 
deprivation index) 
C (stage IIB or III) and R (stage II 
and III), 2000–2005 
Chemotherapy receipt within 12 weeks of 
curative-intent surgery 
CR: adjusted OR 0.4 (0.18, 0.91), C: no variable associated 
with delay, R: adjusted OR 0.31 (0.10, 0.91) 
Helewa* [119] 
(Canada, 2013) 
Income CR, AJCC stage I–IV, 2004–2006 Higher total waiting time quartiles for non-
urgent presentation 
Adjusted OR 1.06 (0.74, 1.52) #St, Cm 
Redaniel* [140] 
(England, 2014) 
IMD CR, Duke’s stage A–B, 1996–
2009 
Time from diagnosis to major surgical resection Coefficient 0.21 (-0.55, 0.98) #St, Cm 
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Table 2.7 Description of socioeconomic variations in receipt of any treatment 
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios (95% CI) in the most deprived group 
unless specified (reference: least deprived group) 
Crawford [125] 
(England, 2012) 
IMD CR, stage I–IV, 1994–2002 Any treatment  C: adjusted OR 0.54 (0.39, 0.76), R: adjusted OR 0.54 (0.34, 
0.84) #St 
Lejeune* [126] 
(England, 2010) 
Townsend index CR, AJCC stage I–IV, 1997–2000 Any treatment within 6 months after first 
contact within the NHS 
Adjusted OR 0.87 (0.82, 0.92) #St 
Maddison [155] 
(Canada, 2012) 
Income C (stage III) and R (stage II or III), 
2001–2005 
Receipt of clinically recommended care 
(chemotherapy for colon cancer, 
chemotherapy and radiotherapy in rectal 
cancer) 
Adjusted OR 0.69 (0.43, 1.10) #Cm 
Jorgensena* [142] 
(Australia, 2014) 
SEIFA CR, all stages who underwent 
surgery, 2007–2008 
Discussed at MDT meeting SES not associated with the outcome (SES not included in the 
multivariable model) #St, Sp 
Rollet [118] 
(France, 2018) 
EDI C, stage I–IV, 2005–2010 Assessment of extension (metastasis) Adjusted OR 1.02 (0.76, 1.36) #St, Cm, EmPr 
Beckman [160] 
(Australia, 2014) 
SEIFA CR, Duke’s stage D, 2003–2008 Receipt of treatment Adjusted OR 0.99 (0.93, 1.07) #Cm 
  CR, Duke’s stage A–D, 2003–2008 Treatment differing from guidelines Adjusted prevalence ratio 0.94 (0.82, 1.09) #St, Cm 
Abbreviations: 95% CI, 95% confidence interval; C, colon cancer; CR, colorectal cancer; EDI, European Deprivation Index; HR, hazard ratio; IMD, Index of Multiple Deprivation; MDT, 
multidisciplinary team; NHS, National Health Service; OR, odds ratio; R, rectal cancer; SEIFA, Socio-Economic Indexes for Areas; SES, socioeconomic status. * has analysis on mortality or survival. 
# shows important factors adjusted in each multivariable model. Cm, comorbidities; EmPr, mode of presentation/admission (emergency or not); Sp, speciality/type of surgeon/hospital or 
surgical/hospital volume; St, stage.  
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Table 2.8 Description of socioeconomic variations in receipt of surgery 
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios (95% CI) in the most deprived group 
unless specified (reference: least deprived group) 
Campbell [159] 
(Scotland, 2002) 
Carstairs index CR, Duke's stage A–D, 1995–1996 Surgery Adjusted OR 0.52 (0.14, 1.87) #St 
Hayes [162] 
(England, 2019) 
IMD C, all stages, 1999–2010 Surgery Adjusted OR 0.62 (0.55, 0.70) #St, Cm 
Beckman [160] 
(Australia, 2014) 
SEIFA CR, Duke’s stage A–C, 2003–2008 Surgery Adjusted OR 1.00 (0.98, 1.02) #St, Cm 
Hall [127] 
(Australia, 2005) 
Index of relative 
socioeconomic 
disadvantage (IRDS) 
CR, no stage information, 1982–
2001 
Surgery 1982–2001: adjusted OR 1.02 (0.80, 1.30), 1991–2001: 
adjusted OR 1.13 (0.88, 1.45) #Cm, EmPr 
Jones [163] 
(England, 2008) 
IMD CR, stage I–IV, 1994–2002 Surgery C: adjusted OR 0.99 (0.99, 1.0), R: adjusted OR 0.99 (0.98, 
0.99) for one increment in the deprivation score (ranging from 
0: least deprived to 80: most deprived) #St 
Rollet [118] 
(France, 2018) 
EDI C, stage I–IV, 2005–2010 Surgical approach in intention to treat Adjusted OR 1.01 (0.77, 1.33) #St, Cm, EmPr 
Paterson [135] 
(Scotland, 2014) 
SIMD score CR, Duke's stage A–D, 2003–2009 Resection for primary tumour Adjusted OR 0.81 (0.63, 1.04) #St 
Harris* [121] 
(England, 2009) 
IMD R, stage I–IV, 2001–2004 Operative procedure OR 0.84 (p=0.003, Fisher's exact test) 
   
Resectional procedure OR 0.85 (p=0.005, Fisher's exact test) 
Bharathan* [120] 
(England, 2011) 
IMD CR, Duke's stage A–D, 1998–2002 Operative treatment OR 0.97 (p=0.18, chi square test for trend) 
   Curative resection Adjusted OR 0.81 (0.66, 0.99) #ASA, EmSx 
Olsson [161] 
(Sweden, 2010) 
Income R, stage I–IV, 1995–2005 Any surgical treatment Adjusted OR 0.81 (0.63, 1.03) #St, Sp 
   
Any resection Adjusted OR 0.76 (0.63, 0.91) #St, Sp 
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Table 2.8 continued 
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios (95% CI) in the most deprived group 
unless specified (reference: least deprived group) 
Morris [131] 
(England, 2010) 
IMD CR, all AJCC stages who underwent 
major resection for CRC (both 
synchronous and metachronous), 
1998–2004 
Liver resection Adjusted OR 0.70 (0.61, 0.80) #St, Cm, CR 
Vallance* [128] 
(England, 2018) 
IMD CR, stage IV (synchronous liver-
limited metastases), 2010–2016 
Liver resection Adjusted OR 0.70 (0.59, 0.85) #EmPr, CR, Sp 
t Lam-Boer* [129] 
(Netherlands, 2015) 
Income CR, stage IV (synchronous liver-only 
metastasis), 2004–2012 
Liver resection Adjusted OR 0.52 (0.31, 0.88) #CR, Cm 
Noren* [130] 
(Sweden, 2016) 
Income CR, stage IV (synchronous liver-only 
metastasis), 2007–2011 
Resection of synchronous liver metastasis Adjusted OR 1.05 (0.75, 1.48) #ASA, CR, Sp 
Abbreviations: 95% CI, 95% confidence interval; C, colon cancer; CR, colorectal cancer; EDI, European Deprivation Index; HR, hazard ratio; IMD, Index of Multiple Deprivation; OR, odds ratio; R, 
rectal cancer; SIMD, Scottish Index of Multiple Deprivation; SES, socioeconomic status.* has analysis on mortality or survival. # shows important factors adjusted in each multivariable model ASA, 
ASA (American Society of Anesthesiologists) grade; CR, site (right/left-sided colon or rectum); Cm, comorbidities; EmPr, mode of presentation/admission (emergency or not); EmSx, urgency of surgery 
(elective or emergency); Sp, speciality/type of surgeon/hospital or surgical/hospital volume; St, stage.  
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Table 2.9 Description of socioeconomic variations in type of surgery and others  
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios (95% CI) in the most deprived group 
unless specified (reference: least deprived group) 
Hole* [137] 
(Scotland, 2002) 
Carstairs index CR, Duke's stage A–D who 
underwent resection, 1991–1994 
Type of resection (curative or palliative) Curative resection: OR 1.04 (p=0.52, chi square test for trend) 
Oliphant* [141] 
(Scotland, 2013) 
SIMD score CR, Duke's stage A–D who 
underwent surgery, 2001–2004 
Intent of curative resection (vs palliative 
resection, no resection) 
Curative resection: OR 0.89 (p <0.001, chi square test for 
trend) 
Radwan* [169] 
(Wales, 2016) 
Welsh Index of 
Multiple 
Deprivation (WIMD) 
R, all TNM stage who underwent 
pelvic exenteration, 2006–2014 
Type of exenteration (total or partial) Total pelvic exenteration: OR 1.40 (p=0.69, chi square test for 
overall) 
Dolet [164] 
(France, 2019) 
EDI R, stage I–IV who underwent 
curative surgery, 1997–2015 
Non-restorative surgery Adjusted OR 1.28 (0.89, 1.83) in the deprived groups (1: least 
deprived as reference vs 2+3+4+5) #St 
Harris* [121] 
(England, 2009) 
IMD R, 2001–2004 Permanent stoma OR 1.36 (p=0.11, Fisher's exact test) 
Paterson [135] 
(Scotland, 2014) 
SIMD score CR, Duke's stage A–D, 2003–2009 Permanent stoma C: OR 1.32, (p=0.25, chi square test for trend), R: OR 1.03 
(p=0.16, chi square test for trend) 
Morris [165] 
(England, 2008) 
IMD R, Duke's stage A–D who 
underwent surgery, 1998–2004 
APER Adjusted OR 1.37 (1.24, 1.50) #St, EmPr, Sp 
Olsson [161] 
(Sweden, 2010) 
Income R, stage I–IV, 1995–2005 APER Adjusted OR 1.14 (0.94, 1.39) #St, Sp 
   
AR Adjusted OR 0.80 (0.69, 0.94) #St, Sp 
   
AR by stratified age groups ≤65 years: adjusted OR 0.79 (0.60, 1.04), 66–79 years: 
adjusted OR 0.91 (0.71, 1.16), ≥80 years: adjusted OR 0.62 
(0.43, 0.91) #St, Sp    
AR by stratified by sex Men: 0.84 (0.68, 1.04), women: OR 0.74 (0.56, 0.97) #St, Sp 
   
AR by stratified period 1995–2000: no difference in OR by income (SES not included in 
the multivariable model), 2001–2005: adjusted OR 0.75 (0.61, 
0.92) #St, Sp 
Raine [144] 
(England, 2010) 
IMD R, no stage information, 1999–
2006 
AR Adjusted OR 0.75 (0.68, 0.82) #EmPr 
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Table 2.9 continued 
Abbreviations: 95% CI, 95% confidence interval; APER, abdominoperineal excision of rectum; AR, anterior resection; C, colon cancer; CR, colorectal cancer; EDI, European Deprivation Index; HR, 
hazard ratio; IMD, Index of Multiple Deprivation; OR, odds ratio; R, rectal cancer; SIMD, Scottish Index of Multiple Deprivation; SES, socioeconomic status; TEM, transanal endoscopic microsurgery. 
* has analysis on mortality or survival. # shows important factors adjusted in each multivariable model. Cm, comorbidities; EmPr, mode of presentation/admission (emergency or not); NATx, use of 
neoadjuvant therapy; Sp, speciality/type of surgeon/hospital or surgical/hospital volume; St, stage; Sx, use/type of surgery.  
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios (95% CI) in the most deprived group 
unless specified (reference: least deprived group) 
Smith* [122] 
(England, 2006) 
Townsend score CR, Duke's stage A–D who 
underwent surgery, 2001–2002 
Surgery procedure (AR, APER, others) AR: OR 0.78, APER: OR 1.09 (p<0.001, chi square test for trend) 
Tilney* [166] 
(England, 2008) 
IMD CR who underwent APER or AR, no 
stage information, 1996–2004 
APER (vs AR) Adjusted OR 1.58 (1.45, 1.74) #EmPr 
Tilney* [167] 
(England, 2009) 
IMD R, Duke's stage A–C who 
underwent APER or AR, 2000–2005 
APER (vs AR) Adjusted OR 1.64 (1.36, 1.97) #NATx 
Byrne [168] 
(England, 2018) 
IMD deciles CR, adults undergoing elective 
surgery, 2002–2012 
Laparoscopic surgery (vs open) Lower level of deprivation (more affluent) by 0.16 deciles 
(0.12-0.20) 
Dik* [143] 
(Netherlands, 2014) 
Mean household 
income and 
postcodes 
CR, stage I–III who underwent 
surgery, 2005–2010 
Laparoscopy C: adjusted OR 0.72 (0.56, 0.93), R: adjusted OR 0.75 (0.50, 
1.14) #St, Cm 
   Laparoscopy converted to laparotomy (C) Adjusted OR 1.89 (1.09, 3.22) #St, Cm    
Resection of primary tumour (R) Adjusted OR 0.69 (0.41, 1.19) #St, Cm    
Endoscopic/TEM followed by surgery (R) Adjusted OR 1.61 (0.63, 4.17) #St, Cm 
   Lymph node yield at least 12 OR 0.93 (p=0.025, chi square test) 
Del Paggio* [138] 
(Canada, 2017) 
SES based on 
Canadian census 
C, stage II or III, 2002–2008 Lymph node yield at least 12 Adjusted OR 0.90 (0.85, 0.94) #St, Cm, Sx, Sp 
Lamy [132] 
(France, 2018) 
EDI CR, stage II, 2010 Lymph node yield at least 12 Adjusted OR 1.02 (0.38, 2.73) #St, Cm, Sp 
Oliphant* [141] 
(Scotland, 2013) 
SIMD score CR, Duke's stage A–D who 
underwent surgery, 2001–2004 
Lymph node yield at least 12 OR 0.92 (p=0.016, chi square test for trend) 
Rollet [118] 
(France, 2018) 
EDI C, stage I– IV, 2005–2010 Lymph node yield at least 12 Adjusted OR 0.82 (0.64, 1.05) #St, Cm, Sx, EmPr 
Tilney* [167] 
(England, 2009) 
IMD R, Duke's stage A–C who 
underwent APER or AR, 2000–2005 
Lymph node yield at least 12 AR: OR 0.95 (p=0.07, chi square test for trend), APER: OR 1.12 
(p=0.78, chi square test for trend) 
Oliphant* [141] 
(Scotland, 2013) 
SIMD score CR, Duke's stage A–D who 
underwent surgery, 2001–2004 
Speciality of surgeon Specialist: OR 1.06 (p=0.001, chi square test for trend) 
Wrigley* [170] 
(England, 2003) 
Townsend score CR, Duke's stage A–D, 1991–1995 Specialist treatment OR 1.01 (p=0.51, chi square test for trend) 
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Table 2.10 Description of socioeconomic variations in receipt of chemotherapy  
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios (95% CI) in the most deprived group 
unless specified (reference: least deprived group) 
Campbell [159] 
(Scotland, 2002) 
Carstairs index CR, Duke's stage A–D, 1995–1996 Chemotherapy Adjusted OR 0.49 (0.22, 1.10) #St, EmPr 
Beckman [160] 
(Australia, 2014) 
SEIFA CR, Duke’s stage C, 2003–2008 Chemotherapy Adjusted OR 0.94 (0.83, 1.96) #Cm 
Jones [163] 
(England, 2008) 
IMD CR, stage I–IV, 1994–2002 Chemotherapy C: adjusted OR 0.99 (0.98, 0.99), R: adjusted OR 0.99 (0.99, 
1.0) for one increment in the deprivation score (ranging from 
0: least deprived to 80: most deprived) #St 
Dejardin* [172] 
(France, 2008) 
Carstairs index C, positive lymph nodes, 
metastasis, 1997–2000 
No receipt of chemotherapy Adjusted OR 1.31 (0.77, 1.86) 
van der Geest [158] 
(Netherlands, 2013) 
SES based on the 
Netherlands 
Institute for Social 
Research 
C, stage III, 2006–2008 Adjuvant chemotherapy SES not associated with chemotherapy receipt (SES not 
included in the multivariable model). #St, Cm, EmSx 
   
Discontinuation of adjuvant chemotherapy SES not associated with discontinuation (SES not included in 
the multivariable model). 
Hayes [162] 
(England, 2019) 
IMD C, all stages, 1999–2010 Adjuvant chemotherapy in surgical patients Adjusted OR 0.72 (0.65, 0.80) #St, Cm 
   
Chemotherapy in non-surgical patients Adjusted OR 0.44 (0.36, 0.55) #St, Cm 
Hole* [137] 
(Scotland, 2002) 
Carstairs index CR who underwent resection, 
Duke's stage A–D, 1991–1994 
Adjuvant therapy OR 0.31 (p=0.01, chi square test for trend) 
Jorgensenb [171] 
(Australia, 2014) 
SEIFA C (lymph node positive) and R 
(high-risk), 2007–2008 
Adjuvant chemotherapy for node-positive 
colon cancer 
Adjusted OR 0.97 (0.41, 2.29) #Cm, EmPr 
Kelsall* [146] 
(Australia, 2008) 
SEIFA CR, AJCC stage I–IV, 1990–1994 Adjuvant chemotherapy OR 0.79 
van Steenbergen 
[174] 
(Netherlands, 2010) 
Income C, stage III, 2001–2007 Adjuvant chemotherapy Adjusted OR 0.67 (0.50, 0.91) #St (stage IIIA–IIIC), Cm 
Lamy [132] 
(France, 2018) 
EDI CR, stage III, 2010 Adjuvant chemotherapy Adjusted OR 0.45 (0.16, 1.24) #Cm, Sp 
  
CR, stage IV, 2010 Access to KRAS testing Adjusted OR 1.42 (0.61, 3.32) #Cm, Sp 
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Table 2.10 continued 
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios (95% CI) in the most deprived group 
unless specified (reference: least deprived group) 
Lemmens* [173] 
(Netherlands, 2005) 
Mean household 
income and 
postcodes 
C, stage III, 1995–2001 Adjuvant chemotherapy Adjusted OR 0.5 (p=0.02) #St, Cm 
Lima* [139] 
(Canada, 2011) 
Median annual 
household income 
C, stage III, 2000–2005 No receipt of adjuvant chemotherapy OR 2.00 
Paterson [135] 
(Scotland, 2014) 
SIMD score CR, Duke's stage A–D, 2003–2009 Any chemotherapy (palliative or adjuvant) Adjusted OR 0.68 (0.55, 0.86) 
Pitchforth [150] 
(Scotland, 2002) 
Carstairs index CR, Duke's stage C, 1992–1996 Chemotherapy 1990–94: adjusted OR 0.73 (0.55, 0.96), 1992–1996: adjusted 
OR 0.55 (0.20, 0.90) #EmPr, Sp 
Rayson [154] 
(Canada, 2012) 
Quebec Model 
(social and material 
deprivation index) 
C (stage IIB or III) and R (stage II 
and III), 2000–2005 
Chemotherapy SES not associated with the outcome (SES not included in the 
multivariable model). #St 
   
Adjuvant chemotherapy C: OR 0.94, R: OR 0.93 
Rollet [118] 
(France, 2018) 
EDI C, stage II, III, IV, 2005–2010 Chemotherapy Adjusted OR 0.89 (0.58, 1.35) #St, Cm, Sx 
Maddison [155] 
(Canada,2012) 
Income C (stage III) and R (stage II or III), 
2001–2005 
Clinically recommended care 
(chemotherapy for colon cancer) 
Adjusted OR 0.69 (0.43, 1.10) #Cm 
Chamberlain [133] 
(England, 2015) 
IMD CR, stage IV, 2011–2013 Access to cancer drug fund OR 0.43 (p=0.001, chi square test for trend) 
Crawford [125] 
(England, 2012) 
IMD CR, stage I–IV, 1994–2002 Chemotherapy for stage IV C: adjusted OR 0.45 (0.27, 0.77), R: adjusted OR 0.73 (0.36, 
1.50) 
Meulenbeld* [134] 
(Netherlands, 2008) 
SES (not 
mentioned) 
C, stage IV, 1990–2004 Chemotherapy 1990–94: OR 0.50, 1995-95: OR 0.41, 2000–02: OR 0.57, 2003–
04: OR 0.94 
Abbreviations: 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; C, colon cancer; CR, colorectal cancer; EDI, European Deprivation Index; HR, hazard ratio; IMD, Index 
of Multiple Deprivation; OR, odds ratio; R, rectal cancer; SIMD, Scottish Index of Multiple Deprivation; SEIFA, Socio-Economic Indexes for Areas; SES, socioeconomic status.* has analysis on 
mortality or survival. # shows important factors adjusted in each multivariable model. Cm, comorbidities; EmPr, mode of presentation/admission (emergency or not); EmSx, urgency of surgery (elective 
or emergency); Sp, speciality/type of surgeon/hospital or surgical/hospital volume; St, stage; Sx, use/type of surgery.  
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Table 2.11 Description of socioeconomic variations in receipt of radiotherapy 
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios (95% CI) in the most deprived group 
unless specified (reference: least deprived group) 
Campbell [159] 
(Scotland, 2002) 
Carstairs index CR, Duke's stage A–D, 1995–1996 Radiotherapy Adjusted OR 0.85 (0.38, 1.91) #St 
Jones [163] 
(England, 2008) 
IMD CR, stage I–IV, 1994–2002 Radiotherapy C: adjusted OR 0.99 (0.99, 1.0), R: adjusted OR 0.99 (0.99, 1.0) 
for one increment in the deprivation score (ranging from 0: 
least deprived to 80: most deprived) #St 
Beckman [160] 
(Australia, 2014) 
SEIFA R, Duke’s stage B–C, 2003–2008 Radiotherapy Adjusted OR 1.38 (1.05, 1.81) #St, Cm 
Jorgensenb [171] 
(Australia, 2014) 
SEIFA C (lymph node positive) and R 
(high-risk), 2007–2008 
Adjuvant radiotherapy for high-risk rectal 
cancer 
SES not associated with the outcome (SES not included in the 
multivariable model) #St, Cm, Sx 
Kelsall* [146] 
(Australia, 2008) 
SEIFA CR, AJCC stage I–IV, 1990–1994 Adjuvant radiotherapy OR 1.39 
Maddison [155] 
(Canada, 2012) 
Income C (stage III) and R (stage II or III), 
2001–2005 
Clinically recommended care 
(chemotherapy and radiotherapy in rectal 
cancer) 
Adjusted OR 0.69 (0.43, 1.10) #Cm 
Vulto [175] 
(Netherlands, 2007) 
Mean household 
income 
R, stage I–IV, 1996–2000 Secondary radiotherapy Adjusted OR 1.11 (0.77, 1.67) #St, Cm 
Olsson [136] 
(Sweden, 2011) 
Income R, stage I– IV, 1995–2005 Neoadjuvant radiotherapy Adjusted OR 0.76 (0.67, 0.86) #St, Sp 
   
Neoadjuvant radiotherapy by age groups –65 years: adjusted OR 0.62 (0.49, 0.77), 66–79 years: 
adjusted OR 0.78 (0.65, 0.93), 80–years: adjusted OR 0.70 
(0.49, 1.02) #St, Sp    
Neoadjuvant radiotherapy by 
sublocalisation (distance from anal verge) 
0–5 cm: adjusted OR 0.72 (0.57, 0.91), 6–10 cm: adjusted OR 
0.81 (0.67, 0.98), 11–15 cm: adjusted OR 0.72 (0.58, 0.91) #St, 
Sp    
Neoadjuvant radiotherapy by sex Men: adjusted OR 0.78 (0.66, 0.93), women: adjusted OR 0.68 
(0.55, 0.83) #St, Sp 
Paterson [135] 
(Scotland, 2014) 
SIMD score R, Duke's stage A–D, 2003–2009 Neoadjuvant radiotherapy OR 1.09 (p=0.75, chi square test for trend) 
Radwan* [169] 
(Wales, 2016) 
WIMD R, all TNM stage who underwent 
pelvic exenteration, 2006–2014 
Neoadjuvant therapy OR 1.00 (p=0.69, chi square test for overall) 
Abbreviations: 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; C, colon cancer; CR, colorectal cancer; EDI, European Deprivation Index; HR, hazard ratio; IMD, Index 
of Multiple Deprivation; OR, odds ratio; R, rectal cancer; SIMD, Scottish Index of Multiple Deprivation; SEIFA, Socio-Economic Indexes for Areas; SES, socioeconomic status; WIMD, Welsh Index 
of Multiple Deprivation.* has analysis on mortality or survival. # shows important factors adjusted in each multivariable model. Cm, comorbidities; Sp, speciality/type of surgeon/hospital or 
surgical/hospital volume; St, stage; Sx, use/type of surgery.  
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Table 2.12 Description of socioeconomic differences in postoperative mortality or survival  
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios (95% CI) or survival in the most deprived 
group unless specified (reference: least deprived group) 
Bharathan [120] 
(England, 2011) 
IMD CR, Duke's stage A–D who 
underwent surgery, 1998–2002 
Postoperative 30-day mortality Adjusted OR 1.39 (0.51, 2.08) #St, ASA, EmSx, Sx 
   
5-year overall survival (entry: start of Sx) Adjusted HR 1.20 (1.05, 1.37) #St, ASA, EmSx, Sx    
5-year net survival (entry: start of Sx) Adjusted EHR 1.35 (1.05, 1.72) #St, ASA, EmSx, Sx 
Jorgensena [142] 
(Australia, 2014) 
SEIFA CR, all stage who underwent 
surgery, 2007–2008 
30-day all-cause mortality SES not associated with the outcome (SES not included in the 
multivariable model) #St, Cm, EmPr    
1-year overall mortality (entry: Sx) SES not associated with the outcome (SES not included in the 
multivariable model) #St, Cm, EmPr 
Dik [143] 
(Netherlands, 2014) 
Mean household 
income and 
postcodes 
CR, stage I–III who underwent 
surgery, 2005–2010 
30-day postoperative mortality C: adjusted OR 1.11 (0.64, 1.96) St, Cm, EmSx, R: adjusted OR 
1.67 (0.56, 4.76) #St, Cm 
Harris [121] 
(England, 2009) 
IMD R, stage I–IV, 2001–2004 Perioperative death OR 1.40 (p=1.00, Fisher's exact test) 
   
Survival after resectional surgery (3-year, 
5-year) 
3-year: 85.0% in the least deprived, 74.6% in the most 
deprived, 5-year: 72% in the least deprived, 49.9% in the most 
deprived (p=0.03, log-rank test) 
Hole [137] 
(Scotland, 2002) 
Carstairs index CR, Duke's stage A–D who 
underwent resection, 1991–1994 
Postoperative 30-day mortality for patients 
who underwent curative resection 
OR 1.24 (p=0.41, chi square test for trend) 
   
Postoperative 30-day mortality for patients 
who underwent palliative resection 
OR 1.18 (p=0.98, chi square test for trend) 
   
5-year overall survival for patients who 
underwent curative resection 
Adjusted HR 1.36 (1.09, 1.69) #St, EmPr 
   
5-year cancer-specific survival who 
underwent curative resection 
Adjusted HR: 1.26 (0.95, 1.67) #St, EmPr 
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Table 2.12 continued 
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios (95% CI) or survival in the most deprived 
group unless specified (reference: least deprived group) 
Oliphant [141] 
(Scotland, 2013) 
SIMD score CR, Duke's stage A–D who 
underwent surgery, 2001–2004 
Postoperative 30-day mortality from any 
cause 
Adjusted OR 2.26 (1.45, 3.53) #St, EmPr, Sx, Sp 
   
5-year net survival (entry: Sx) Adjusted relative excess risk 1.25 (1.03, 1.51) #St, EmPr, Sx, Sp 
Smith [122] 
(England, 2006) 
Townsend score CR, Duke's stage A–D who 
underwent surgery, 2001–2002 
Postoperative mortality Adjusted OR 1.02 (p=0.14) per unit increase in SES #St, ASA, 
EmSx, Sx 
Tilney [166] 
(England, 2008) 
IMD CR who underwent APER or SR, no 
information on stage, 1996–2004 
Postoperative 30-day mortality AR: OR 1.21 (p=0.004, chi square for trend), APER: 1.31 
(p=0.058, chi square test for trend) 
Tilney [167] 
(England, 2009) 
IMD R, Duke's stage A–C who 
underwent APER or AR, 2000–2005 
Postoperative 30-day mortality AR: OR 1.53 (p=0.058, chi square test for trend), APER: OR 1.04 
(p=0.90, chi square test for trend) 
Del Paggio [138] 
(Canada, 2017) 
SES based on 
Canadian census 
C, stage II or III, 2002–2008 Overall survival (entry: Sx) Stage II: adjusted HR 1.11 (0.89, 1.39) #St, Cm, Sx, ATx, Sp, 
stage III: adjusted HR 0.99 (0.84, 1.17) #St, Cm, Sx, ATx, Sp 
   Cancer-specific survival (entry: Sx) Stage II: adjusted HR 0.98 (0.73, 1.32) #St, Cm, Sx, ATx, Sp, 
stage III: adjusted HR 1.00 (0.82, 1.21) #St, Cm, Sx, ATx, Sp 
Lima [139] 
(Canada, 2011) 
Median annual 
household income 
C, stage III, 2000–2005 Overall survival (entry: 16 weeks after Sx) Adjusted HR 1.14 (0.77, 1.68) #Cm, TmCTx 
   Cancer-specific survival (entry: 16 weeks 
after Sx) 
Adjusted HR 0.98 (0.63, 1.54) #Cm, TmCTx 
Radwan [169] 
(Wales, 2016) 
WIMD R, all TNM stage who underwent 
pelvic exenteration, 2006–2014 
5-year survival (entry: Sx) 73% in the least deprived, 53% in the most deprived (p=0.015, 
log-rank test) 
Noren [130] 
(Sweden, 2016) 
Income CR, stage IV (synchronous liver-only 
metastasis), 2007–2011 
5-year overall survival (entry: Sx for 
primary lesion) 
Adjusted HR 1.02 (0.90, 1.16) #ASA, Cm, Sx (liver resection), Sp 
Redaniel [140] 
(England, 2014) 
IMD CR who underwent major 
resection, Duke’s stage A–B, 1996–
2009 
Postoperative 5-year relative survival 
(entry: Sx) 
Adjusted EHR 1.29 (1.13, 1.46) #St, TmSx 
Abbreviations: 95% CI, 95% confidence interval; APER, abdominoperineal excision of rectum; AR, anterior resection; C, colon cancer; CR, colorectal cancer; EDI, European Deprivation Index; HER, 
excess hazard ratio; HR, hazard ratio; IMD, Index of Multiple Deprivation; OR, odds ratio; R, rectal cancer; SIMD, Scottish Index of Multiple Deprivation; SEIFA, Socio-Economic Indexes for Areas; 
SES, socioeconomic status; Sx, surgery; WIMD, Welsh Index of Multiple Deprivation. # shows important factors adjusted in each multivariable model. ASA, ASA (American Society of 
Anesthesiologists) grade; ATx, use of adjuvant therapy; Cm, comorbidities; EmPr, mode of presentation/admission (emergency or not); EmSx, urgency of surgery (elective or emergency); Sp, 
speciality/type of surgeon/hospital or surgical/hospital volume; St, stage; Sx, use/type of surgery; TmCTx, time to chemotherapy; TmSx, time to major resection.  
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Table 2.13 Description of socioeconomic differences in survival 
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios (95% CI) or survival in the most deprived 
group unless specified (reference: least deprived group) 
Meulenbeld [134] 
(Netherlands, 2008) 
SES (not 
mentioned) 
C, stage IV, 1990–2004 Overall survival Adjusted HR 1.02 (0.91, 1.15) #Cm, CTx 
Lemmens [173] 
(Netherlands, 2005) 
Mean household 
income and 
postcodes 
C, stage III, 1995–2001 Overall survival Adjusted HR 1.00 (p=0.9) #St, Cm, CTx 
Dejardin [172] 
(France, 2008) 
Carstairs index C, positive lymph nodes, 
metastasis, 1997–2000 
Overall survival Adjusted relative risk 0.99 (0.72, 1.26) #CTx 
Kelsall [146] 
(Australia, 2008) 
SEIFA CR, AJCC stage I–IV, 1990–1994 Overall survival Adjusted HR 1.37 (1.00, 1.89) #St, ATx 
   
Cancer-specific survival Adjusted HR 1.25 (0.89, 1.75) #St, ATx 
Harris [121] 
(England, 2009) 
IMD R, stage I–IV, 2001–2004 Overall survival (3-year, 5-year) 3-year:80.7% in the least deprived, 46.6% in the most 
deprived, 5-year: 64.0% in the least deprived, 32.8% in the 
most deprived (p<0.001, log-rank test) 
Wrigley [170] 
(England, 2003) 
Townsend score CR, Duke's stage A–D, 1991–1995 Overall survival Adjusted HR 1.15 (1.04, 1.27) #St, Cm, EmSx, Sp 
   
Cancer-specific survival Adjusted HR 1.11 (0.99, 1.25) #St, Cm, EmSx, Sp 
Lejeune [126] 
(England, 2010) 
Townsend index CR, AJCC stage I–IV, 1997–2000 Excess hazard of death≤3years All patients: adjusted EHR 1.12 (1.07, 1.17), treatment within 1 
weeks: adjusted EHR 1.05 (0.96, 1.14), treatment within 1 
month: adjusted EHR 1.04 (0.95, 1.15), treatment within 2–3 
months: adjusted EHR 1.20 (1.09, 1.31), treatment within 4–6 
months: adjusted EHR 1.14 (0.93, 1.39), no treatment: 
adjusted EHR 1.15 (1.08, 1.24) # St, TmTx 
Hall [127] 
(Australia, 2005) 
IRDS CR, no stage information,1982–
2001 
5-year overall survival 1982–2001: adjusted HR 1.13 (0.98,1.31), 1991–2001: 
adjusted HR 1.13 (0.98, 1.31) #Cm, EmPr 
Helewa [119] 
(Canada, 2013) 
Income CR, AJCC stage I–IV, 2004–2006 5-year overall survival Adjusted HR 1.54 (1.14, 2.08) #St, Cm, EmPr, CTx, Tm (total 
waiting time: from index contact to first treatment)  
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Table 2.13 continued 
First author 
(country, year) 
SES Site, stage, year of study Cancer care outcome Description of ratios (95% CI) or survival in the most deprived 
group unless specified (reference: least deprived group) 
Field*[147] Index of Relative 
Socioeconomic 
Advantage and 
Disadvantage 
(IRSAD) score 
CR, AJCC stage IV, 2009–2014 5-year overall survival Adjusted HR 1.04 (0.85, 1.28) for four deprived groups 
(reference: one least deprived group) #Sp, Cm, CR, PS, Nm, Pre 
Vallance [128] 
(England, 2018) 
IMD CR, stage IV (synchronous liver-
limited metastases), 2010–2016 
3-year overall survival Adjusted HR 0.83 (0.77, 0.90) #St, Cm, CR, EmPr, Sp 
   3-year overall survival for patients who 
underwent liver resection 
Adjusted HR 1.03 (0.81, 1.32) #St, Cm, CR, EmPr, Sp 
   3-year overall survival for patients without 
liver resection 
Adjusted HR 0.86 (0.79, 0.93) #St, Cm, CR, EmPr, Sp 
t Lam-Boer [129] 
(Netherlands, 2015) 
Income CR, stage IV (synchronous liver-only 
metastasis), 2004–2012 
5-year overall survival Adjusted HR 1.08 (0.87, 1.33) #Cm, CR, Sx (liver resection), Tx 
Abbreviations: 95% CI, 95% confidence interval; C, colon cancer; CR, colorectal cancer; EDI, European Deprivation Index; EHR, excess hazard ratio; HR, hazard ratio; IMD, Index of Multiple 
Deprivation; IRDS, Index of Relative Socioeconomic Disadvantage; OR, odds ratio; R, rectal cancer; SEIFA, Socio-Economic Indexes for Areas; SES, socioeconomic status. # shows important adjusted 
factors in multivariable model. ATx, use of adjuvant therapy; Cm, comorbidities; CR, site (right/left-sided colon or rectum); CTx, use of chemotherapy; EmPr, mode of presentation/admission 
(emergency or not); EmSx, urgency of surgery (elective or emergency);Nm, number of metastatic sites; Pre, clinical or other presentation; PS, performance status; Sp, speciality/type of 
surgeon/hospital or surgical/hospital volume; St, stage; Sx, use of surgery; Tx, use of systemic treatment; TmTx, time to treatment.  
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Table 2.14 Summary of quality of studies by Newcastle-Ottawa Scale (NOS) for case-control and cohort studies 
Study Selection Comparability Outcome/Exposure Total score 
Question 1 2 3 4 1 a) 1 b) 1 2 3  
Mode of presentation 
Rollet [118] (France, 2018) * * * * * * *  * 8 
Raine [144] (England, 2010) * * * *   * * * 7 
Helewa* [119] (Canada, 2013) *  * * * * * * * * 9 
Borowski [145] (England, 2016) * * * *   * * * 7 
Hole* [137] (Scotland, 2002) * * * *   * * * 7 
Oliphant* [141] (Scotland, 2002) * * * *   * * * 7 
Bharathan [120] (England, 2011) * * * *   * * * 7 
Harris* [121] (England, 2009) *  * * *    * * 6 
Smith [122] (England, 2006) * * * *   * * * 7 
Place of treatment 
Blais [148] (France, 2006) *  * * * * * * * * 9 
Dejardin [149] (France, 2005) *  * * * *  * * * 8 
Kelsall* [146] (Australia, 2008) * * * *   *  * 6 
Kim [152] (Korea, 2010) * * * *  * * * * 8 
Pitchforth [150] (Scotland,2002) * * * *   * * * 7 
Field [147] (Australia, 2015) * * * *   * * * 7 
Vallance [151] (England, 2017) * * * *   * * * 7 
Borowski [145] (England, 2016) * * * *   * * * 7 
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Table 2.14 continued 
 Selection Comparability Outcome/Exposure Total score 
 1 2 3 4 5 6 7 8 9  
Time to treatment 
Maddison [155] (Canada, 2012) *  * * * * * * * * 9 
Moriceau [157] (France, 2016) *  * * * * * * * * 9 
Neal [123] (England, 2005)  * * *    *  4 
Porter [124] (Canada, 2005)    *    *  2 
Bardell [153] (Canada, 2006) * * * *   * * * 7 
Campbell [159](Scotland, 2002) * * * * *  * * * 8 
Chamberlain [133] (England, 2015) * * * * *  * *  7 
Jorgensen a* [142] (Australia, 2014) *  * * * * * * * * 9 
Paterson [135] (Scotland, 2014) *  * * * *  * * * 8 
Lejeune* [126] (England, 2010) *  * * * *  * * * 8 
Johnston [156] (Canada, 2004) *  * * * *  * * * 8 
Lima* [139] (Canada, 2011) *  * * * * * * * * 9 
van der Geest [158] (Netherlands, 2013) *  * * * * * * * * 9 
Maddison [155] (Canada, 2012) *  * * * * * * * * 9 
Rayson [154] (Canada, 2012) *  * * * * * * * * 9 
Helewa* [119] (Canada, 2013) *  * * * * * * * * 9 
Redaniel* [140] (England, 2014) *  * * * *  * * * 8 
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Table 2.14 continued 
 Selection Comparability Outcome/Exposure Total score 
 1 2 3 4 5 6 7 8 9  
Any treatment 
Crawford [125] (England, 2012) * * * * *  * * * 8 
Lejeune* [126] (England, 2010) *  * * * *  * * * 8 
Maddison [155] (Canada, 2012) *  * * * * * * * * 9 
Jorgensena* [142] (Australia, 2014) *  * * * * * * * * 9 
Rollet [118] (France, 2018) * * * * * * *  * 8 
Beckman [160] (Australia, 2014) * * * * * * * * * 9 
Surgical treatment 
Campbell [159] (Scotland, 2002) *  * * * *  * * * 8 
Hayes [162] (England, 2019) * * * * * * * * * 9 
Beckman [160] (Australia, 2014) * * * * * * * * * 9 
Hall [127] (Australia, 2005) *  * * *  * * * * 8 
Jones [163] (England, 2008) *  * * * *  * * * 8 
Rollet [118] (France, 2018) * * * * * * * * * 9 
Paterson [135] (Scotland, 2014) *  * * * *  * * * 8 
Harris* [121] (England, 2009) *  * * *    * * 6 
Bharathan* [120] (England, 2011) * * * * * * * * * 9 
Olsson [161] (Sweden, 2010) *  * * * *  * * * 8 
Morris [131] (England, 2010) * * * * * * * * * 9 
Vallance* [128] (England, 2018) * * * * * * * * * 9 
t Lam-Boer* [129] (Netherlands, 2015) * * * * * * * * * 9 
Noren [130] (Sweden, 2016) * * * * * * * * * 9 
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Table 2.14 continued 
 Selection Comparability Outcome/Exposure Total score 
 1 2 3 4 5 6 7 8 9  
Type of surgery 
Hole* [137] (Scotland, 2002) * * * *   * * * 7 
Oliphant* [141] (Scotland, 2013) * * * *   * * * 7 
Radwan* [169] (Wales, 2016) * * * *   * * * 7 
Dolet [164] (France, 2019) * * * * *  * * * 8 
Harris* [121] (England, 2009) * * * *    * * 6 
Paterson [135] (Scotland, 2014) * * * * *  * * * 8 
Morris [165] (England, 2008) * * * * * * * * * 9 
Olsson [161] (Sweden, 2010) * * * * *  * * * 8 
Raine [144] (England, 2010) * * * * *  * * * 8 
Smith* [122] (England, 2006) * * * *   * * * 7 
Tilney* [166] (England, 2008) * * * *   * * * 7 
Tilney* [167] (England, 2009) * * * *   * * * 7 
Byrne [168] (England, 2018) * * * *   * * * 7 
Dik* [143] (Netherlands, 2014) * * * * * * * * * 9 
Del Paggio* [138] (Canada, 2017) * * * * * * * * * 9 
Lamy [132] (France, 2018) * * * * * * * * * 9 
Rollet [118] (France, 2018) * * * * * * *  * 8 
Wrigley* [170] (England, 2003) * * * *   * * * 7 
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Table 2.14 continued 
 Selection Comparability Outcome/Exposure Total score 
 1 2 3 4 5 6 7 8 9  
Receipt of chemotherapy 
Campbell [159] (Scotland, 2002) * * * * *  * * * 8 
Beckman [160] (Australia, 2014) * * * * * * * * * 9 
Jones [163] (England, 2008) * * * * *  *  * 7 
Dejardin* [172] (France, 2008) * * * *   *  * 6 
van der Geest [158] (Netherlands, 2013) * * * * * * * * * 9 
Hayes [162] (England, 2019) * * * * * * * * * 9 
Hole* [137] (Scotland, 2002) * * * *   * * * 7 
Jorgensenb [171] (Australia, 2014) * * * * * * *  * 8 
Kelsall* [146] (Australia, 2008) * * * *   *    * 6 
van Steenbergen [174] (Netherlands, 2010) * * * * * * *  * 8 
Lamy [132] (France, 2018) * * * * * * *  * 8 
Lemmens* [173] (Netherlands, 2005) * * * * * * * * * 9 
Lima* [139] (Canada, 2011) * * * * * * * * * 9 
Paterson [135] (Scotland, 2014) * * * * *  *  * 7 
Pitchforth [150] (Scotland, 2002) * * * * *  * * * 8 
Rayson [154] (Canada, 2012) * * * * * * * * * 9 
Rollet [118] (France, 2018) * * * * * * *  * 8 
Maddison [155] (Canada,2012) * * * * * * * * * 9 
Chamberlain [133] (England, 2015) * * * * *  * *  7 
Crawford [125] (England, 2012) * * * * *  * * * 8 
Meulenbeld* [134] (Netherlands, 2008) * * * *   *  * 6 
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Table 2.14 continued 
 Selection Comparability Outcome/Exposure Total score 
 1 2 3 4 5 6 7 8 9  
Receipt of radiotherapy 
Campbell [159] (Scotland, 2002) * * * * *  * * * 8 
Jones [163] (England, 2008) * * * * *  *  * 7 
Beckman [160] (Australia, 2014) * * * * * * * * * 9 
Jorgensenb [171] (Australia, 2014) * * * * * * *  * 8 
Kelsall* [146] (Australia, 2008) * * * *   *    * 6 
Maddison [155] (Canada, 2012) * * * * * * * * * 9 
Vulto [175] (Netherlands, 2007) * * * * * * * * * 9 
Olsson [136] (Sweden, 2011) * * * * *  * * * 8 
Paterson [135] (Scotland, 2014) * * * * *  *  * 7 
Radwan* [169] (Wales, 2016) * * * *   * * * 7 
Postoperative mortality or survival 
Bharathan [120] (England, 2011) * * * * * * * * * 9 
Jorgensena [142] (Australia, 2014) * * * * * * * * * 9 
Dik [143] (Netherlands, 2014) * * * * * * * * * 9 
Harris [121] (England, 2009) * * * *    * * 6 
Hole [137] (Scotland, 2002) * * * * *  * * * 8 
Oliphant [141] (Scotland, 2013) * * * * *  * * * 8 
Smith [122] (England, 2006) * * * * * * * * * 9 
Tilney [166] (England, 2008) * * * *   * * * 7 
Tilney [167] (England, 2009) * * * *   * * * 7 
Del Paggio [138] (Canada, 2017) * * * * * * * * * 9 
Lima [139] (Canada, 2011) * * * * * * * * * 9 
Radwan [169] (Wales, 2016) * * * *   * * * 7 
Noren [130] (Sweden, 2016) * * * * * * * * * 9 
Redaniel [140] (England, 2014) * * * * *  * * * 8 
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Table 2.14 continued 
 Selection Comparability Outcome/Exposure Total score 
 1 2 3 4 5 6 7 8 9  
Survival 
Meulenbeld [134] (Netherlands, 2008) * * * * * * * * * 9 
Lemmens [173] (Netherlands, 2005) * * * * * * * * * 9 
Dejardin [172] (France, 2008) * * * * *  * * * 8 
Kelsall [146] (Australia, 2008) * * * * *  * * * 8 
Harris [121] (England, 2009) * * * *    * * 6 
Wrigley [170] (England, 2003) * * * * * * * * * 9 
Lejeune [126] (England, 2010) * * * * *  * * * 8 
Hall [127] (Australia, 2005) * * * *  * * * * 8 
Helewa [119] (Canada, 2013) * * * * * * * * * 9 
Field [147] (Australia, 2015) * * * * * * * * * 9 
Vallance [128] (England, 2018) * * * * * * * * * 9 
t Lam-Boer [129] (Netherlands, 2015) * * * * * * * * * 9 
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2.1.3 Discussion 
Socioeconomic variations in access to treatment were observed widely. This review revealed 
that treatment receipt was generally lower in the deprived groups in terms of surgery, 
chemotherapy and radiotherapy. Also, emergency presentation was likely to be more frequent 
among the deprived groups. Although definitions of SES and categorisation varied by countries 
and over time, persistent inequalities in access to treatment were found. As in line with previous 
reviews on time to treatment [176, 177], this review found a wide diversity in the definition of 
‘delay’. The reported outcome also differed by studies (e.g. days, HRs, ORs at a cut-off time); 
therefore, the studies were not easily comparable and pooling (i.e. meta-analysis) was not 
possible. 
The relationship between time interval (expressed as ‘delay’) to diagnosis or treatment and 
survival was explored in a recent meta-analysis, concluding that the delay was not associated 
with survival [176]. However, in quality assessment by NOS, some studies included in that 
meta-analysis were low quality (with less than 7 stars). There is no clear definition of ‘delay’. 
Although meta-analysis was not conducted in this thesis, evidence for the association between 
diagnostic or therapeutic ‘delay’ and survival is inconclusive. 
After 2010, socioeconomic inequalities in receipt of liver resection for stage IV CRC have 
begun to be reported. Indications for liver resection started to change in the 1990s [178, 179] 
and currently, candidates for liver resection include some complicated cases (e.g. patients with 
extrahepatic disease or multiple liver metastases) [180]. However, some of these complications 
are continuously reported to be associated with for poorer survival. The known clinical 
prognostic factors include tumour grade, number of liver metastases and tumour size [178, 179, 
181]. Synchronous over metachronous liver metastasis is also related to worse outcome [182, 
183]. In Japan, involvement of hepatic hilar lymph nodes is considered to be associated with 
worse survival [184]. In the literature, only three (out of five articles) confined the study 
population to synchronous liver metastasis, but no studies controlled for the positivity of the 
hepatic hilar lymph nodes. Considering that the studies are population-based data, it might be 
difficult to obtain detailed clinical factors. 
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Most studies used population-based data. Therefore, regarding quality of study assessed by 
NOS, selection of the study population and definition of the outcome were clearly stated in 
general. Mostly, missingness in the vital status was low (<10%), which reflects the 
characteristic of the population-based data. Follow-up period to observe an outcome was less 
articulated in receipt of chemotherapy. Stage and comorbidities are essential information for 
receipt of treatment, and majority studies controlled for these variables. 
Because the aim of this review is to assess differential receipt of treatment by SES, some 
important reports were excluded. One study reported postoperative 30-day morality by SES, but 
not reporting variations in receipt of treatment by SES, thus excluded [107]. One study reported 
failure-to-rescue by laparoscopic vs open surgery [168] but not by SES, thus not included. 
Pooling of the results was not done; meta-analysis carries risks of comparing studies that are not 
comparable, and random effects may disregard the problem of heterogeneity (for example 
between countries) [185]. 
Evidence of socioeconomic inequalities in postoperative mortality suggests that the quality of 
care/hospital may differ among SES groups [106, 107, 186]. Even after being adjusted for stage 
and treatment factors, inequalities in long-term survival remained. This fact implies that there 
may be other unmeasured factors, which confound the effect of SES on survival. Of the 
reviewed studies, one study on survival controlled for three treatment factors (receipt/type of 
surgery, adjuvant chemotherapy and hospital volume) [138]. The study provided evidence that 
the hazard of the deprived groups is not inferior to that of the affluent group if patient factors 
(age, comorbidities), tumour factors (site and stage) and all potential treatment factors (receipt 
of surgery, adjuvant therapy and hospital volume) were controlled. A report on survival 
comparing England and France also showed that the survival difference between the two 
countries was nullified when all treatment receipt (surgery, chemotherapy and radiotherapy use) 
were controlled [187]. From the fact that inequalities in access to cancer care were observed in 
all treatment steps, other studies on survival found in this review may have marked weaker 
socioeconomic gradient if the other unmeasured treatment factors were adjusted. 
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Treatment is influenced by tumour and patient factors such as stage and comorbidities; 
nevertheless, the findings of this review represented differential access in important steps of 
treatment through the CRC care. The effect of one differential treatment giving on survival 
inequalities may amplify as a patient goes through neoadjuvant therapy, surgery and adjuvant 
therapy.  
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Chapter 3: Data materials and methods 
3.1 Data acquisition and ethics approval 
For this thesis, I use population-based cancer registry data from England, held by the Cancer 
Survival Group (CSG) at the London School of Hygiene & Tropical Medicine (LSHTM). All 
ethics and statutory approvals, for data access and analyses in England, have been obtained by 
the CSG (LSHTM Ethics Reference 11984). 
I use hospital-based cancer registry data and administrative data from Japan, held by Osaka 
University Hospital (OUH). Ethics approval was obtained by Dr Yuri Kitamura at OUH (OUH 
Ethics Reference 18127), and by the author of this thesis at the LSHTM (LSHTM Ethics 
Reference 16219). Letters of the ethics approvals are attached in Appendix 2. 
3.2 Study settings 
3.2.1 England 
Study population 
Residents in England, who were diagnosed with a primary colon or rectal cancer between 
January 2010 and March 2013 and followed up until the end of 2014, were included. Inclusion 
criteria were CRC (coded by the International Classification of Diseases tenth version: ICD-10 
with C18, C19 and C20) of any histological type and age at diagnosis younger than 100 years 
old. Tis (carcinoma in situ) was excluded from the analysis. Vital status, socioeconomic status, 
date of birth, date of death, sex, tumour site (coded by ICD-10) and stage at diagnosis were 
obtained from the national cancer registry (Office for National Statistics: ONS) in England. 
These data were linked to Cancer Analysis System (CAS) data, National Bowel Cancer Audit 
(NBOCA) data and Hospital Episode Statistics (HES) data. CAS data provide information on 
pathology (histology and tumour grade). Histology and tumour grade recorded on CAS were 
included in analysis to explore any biological variations among different SES groups, since 
tumour grade independently affects survival from stage. NBOCA data record information on 
clinical diagnosis (date), referral (routes to diagnosis and date), screen-detected cancer or not, 
clinical staging, treatment and pathology (histology and tumour grade). HES provides 
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information on referral (routes to diagnosis and date), treatment (date and type of procedures 
coded by the Office of Population Censuses and Surveys fourth version: OPCS-4, Classification 
of Interventions and Procedures) and comorbidities. 
Stage information (the fifth edition of UICC TNM Classification [188]) was finally derived by a 
restrictive approach using both national cancer registry data and NBOCA data [189]. Histology 
and tumour grade were derived from CAS data and categorised into three and two groups, 
respectively (Appendix 3 shows histology categorisation). Emergency presentation before the 
first definitive treatment (i.e. emergency presentation recorded at the time of diagnosis or the 
time of the first major surgery for the primary lesion) was derived from routes to diagnosis 
recorded in NBOCA data and supplemented by HES data. Information on the first major 
surgery for the primary lesion (dates and type of surgery procedure) was also derived from 
NBOCA data and supplemented by HES data. Appendix 4 and Appendix 5 shows the type of 
surgery defined as major surgery for the primary lesion in this thesis. Surgery information was 
extracted from 30 days before to 180 days after the diagnosis date. Hospital record has a 
maximum of 20 diagnostic fields; thus, 17 comorbidities defined in Charlson Index and obesity 
were extracted from HES based on an algorithm [190, 191]. 
Income domain of the Index of Multiple Deprivation (IMD 2010) was used for deriving 
information on deprivation level of patients, according to their residence at the time of cancer 
diagnosis. The Index is an ecological measure defined at lower-layer super output area (LSOA) 
level (1,500 inhabitants on average) [192]. 
Comorbidities 
When measuring the quality of cancer care and outcomes, comorbidities are one of the most 
important factors which may relate to both cancer care outcomes and survival. Comorbidities 
can be defined as important medical conditions not related to the main cause of hospitalisation 
(in this thesis, CRC), but may lead to a poorer outcome [193]. I extracted the comorbidities that 
were recorded from five to zero years before the diagnosis of CRC. 
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Comorbidities, which appeared on HES at least once between 0.5 and five years before 
diagnosis, were categorised as chronic comorbidities. Comorbidities, which were recorded for 
the first time, between the date of diagnosis and 0.5 years before diagnosis, were categorised as 
acute comorbidities. Unlike the Charlson Index, comorbidities were not assigned weight but 
were just counted. 
Of the 17 comorbidities, I further selected ten and 14 comorbidities for the chronic and acute 
comorbidities, respectively, based on its clinical relevance to CRC treatment [191, 193] 
(Appendix 6). 
Comorbidities not directly related to CRC but which imply irreversible conditions of vital 
organs (brain, heart, lung, liver, kidney, immune system or vascular system), which may affect 
the timeline of or selection of CRC treatment (e.g. invasive or less invasive treatment, curative 
or palliative treatment), were chosen as chronic comorbidities. Obesity was included 
independently in acute phase only (0 to 0.5 years before CRC diagnosis) since body mass index 
(BMI) is a time-varying variable (i.e. reversible condition) and may confound with stage at 
diagnosis (e.g. patients with advanced stage may have suddenly lost weight just before the 
diagnosis and record low BMI). 
3.2.2 Japan 
Study population 
Residents in Osaka Prefecture, who were diagnosed with colon or rectal cancer at Osaka 
University Hospital (OUH) between January 2012 and December 2015 and followed up until 
the end of July 2018, were included in the analysis. The OUH is one of the DCHs, which sits in 
the north of Osaka Prefecture. The OUH has approximately 1,000 beds in total, with around 100 
beds for the gastrointestinal surgery unit and 29 beds for the intensive care unit (ICU). 
Inclusion criteria were primary CRC of any histological type and age at diagnosis younger than 
100 years old. Tis (carcinoma in situ) was excluded from the analysis. Vital status, date of birth, 
date of death, sex, tumour site (coded by ICD-10) were obtained from the hospital-based cancer 
registry in OUH. Hospital-based cancer registry data also provide information on pathology 
(histology and tumour grade), information on clinical diagnosis (date of diagnosis, place of 
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diagnosis), referral route, clinical staging, treatment (open or laparoscopic surgery, 
chemotherapy and radiotherapy at OUH, coded by yes/no) at the institution. Date of diagnosis is 
defined as the date of the first diagnostic test (endoscopy) conducted. If a patient received a 
diagnostic test in other clinics or hospitals before consultation at OUH, the date of the 
diagnostic test in the other clinics is recorded. The UICC TNM staging is not used in clinical 
settings in Japan. Instead, Japanese Classification of Colorectal Carcinoma seventh edition 
[194] (eighth edition for the cases diagnosed after July 2013 [195]) is used. The Japanese 
Classification was converted to UICC TNM stages (seventh edition [196]) first, then to four 
stages (localised, positive regional lymph nodes, invasion to adjacent organs and distant 
metastasis). The dataset was linked to Diagnostic Procedure Combination (DPC) data at OUH. 
DPC data were missing for 24.1% of CRC patients who were registered in the hospital-based 
cancer registry. DPC data provide detailed information on treatment (date and types of 
procedures coded by medical fee points), emergency admission, use of ICU, height and weight, 
activities of daily living (ADL), Brinkman index and comorbidities present at admission. 
Operation codes, extracted as major surgery for the primary lesion, are listed in Appendix 7. 
Information on treatment was not restricted to procedures for CRC but extracted also for any 
other co-existing diseases. Nor was the period of the extraction of treatment information 
restricted from 30 days before diagnosis to 180 days after diagnosis, as in England. 
The relative measure of SES, the area deprivation index (ADI) in Osaka Prefecture divided into 
quintiles, was linked to the hospital-based cancer registry data. A national census is performed 
every five years and contains data for income, education and employment status. Ecological 
deprivation information was constructed using the national census and Japanese General Social 
Survey (JGSS) data, defined at ‘Cho-Aza’ level (3,000 inhabitants on average) [197]. 
Comorbidities 
Comorbidities were coded by ICD-10 for up to four concurrent diseases in the DPC data. As 
was done for data in England, 14 acute comorbidities were selected based on the Charlson Index 
and Elixhauser’s comorbidity scoring system [191, 193, 198], and the number of the 
comorbidities was counted. Information on chronic comorbidities (i.e. coded five years to six 
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months before CRC diagnosis) was not used since no such data is available in Japan. In addition 
to the acute comorbidities, Brinkman index (number of cigarettes per day times number of years 
of smoking), BMI and ADL were analysed.  
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3.3 Statistical analysis 
Stata 14 (StataCorp, College Station, TX, US) was used for all analyses. Details of the statistical 
methods are described in each chapter. An extended analysis, called mediation analysis, is used 
in Chapter 4.5 under the causal inference framework. 
Mediation analysis is useful when one wants to not only measure the magnitude of the causal 
effect of an exposure variable on an outcome but also isolate the causal effect(s) passing via 
mediator(s). For instance, in this thesis, I aim to measure the magnitude of the effect of an 
exposure variable, SES, on an outcome (survival status), mediated by a patient factor 
(comorbidities), a tumour factor (stage) and a healthcare system factor (receipt of treatment). 
The simplified example is shown in a directed acyclic graph (DAG) (Figure 3.1). 
Figure 3.1 Example of DAG in mediation analysis 
The stage at diagnosis and comorbidities could be affected by SES, and act as exposure-induced 
mediator-outcome confounders. Treatment could act as a mediator between SES and survival 
status, affected by SES, comorbidities and stage. Age at diagnosis, sex, year of diagnosis are the 
baseline confounders (not shown in Figure 3.1). I applied g-computation for the mediation 
analysis, initially developed by Robins to address the issue of a mediator being affected by 
exposure [199, 200]. The final models in Chapter 4.5 have multiple mediators. When multiple 
mediators exist, the effect of the mediators will be measured jointly [201, 202].  
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3.3.1 Mediation analysis under the causal inference framework 
Evaluation of causal effects needs to compare factual and counterfactuals. Factual refers to the 
fact outcomes that actually happened, and counterfactuals refer to potential outcomes that 
people would have experienced if they had taken a different path. I present definitions with 
examples. 
Total causal effect 
The total causal effect (TCE) of SES on survival variation at a population level can be 
decomposed in natural direct and indirect effect. 
Y(X) stands for the outcome: survival status Y, when SES is set at X. If we denote X=1 as the 
SES set as the most deprived, and X=0 as the least deprived, individual causal effect of the SES 
is defined as Y(1)-Y(0). 
The average causal effect in the population is defined as E{Y(1)-Y(0)} and it represents TCE of 
SES on survival status. 
Natural direct effect 
Natural direct effect (NDE) is defined as an effect of SES (X) on survival status (Y), when 
mediators (denoted as M, treatment: e.g. receipt of major surgery for the primary lesion) set as a 
natural value of M(x*) under X=x*. The NDE is the effect unmediated by M, thus, in a simple 
example, the NDE is the effect of SES on survival status unmediated by healthcare system 
factors. 
NDE=E{Y(x, M(x*))}-E{Y(x*, M(x*))} 
Natural indirect effect 
Natural indirect effect (NIE) is defined as an effect of SES (X) on survival status (Y) mediated 
by M (healthcare system factors). We compare two hypothetical worlds with the reference 
condition of X set as x and compare M(x) and M(x*). 
NIE=E{Y(x, M(x))}-E{Y(x, M(x*))} 
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Proportion mediated 
The proportion of the total effect which healthcare system factors mediate, are measured by 
proportion mediated (PM). 
PM=NIE/TCE 
The PM quantifies how much of the total causal effect (effect of SES on survival status) is due 
to the effect of the mediated pathway (effect of SES on the mediator: treatment) [203]. 
Assumptions 
There are several assumptions for mediation analysis. 
• Conditional exchangeability: conditional on the observed confounders (e.g. same age 
group), the allocation to SES is random in the age group. Once patients are stratified by 
SES and age group, their allocation to mediators (e.g. receipt of major surgery) is 
random within these strata. 
• Positivity: each level of mediator(s) can be observed at every level of the confounders. 
• No unmeasured confounding between mediators and outcome in order to identify the 
path-specific effects. 
• No interference between patients: a patient’s mediator level is not affected by the 
mediator level of other patients. A patient’s mediator level does not affect the outcome 
of other patients. For example, the option in receipt of surgery by a patient does not 
influence the outcome (survival status) of another. 
• Consistency: the observed (factual) outcome of a patient receiving treatment is equal to 
the potential (counterfactual) outcome of a patient assigned to the same treatment [204, 
205]. 
• Correct model specification of outcome or mediators. 
Detailed models of the mediation analysis are explained in Chapter 4.5 with DAGs.  
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Chapter 4: Colorectal cancer in England 
Chapter 4 explored socioeconomic inequalities in both care and survival of CRC patients in 
England. In Chapter 4.1, I examined socioeconomic variations in receipt of major surgery. In 
Chapter 4.2, I confined the study population to the patients who received major surgery and 
explored whether there was a difference by SES in postoperative 30-day mortality. Chapter 4.3 
explored general patterns of mortality rate and survival by five SES groups not controlling for 
other factors. In Chapter 4.4, I examined socioeconomic disparities in survival incorporating 
receipt of major surgery. Finally, in Chapter 4.5, I investigated the potential magnitude of the 
effects of inequalities in cancer care on socioeconomic inequalities in survival. 
4.1. Factors associated with receipt of major surgery and socioeconomic 
inequalities in receipt of surgery 
The objective of this analysis was twofold. The first analysis explored potential factors 
associated with receipt of major surgery for the primary lesion and examined whether there was 
a difference by SES group in the receipt of major surgery. The second analysis explored factors 
associated with time to treatment and examined whether it varied by SES. 
4.1.1 Methods 
Study population 
Patients with colon or rectal cancer, who resided in England and diagnosed between January 
2010 and March 2013 and followed up until the end of December 2014, were included. Patients 
with Tis (carcinoma in situ) and those above 100 years old at the time of diagnosis were 
excluded from the analysis. 
Outcome measure 
In the first analysis, whether a patient received major surgery for the primary lesion (0 yes, 1 
no) was set as a surrogate outcome to measure appropriate cancer care. Other potential surrogate 
outcomes could include the percentage of patients who received major surgery for curative 
intent, the number of lymph nodes yielded or complications of surgery. However, due to the 
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large proportion of missing data, those measures were not used as the outcome measure. Type 
of surgery (e.g. APER or AR for rectal cancer) could also be an outcome; however, this was not 
used because the type of operation in rectal cancer largely depends on the sublocalisation of the 
tumour (i.e. height from the anal verge), for which data were again largely missing [84, 206, 
207]. 
Regarding the extraction of the date and type of operation procedure of the first major surgery, I 
defined the NBOCA data as the priority. Information on operation procedure and date of the 
first major surgery was extracted from HES if NBOCA data had no information. A major 
operation for the primary lesion was extracted from 30 days before diagnosis to 180 days after 
diagnosis. NBOCA data covered 82.0% and 80.3% of the total information on the first major 
surgery for the primary lesion in colon and rectal cancers, respectively. Operation procedure 
codes identified as major surgery are displayed in Appendix 4 for colon cancer and Appendix 5 
for rectal cancer. 
The first analysis was extended to the second analysis to examine whether timely cancer care 
was provided equally to the different SES groups. The outcome of the second analysis was the 
number of days from diagnosis to surgical treatment (major surgery for the primary lesion). 
For colon cancer, sites were categorised into three groups: right-sided colon (ascending colon, 
hepatic flexure, caecum and appendix), transverse colon (transverse colon and splenic flexure) 
and left-sided colon (descending colon and sigmoid colon). A sub-group analysis was conducted 
for the left-sided colon, by analysing descending and sigmoid colon separately. 
Analysis strategy 
For the first analysis, I applied logistic regression. To examine the length of the time from 
diagnosis to treatment in the second analysis, I applied linear regression. 
In both analyses, a priori exposure was SES, and an interaction term between SES and stage 
was added as the main interest. Since important information (stage, tumour grade and 
emergency presentation) was missing, I conducted analyses with multiply imputed data and 
with complete cases (i.e. without imputations) as sensitivity analyses. The stage was missing at 
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31.1% and 27.3%, and tumour grade was missing at 24.3% and 22.3%, respectively, for colon 
and rectal cancers. Emergency presentation (i.e. routes to diagnosis or to the first major surgery 
for the primary lesion) was missing at 10% for colon and 6.7% for rectal cancer. Those three 
variables and histology (missing at less than 3% for each cancer) were imputed 30 times by 
multiple imputation with chained equations after the mechanisms of missingness in all three 
variables were examined to have missingness at random (MAR) dependent on covariates and 
outcome. Missingness of all three variables was associated with age group, cancer site, number 
of chronic or acute comorbidities, receipt of major surgery for the primary lesion, vital status 
(dead or alive) at the end of follow-up and government office region. Socioeconomic status was 
not associated with the missingness of stage but was associated with the missingness of tumour 
grade and emergency presentation in both cancers. Sex was associated with the missingness of 
stage in both cancers, but not with the missingness of tumour grade in either cancer or with 
emergency presentation in colon cancer. Year of diagnosis was not associated with the 
missingness of tumour grade in rectal cancer or the missingness of emergency presentation in 
colon cancer. Therefore, for the imputation, I used the following variables: sex, age group, 
cancer site, number of chronic and acute comorbidities, receipt of major surgery, vital status, 
Nelson-Aalen estimator and government office region. The distributions of the imputed stage, 
histology, tumour grade and emergency presentation are illustrated in Appendix 8. 
In the second analysis, patients who received surgery within seven days of the date of diagnosis 
were defined as having received an ‘urgent operation’ and were thus excluded from the analysis; 
undergoing an urgent operation could mean that the patient did not receive an adequate 
assessment of cancer stage and comorbidities. As the distribution of the days from the diagnosis 
to treatment was right-skewed, the outcome in days was log-transformed. After the log-
transformation, the distribution of the outcome became normally distributed only for colon 
cancer. The distribution of the days from diagnosis to treatment for rectal cancer patients was 
bi-modal with a truncation at 180 days. The distribution did not become normally distributed 
even after a log-transformation; therefore, I did not conduct the second analysis for rectal 
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cancer. The distribution of the number of days for rectal cancer patients is illustrated in 
Appendix 9. 
In both analyses using logistic and linear regression, I conducted bivariable analyses with a 
priori interest variable SES, to assess the changes in the association between SES and the 
outcome (i.e. the confounding effect of each variable). Each variable was also retained in the 
multivariable analysis based on the Wald test (p-value< 0.05) of the bivariable analysis. The 
Wald test was unifiedly used rather than likelihood ratio test for both imputed and completed 
data (i.e. data of complete cases) to account for the uncertainty in imputed data [208]. Variables 
were finally selected by backward elimination. A removed variable was added to the 
multivariable model again as a confounder if a model with the variable changed the effect of 
SES (OR of the most deprived in the first analysis) by more than 10%. Age group and sex were 
added as a priori confounders. 
4.1.2 Results 
There were 69,766 patients with colon cancer and 38,267 patients with rectal cancer. Baseline 
characteristics of the patients with colon and rectal cancer are displayed separately in Table 4.1 
and Table 4.2. For both cancers, over half of the patients were male (53% for colon, 63% for 
rectal cancer). While the median age for both cancers was over 70 years old, the median age of 
the patients with rectal cancer was three years smaller than that of patients with colon cancer. 
Noticeable socioeconomic gradients were observed in emergency presentation and number of 
chronic and acute comorbidities, which all showed better figures for the least deprived group. 
Mortalities at the end of the follow-up and postoperative 30-day mortality were also better 
among the less deprived groups in both cancers. Worse stage distribution among the deprived 
groups was only observed in rectal cancer. Stage information was missing at approximately 
30% in both colon and rectal cancer. Socioeconomic gradient in histology and tumour grade 
was unclear. However, there was higher missingness in tumour grade in more deprived groups. 
Screen-detected cancer was approximately 5% in both cancers with smaller percentages in more 
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deprived groups. However, in both cancers, missingness of data on screen-detected cancer 
exceeded 65% equally across all SES groups.
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Table 4.1 Baseline characteristics of patients with colon cancer, England  
  
SES  
Total number 1st 
(least deprived) 
2nd 3rd 4th 5th 
(most deprived) 
Total number 69766 15257 15472 14676 13720 10641 
(%) 100 21.9 22.2 21.0 19.7 15.3 
Median age at diagnosis 73.9 73.4 74.2 74.2 74.1 73.2 
IQR 64.8–81.4 65.0–81.0 65.2–81.6 65.3–81.7 64.7–81.6 63.5–80.9 
Female (%) 33081 (47.4) 7077 (46.4) 7241 (46.8) 7047 (48.0) 6648 (48.5) 5068 (47.6) 
Death at the end of follow up (%) 32140 (46.1) 6392 (41.9) 6886 (44.5) 6781 (46.2) 6715 (48.9) 5366 (50.4) 
Year of diagnosis (%)       
2010 21010 (30.1) 4484 (29.4) 4721 (30.5) 4515 (30.8) 4097 (29.9) 3193 (30.0) 
2011 21692 (31.1) 4811 (31.5) 4799 (31.0) 4570 (31.1) 4265 (31.1) 3247 (30.5) 
2012 21804 (31.3) 4761 (31.2) 4792 (31.0) 4508 (30.7) 4318 (31.5) 3425 (32.2) 
2013 5260 (7.5) 1201 (7.9) 1160 (7.5) 1083 (7.4) 1040 (7.6) 776 (7.3) 
Cancer site (%)       
Right-sided colon (ascending colon, hepatic flexure, caecum, appendix) 29213 (41.9) 6444 (42.2) 6414 (41.5) 6161 (42.0) 5750 (41.9) 4444 (41.8) 
Transverse colon (transverse colon, splenic flexure) 7984 (11.4) 1752 (11.5) 1776 (11.5) 1707 (11.6) 1590 (11.6) 1159 (10.9) 
Left-sided colon (descending colon, sigmoid colon) 26887 (38.5) 5923 (38.8) 5995 (38.8) 5679 (38.7) 5246 (38.2) 4044 (38.0) 
        Descending colon 3235 (4.6) 701 (4.6) 713 (4.6) 643 (4.4) 642 (4.7) 536 (5.0) 
        Sigmoid colon 23652 (33.9) 5222 (34.2) 5282 (34.1) 5036 (34.3) 4604 (33.6) 3508 (33.0) 
Overlapping site or unspecified 5682 (8.1) 1138 (7.5) 1287 (8.3) 1129 (7.7) 1134 (8.3) 994 (9.3) 
Stage at diagnosis (%)       
I 6002 (8.6) 1401 (9.2) 1308 (8.5) 1282 (8.7) 1129 (8.2) 882 (8.3) 
II 13655 (19.6) 3021 (19.8) 3100 (20.0) 2836 (19.3) 2607 (19.0) 2091 (19.7) 
III 12673 (18.2) 2812 (18.4) 2827 (18.3) 2615 (17.8) 2459 (17.9) 1960 (18.4) 
IV 15722 (22.5) 3349 (22.0) 3410 (22.0) 3304 (22.5) 3232 (23.6) 2427 (22.8) 
Missing 21714 (31.1) 4674 (30.6) 4827 (31.2) 4639 (31.6) 4293 (31.3) 3281 (30.8) 
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Table 4.1 continued 
  SES  
Total number 1st 
(least deprived) 
2nd 3rd 4th 5th 
(most deprived) 
Histology (%)       
Adenocarcinoma 66650 (95.5) 14554 (95.4) 14790 (95.6) 13998 (95.4) 13145 (95.8) 10163 (95.5) 
Adenosquamous cell, squamous cell carcinoma 272 (0.4) 48 (0.3) 63 (0.4) 64 (0.4) 52 (0.4) 45 (0.4) 
Non-epithelial tumours 1207 (1.8) 256 (1.7) 252 (1.6) 239 (1.6) 240 (1.8) 220 (2.1) 
Missing 1636 (2.3) 399 (2.6) 366 (2.4) 375 (2.6) 283 (2.1) 213 (2.0) 
Tumour grade (%) 
      
Well/moderately differentiated (G1/G2) 42944 (61.6) 9679 (63.4) 9656 (62.4) 8949 (61.0) 8279 (60.3) 6381 (60.0) 
Poorly differentiated/undifferentiated (G3/G4) 9829 (14.1) 2254 (14.8) 2186 (14.1) 2115 (14.4) 1846 (13.5) 1428 (13.4) 
Missing (GX) 16993 (24.4) 3324 (21.8) 3630 (23.5) 3612 (24.6) 3595 (26.2) 2832 (26.6) 
Screening-detected cancer (%) 3743 (5.4) 946 (6.2) 885 (5.7) 756 (5.2) 673 (4.9) 483 (4.5) 
Emergency presentation (%)    
   
No 45794 (65.6) 10398 (68.2) 10322 (66.7) 9787 (66.7) 8796 (64.1) 6491 (61.0) 
Yes 17105 (24.5) 3325 (21.8) 3581 (23.2) 3538 (24.1) 3580 (26.1) 3081 (29.0) 
Missing 6867 (9.8) 1534 (10.1) 1569 (10.1) 1351 (9.2) 1344 (9.8) 1069 (10.0) 
Number of chronic comorbidities (%) 
      
0 59779 (85.7) 13480 (88.4) 13417 (86.7) 12634 (86.1) 11560 (84.3) 8688 (81.7) 
1 7976 (11.4) 1479 (9.7) 1656 (10.7) 1627 (11.1) 1708 (12.5) 1506 (14.2) 
2 1640 (2.4) 254 (1.7) 340 (2.2) 328 (2.2) 366 (2.7) 352 (3.3) 
3+ 367 (0.5) 42 (0.3) 59 (0.4) 87 (0.6) 84 (0.6) 95 (0.9) 
Number of acute comorbidities (%)  
     
0 57964 (83.1) 13077 (85.7) 13048 (84.3) 12213 (83.2) 11197 (81.6) 8429 (79.2) 
1 9712 (13.9) 1819 (11.9) 2036 (13.2) 2049 (14.0) 2047 (14.9) 1761 (16.6) 
2 1705 (2.4) 294 (1.9) 329 (2.1) 333 (2.3) 380 (2.8) 369 (3.5) 
3+ 381 (0.6) 65 (0.4) 59 (0.4) 81 (0.6) 94 (0.7) 82 (0.8) 
Obesity at diagnosis (BMI>30) (%) 1004 (1.4) 144 (0.9) 191 (1.2) 237 (1.6) 236 (1.7) 196 (1.8) 
Received major surgery for primary lesion (%) 45907 (65.8) 10258 (67.2) 10322 (66.7) 9655 (65.8) 8845 (64.5) 6827 (64.2) 
Postoperative 30-day mortality (%)* 1855 (4.0) 308 (3.0) 384 (3.7) 397 (4.1) 407 (4.6) 359 (5.3) 
Abbreviations: BMI, body mass index; G, grade; IQR, interquartile range; SES, socioeconomic status. * Denominator is the number of patients who received major surgery (n=45907).  
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Table 4.2 Baseline characteristics of patients with rectal cancer, England  
  
SES  
Total number 1st 
(least deprived) 
2nd 3rd 4th 5th 
(most deprived) 
Total number 38267 7977 8363 8057 7649 6221 
(%) 100 20.9 21.9 21.1 20.0 16.3 
Median age at diagnosis 70.8 70.8 70.8 70.9 71.2 70.1 
IQR 62.2–79.1 62.3–78.8 62.4–79.1 62.5–79.2 62.3–79.5 60.7–78.6 
Female (%) 14238 (37.2) 2982 (37.4) 3130 (37.4) 2967 (36.8) 2917 (38.1) 2242 (36.0) 
Mortality at the end of follow up (%) 15668 (40.9) 2913 (36.5) 3205 (38.3) 3287 (40.8) 3328 (43.5) 2935 (47.2) 
Year of diagnosis (%) 
      
2010 11621 (30.4) 2417 (30.3) 2575 (30.8) 2413 (30.0) 2299 (30.1) 1917 (30.8) 
2011 11793 (30.8) 2475 (31.0) 2567 (30.7) 2478 (30.8) 2344 (30.6) 1929 (31.0) 
2012 12019 (31.4) 2504 (31.4) 2605 (31.2) 2560 (31.8) 2457 (32.1) 1893 (30.4) 
2013 2834 (7.4) 581 (7.3) 616 (7.4) 606 (7.5) 549 (7.2) 482 (7.8) 
Cancer site (%) 
      
Rectosigmoid junction 7247 (18.9) 1489 (18.7) 1591 (19.0) 1489 (18.5) 1437 (18.8) 1241 (20.0) 
Rectum 30771 (80.4) 6446 (80.8) 6733 (80.5) 6511 (80.8) 6153 (80.4) 4928 (79.2) 
Overlapping site or unspecified 249 (0.7) 42 (0.5) 39 (0.5) 57 (0.7) 59 (0.8) 52 (0.8) 
Stage at diagnosis (%) 
      
I 6355 (16.6) 1417 (17.8) 1408 (16.8) 1379 (17.1) 1220 (16.0) 931 (15.0) 
II 5866 (15.3) 1229 (15.4) 1300 (15.5) 1223 (15.2) 1195 (15.6) 919 (14.8) 
III 8312 (21.7) 1720 (21.6) 1842 (22.0) 1764 (21.9) 1635 (21.4) 1351 (21.7) 
IV 7286 (19.0) 1426 (17.9) 1566 (18.7) 1518 (18.8) 1497 (19.6) 1279 (20.6) 
Missing 10448 (27.3) 2185 (27.4) 2247 (26.9) 2173 (27.0) 2102 (27.5) 1741 (28.0) 
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Table 4.2 continued 
  SES  
Total number 1st 
(least deprived) 
2nd 3rd 4th 5th 
(most deprived) 
Histology (%)       
Adenocarcinoma 36240 (94.7) 7581 (95.0) 7956 (95.1) 7621 (94.6) 7229 (94.5) 5853 (94.1) 
Adenosquamous cell, squamous cell carcinoma 486 (1.3) 81 (1.0) 95 (1.1) 111 (1.4) 110 (1.4) 89 (1.4) 
Non-epithelial tumours 539 (1.4) 111 (1.4) 87 (1.0) 104 (1.3) 108 (1.4) 129 (2.1) 
Missing 1002 (2.6) 204 (2.6) 225 (2.7) 221 (2.7) 202 (2.6) 150 (2.4) 
Tumour grade (%) 
      
Well/moderately differentiated (G1/G2) 25919 (67.7) 5550 (69.6) 5759 (68.9) 5426 (67.4) 5098 (66.7) 4086 (65.7) 
Poorly differentiated/undifferentiated (G3/G4) 3831 (10.0) 807 (10.1) 807 (9.7) 843 (10.5) 763 (10.0) 611 (9.8) 
Missing (GX) 8517 (22.3) 1620 (20.3) 1797 (21.5) 1788 (22.2) 1788 (23.4) 1524 (24.5) 
Screen-detected cancer (%) 2195 (5.7) 490 (6.1) 524 (6.3) 434 (5.4) 424 (5.5) 323 (5.2) 
Emergency presentation (%) 
      
No 31507 (82.3) 6675 (83.7) 6977 (83.4) 6689 (83.0) 6277 (82.1) 4889 (78.6) 
Yes 4210 (11.0) 685 (8.6) 795 (9.5) 869 (10.8) 924 (12.1) 937 (15.1) 
Missing 2550 (6.7) 617 (7.7) 591 (7.1) 499 (6.2) 448 (5.9) 395 (6.4) 
Number of chronic comorbidities (%) 
      
0 33858 (88.5) 7228 (90.6) 7539 (90. 2) 7128 (88.5) 6716 (87.8) 5247 (84.3) 
1 3611 (9.4) 628 (7.9) 672 (8.0) 769 (9.5) 767 (10.0) 775 (12.5) 
2 647 (1.7) 106 (1.3) 114 (1.4) 133 (1.7) 136 (1.8) 158 (2.5) 
3+ 151 (0.4) 15 (0.2) 38 (0.5) 27 (0.3) 30 (0.4) 41 (0.7) 
Number of acute comorbidities (%) 
      
0 33942 (88.7) 7295 (91.5) 7540 (90.2) 7148 (88.7) 6665 (87.1) 5294 (85.1) 
1 3643 (9.5) 578 (7.3) 685 (8.2) 764 (9.5) 832 (10.9) 784 (12.6) 
2 575 (1.5) 92 (1.2) 116 (1.4) 117 (1.5) 126 (1.7) 124 (2.0) 
3+ 107 (0.3) 12 (0.2) 22 (0.3) 28 (0.4) 26 (0.3) 19 (0.3) 
Obesity at diagnosis (BMI>30) (%)  422 (1.1) 63 (0.8) 81 (1.0) 79 (1.0) 104 (1.4) 95 (1.5) 
Received major surgery for primary lesion (%) 19703 (51.5) 4333 (54.3) 4452 (53.2) 4205 (52.2) 3871 (50.6) 2842 (45.7) 
Postoperative 30-day mortality (%)* 487 (2.5) 86 (2.0) 85 (1.9) 126 (3.0) 99 (2.6) 91 (3.2) 
Abbreviations: BMI, body mass index; G, grade; IQR, interquartile range; SES, socioeconomic status. * Denominator is the number of patients who received major surgery (n=19703).
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First analysis (logistic regression for receipt of major surgery and odds ratios by SES) 
Multivariable logistic regression included 69,762 colon and 37,265 rectal cancer patients in 
imputed data. Sensitivity analyses using completed data included 38,624 colon (55.4% of total) 
and 22,630 rectal (59.1% of total) cancer patients. For colon cancer, 45,907 (65.8% of total) 
patients received major surgery. For rectal cancer, 19,703 (51.5% of total) received major 
surgery (Table 4.1 and Table 4.2). Table 4.3 and Table 4.4 illustrate the results of the bivariable 
and multivariable logistic regression analyses. To show the overall change in the effect of SES, 
the adjusted ORs of SES in those tables were based on a model without interaction between 
SES and stage. For the rest, adjusted ORs were based on the multivariable model with 
interaction between SES and stage (final model). The sub-group analysis of changing the 
category of site (left-sided colon separated to descending and sigmoid colon) did not affect the 
results of other variables in multivariable analyses in an important amount. Therefore, the 
results of the adjusted ORs for the other variables in the sub-group analyses were omitted. 
Factors associated with receipt of major surgery 
All examined factors except obesity were associated with receipt of major surgery in both 
cancers. With imputed data, age of 80+ with colon or rectal cancer had approximately three 
times the odds of not receiving surgery after adjusting for other factors, compared with the 
patients aged under 65 years. Patients with an emergency presentation had lower adjusted odds 
of not receiving surgery than the patients without an emergency presentation in colon cancer but 
had higher adjusted odds in rectal cancer. In both cancers, patients with an increased number of 
chronic and acute comorbidities had higher adjusted odds of not receiving surgery than patients 
without comorbidities. 
In a bivariable analysis for colon cancer, patients with an emergency presentation had 1.2 times 
the odds of not receiving surgery compared with the patients without an emergency presentation 
(Table 4.3). However, the effect of emergency presentation on the receipt of surgery was 
reduced by stage, making the ORs of emergency presentation less than 1 in the multivariable 
analysis. 
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Receipt of major surgery by SES 
Although deprived groups were more likely not to receive a major surgery in the bivariable 
analysis, after controlling for all potential confounders, the trend weakened to almost null in 
both imputed and completed data only for colon cancer (adjusted ORs of SES in Table 4.3 and 
Table 4.4). 
In bivariable analyses, no factors cancelled the socioeconomic gradient favouring the least 
deprived in the receipt of major surgery. For both cancers, the gradient was slightly weakened 
when stage was adjusted in the bivariable analysis. Chronic and acute comorbidities also 
weakened the gradient, but age worsened the gradient in both cancers. The reduction of the 
gradient made by acute comorbidities was smaller than that made by chronic comorbidities. The 
effects of site and emergency presentation reduced the effect of SES on non-receipt of surgery 
for colon cancer but increased the effect of SES for rectal cancer. 
The multivariable analyses stratified on stage showed that, among rectal cancer patients using 
imputed data, the most deprived group, compared with the least deprived, had higher adjusted 
odds of not receiving surgery at a significant level for stage II, III, and IV (Table 4.5). A similar 
trend was observed for colon cancer patients with stage III, but this did not reach a statistical 
significance. In other stages and sites (stage I, II and IV in colon cancer, stage I in rectal 
cancer), the socioeconomic gradient was weak. 
In the sensitivity analyses using completed data, socioeconomic trends of the stage-specific ORs 
confirmed similar results with the analyses using imputed data. Deprived groups had increased 
odds of not receiving surgery among stage II, III and IV in rectal cancer patients (Table 4.5). 
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Table 4.3 Odds ratios of not receiving major surgery for primary lesion using logistic regression for colon cancer, England  
Variable  Bivariable analysis Multivariable analysis Multivariable sensitivity analysis 
  Multiple imputation (n=69762) Complete cases (n=38624) 
 OR* 95% CI p-value† OR** 95% CI p-value† OR** 95% CI p-value† 
SES          
1 (least deprived) 1.00  
<0.001‡ 
1.00  
0.05‡ 
1.00  
0.51‡ 
2 1.02 (0.98, 1.07) 0.99 (0.93, 1.05) 0.96 (0.88, 1.06) 
3 1.07 (1.02, 1.12) 1.00 (0.94, 1.06) 1.00 (0.91, 1.10) 
4 1.13 (1.08, 1.19) 1.03 (0.97, 1.09) 0.96 (0.87, 1.06) 
5 (most deprived) 1.15 (1.09, 1.21) 1.06 (0.99, 1.13) 0.96 (0.87, 1.07) 
Sex 
    
     
Male 1.00 
 
 1.00   1.00   
Female 1.02 (0.99, 1.06) 0.15 0.96 (0.92, 1.00) 0.08 0.86 (0.81, 0.92) <0.001 
Age 
     
    
<65 1.00 
 
<0.001‡ 
1.00 
 
<0.001‡ 
1.00  
<0.001‡ 65–79 0.89 (0.86, 0.93) 0.99 (0.94, 1.05) 0.91 (0.84, 0.98) 
80–99 2.13 (2.04, 2.22) 2.82 (2.66, 2.99) 1.36 (1.24, 1.49) 
Year of diagnosis 
     
    
2010 1.00 
  
1.00 
 
 1.00   
2011 1.06 (1.01, 1.10) 0.009 1.18 (1.12, 1.25) <0.001 1.15 (1.05, 1.26) 0.002 
2012 1.08 (1.03, 1.12) <0.001 1.29 (1.22, 1.36) <0.001 1.41 (1.30, 1.54) <0.001 
2013 1.17 (1.10, 1.25) <0.001 1.42 (1.31, 1.54) <0.001 1.44 (1.28, 1.64) <0.001 
Cancer site 
     
    
Right-sided colon# 1.00 
  
1.00 
 
 1.00   
Transverse colon# 0.90 (0.86, 0.96) <0.001 1.03 (0.96, 1.11) 0.37 1.13 (1.01, 1.26) 0.04 
Left-sided colon# 1.27 (1.22, 1.31) <0.001 1.72 (1.64, 1.80) <0.001 2.11 (1.97, 2.27) <0.001 
   Descending colon 1.11 (1.02, 1.20) <0.001 1.56 (1.41, 1.73) <0.001 1.96 (1.68, 2.28) <0.001 
   Sigmoid colon 1.29 (1.24, 1.34) <0.001 1.74 (1.66, 1.83) <0.001 2.13 (1.98, 2.30) <0.001 
Overlapping site or unspecified 4.98 (4.68, 5.29) <0.001 4.27 (3.95, 4.63) <0.001 3.48 (3.02, 4.02) <0.001 
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Table 4.3 continued  
Variable Bivariable analysis Multivariable analysis Multivariable sensitivity analysis 
  Multiple imputation (n=69762) Complete cases (n=38624) 
 OR* 95% CI p-value† OR** 95% CI p-value† OR** 95%CI p-value† 
Stage at diagnosis          
I 1.00  
<0.001‡ 
   1.00  
<0.001‡ 
II 0.25 (0.23, 0.27)    0.19 (0.15, 0.24) 
III 0.35 (0.32, 0.38)    0.23 (0.18, 0.29) 
IV 4.62 (4.32, 4.93)    3.34 (2.82, 3.97) 
Stage at diagnosis§          
I 1.00  
<0.001‡ 
1.00  
<0.001‡ 
   
II 0.24 (0.22, 0.26) 0.23 (0.19, 0.27)    
III 0.32 (0.30, 0.35) 0.31 (0.26, 0.36)    
IV 3.79 (3.56, 4.02) 4.15 (3.64, 4.72)    
Histology          
Adenocarcinoma 1.00 
  
1.00 
  
1.00   
Adenosquamous and squamous cell carcinoma 1.63 (1.29, 2.08) <0.001 4.28 (3.11, 5.90) <0.001 3.28 (1.94, 5.56) <0.001 
Non-epithelial tumours 3.66 (3.25, 4.13) <0.001 7.81 (6.68, 9.13) <0.001 7.66 (6.11, 9.58) <0.001 
Tumour grade          
Well/moderately differentiated 1.00      1.00   
Poorly/undifferentiated 1.11 (1.05, 1.17) <0.001    1.08 (1.00, 1.17) 0.06 
Tumour grade§ 
      
   
Well/moderately differentiated 1.00 
 
 1.00 
 
    
Poorly/undifferentiated 1.47 (1.39, 1.55) <0.001 1.14 (1.07, 1.22) <0.001    
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Table 4.3 continued 
Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio; SES, socioeconomic status. * Adjusted for SES in all variables. Results of bivariable analysis on histology with imputed data and 
completed data did not differ in an important amount. Thus, results with only imputed data are shown. ** All variables are mutually adjusted. For SES only, adjusted ORs are shown without interaction 
between SES and stage. For other variables, interaction between SES and stage is adjusted. # Right-sided colon includes ascending colon, hepatic flexure, caecum and appendix. Transverse colon 
includes transverse colon and splenic flexure. Left-sided colon includes descending colon and sigmoid colon. † P-value of Wald test. ‡ P-value of Wald test for trend. § Multiply imputed.  
Variable Bivariable analysis Multivariable analysis Multivariable sensitivity analysis 
  Multiple imputation (n=69762) Complete cases (n=38624) 
 OR* 95% CI p-value† OR** 95% CI p-value† OR** 95%CI p-value† 
Emergency presentation          
No 1.00      1.00   
Yes 1.10 (1.05, 1.14) <0.001    0.65 (0.60, 0.70) <0.001 
Emergency presentation§ 
  
 
  
    
No 1.00 
 
 1.00 
 
    
Yes 1.20 (1.16, 1.25) <0.001 0.72 (0.68, 0.76) <0.001    
Number of chronic comorbidities 
  
 
  
    
0 1.00 
 
<0.001‡ 
1.00 
 
<0.001‡ 
1.00  
<0.001‡ 
1 1.51 (1.44, 1.58) 1.55 (1.45, 1.65) 1.32 (1.20, 1.47) 
2 2.90 (2.62, 3.20) 3.42 (2.99, 3.92) 2.84 (2.29, 3.53) 
3+ 4.10 (3.30, 5.10) 4.89 (3.66, 6.55) 4.05 (2.59, 6.34) 
Number of acute comorbidities          
0 1.00 
 
<0.001‡ 
1.00 
 
<0.001‡ 
1.00  
<0.001‡ 
1 1.27 (1.21, 1.32) 1.23 (1.16, 1.30) 1.11 (1.01, 1.22) 
2 1.93 (1.75, 2.13) 1.82 (1.60, 2.06) 1.52 (1.22, 1.90) 
3+ 2.20 (1.80, 2.69) 2.37 (1.80, 3.13) 1.67 (1.04, 2.70) 
Obesity at diagnosis 
  
 
  
    
No 1.00 
 
 1.00 
 
    
Yes 0.69 (0.60, 0.79) <0.001 0.74 (0.62, 0.88) 0.002    
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Table 4.4 Odds ratios of not receiving major surgery for primary lesion using logistic regression for rectal cancer, England  
Variable Bivariable analysis Multivariable analysis Multivariable sensitivity analysis 
  Multiple imputation (n=37265) Complete cases (n=22630) 
 OR* 95% CI p-value† OR** 95% CI p-value† OR** 95%CI p-value† 
SES          
1 (least deprived) 1.00 
 
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 
2 1.04 (0.98, 1.11) 1.02 (0.95, 1.09) 1.06 (0.97, 1.17) 
3 1.09 (1.02, 1.16) 1.02 (0.95, 1.10) 1.07 (0.98, 1.18) 
4 1.16 (1.09, 1.24) 1.05 (0.98, 1.13) 1.11 (1.01, 1.22) 
5 (most deprived) 1.41 (1.32, 1.51) 1.29 (1.19, 1.39) 1.35 (1.22, 1.49) 
Sex 
  
       
Male 1.00 
 
 1.00 
 
 1.00   
Female 1.16 (1.11, 1.21) <0.001 1.05 (1.00, 1.11) 0.04 1.00 (0.94, 1.06) 0.92 
Age 
  
 
  
    
<65 1.00 
 
<0.001‡ 
1.00 
 
<0.001‡ 
1.00  
<0.001‡ 65–79 1.05 (1.00, 1.10) 1.12 (1.06, 1.18) 1.10 (1.02, 1.18) 
80–99 2.79 (2.63, 2.95) 2.84 (2.65, 3.04) 2.16 (1.98, 2.36) 
Year of diagnosis  
 
 
  
    
2010 1.00 
 
 1.00 
 
 1.00   
2011 1.03 (0.98, 1.09) 0.24 1.12 (1.06, 1.20) <0.001 1.11 (1.02, 1.21) 0.01 
2012 1.06 (1.01, 1.12) 0.02 1.19 (1.12, 1.27) <0.001 1.20 (1.10, 1.29) <0.001 
2013 1.08 (0.99, 1.17) 0.08 1.23 (1.12, 1.35) <0.001 1.22 (1.08, 1.38) 0.001 
Cancer site  
 
 
  
    
Rectosigmoid junction 1.00 
 
 1.00 
 
 1.00   
Rectum 1.52 (1.44, 1.60) <0.001 2.21 (2.07, 2.36) <0.001 2.95 (2.69, 3.22) <0.001 
Overlapping site or unspecified 9.69 (6.70, 14.02) <0.001 6.60 (4.24, 10.28) <0.001 14.09 (6.94, 28.63) <0.001 
Stage at diagnosis  
 
  
 
    
I 1.00 
 
<0.001‡ 
   1.00  
<0.001‡ II 0.72 (0.67, 0.78)    0.54 (0.44, 0.66) 
III 1.04 (0.98, 1.12)    0.86 (0.72, 1.02) 
IV 6.33 (5.87, 6.82)    5.79 (4.80, 6.98)  
Stage at diagnosis§  
 
  
 
    
I 1.00 
 
<0.001‡ 
1.00  
<0.001‡ 
   
II 0.72 (0.66, 0.78) 0.59 (0.50, 0.70)    
III 1.03 (0.96, 1.11) 0.96 (0.82, 1.12)    
IV 6.16 (5.72, 6.63) 6.33 (5.32, 7.54)    
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Table 4.4 continued 
Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio; SES, socioeconomic status. * Adjusted for SES in all variables. Results of bivariable analysis on histology with imputed data and 
completed data did not differ in an important amount. Thus, results with only imputed data are shown. ** All variables are mutually adjusted. For SES only, adjusted ORs are shown without interaction 
between SES and stage. For other variables, interaction between SES and stage is adjusted. † P-value of Wald test. ‡ P-value of Wald test for trend. § Multiply imputed.  
Variable Bivariable analysis Multivariable analysis Multivariable sensitivity analysis 
  Multiple imputation (n=37265) Complete cases (n=22630) 
 OR* 95% CI p-value† OR** 95% CI p-value† OR** 95%CI p-value† 
Histology          
Adenocarcinoma 1.00   1.00   1.00   
Adenosquamous and squamous cell carcinoma 20.48 (13.70, 30.61) <0.001 22.71 (14.56, 33.36) <0.001 20.65 (12.23, 34.87) <0.001 
Non-epithelial tumours 7.87 (6.07, 10.20) <0.001 8.48 (6.83, 11.83) <0.001 3.59 (2.46, 5.42) <0.001 
Tumour grade          
Well/moderately differentiated 1.00      1.00   
Poorly/undifferentiated 1.63 (1.53, 1.75) <0.001    1.13 (1.03, 1.24) 0.009 
Tumour grade§          
Well/moderately differentiated 1.00   1.00      
Poorly/undifferentiated 1.72 (1.60, 1.84) <0.001 1.14 (1.05, 1.24) <0.001    
Emergency presentation          
No 1.00      1.00   
Yes 2.40 (2.24, 2.56) <0.001    1.44 (1.30, 1.60) <0.001 
Emergency presentation§          
No 1.00   1.00      
Yes 2.57 (2.40, 2.74) <0.001 1.61 (1.48, 1.75) <0.001    
Number of chronic comorbidities          
0 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 
1 1.65 (1.54, 1.77) 1.58 (1.46, 1.72) 1.44 (1.29, 1.60) 
2 2.80 (2.36, 3.33) 2.46 (2.02, 2.99) 1.94 (1.50, 2.52) 
3+ 5.57 (3.63, 8.57) 4.50 (2.82, 7.22) 2.08 (1.10, 3.87) 
Number of acute comorbidities          
0 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 
1 1.50 (1.40, 1.60) 1.25 (1.15, 1.36) 1.23 (1.11, 1.37) 
2 2.79 (2.33, 3.35) 2.16 (1.75, 2.68) 1.94 (1.46, 2.60) 
3+ 3.13 (2.03, 4.82) 2.14 (1.31, 3.50) 1.48 (0.77, 2.98) 
Obesity at diagnosis          
No 1.00         
Yes 0.84 (0.69, 1.02) 0.07       
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Table 4.5 Stage-specific odds ratios of not receiving major surgery for primary lesion using multivariable logistic regression with interaction between SES and stage 
for colon and rectal cancer, England 
 Colon Rectum 
 Multiple imputationa Complete casesb Multiple imputationc Complete casesd 
 OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Stage I             
SES             
1 (least deprived) 1.00  
0.38 
1.00  
0.24 
1.00  
0.68 
1.00  
0.49 
2 0.89 (0.76, 1.04) 0.89 (0.72, 1.09) 0.93 (0.80, 1.09) 0.99 (0.83, 1.19) 
3 0.99 (0.84, 1.15) 1.03 (0.84, 1.27) 0.96 (0.82, 1.12) 0.97 (0.81, 1.16) 
4 1.04 (0.89, 1.22) 1.08 (0.88, 1.34) 0.99 (0.85, 1.15) 1.06 (0.88, 1.27) 
5 (most deprived) 1.00 (0.84, 1.19) 1.05 (0.84, 1.32) 1.02 (0.86, 1.21) 1.05 (0.86, 1.28) 
Stage II       
 
     
1 (least deprived) 1.00  
0.29 
1.00  
0.51 
1.00  
0.004 
1.00  
0.004 
2 0.96 (0.81, 1.14) 1.03 (0.79, 1.34) 1.16 (0.98, 1.38) 1.28 (1.03, 1.58) 
3 0.98 (0.83, 1.16) 0.99 (0.75, 1.30) 1.14 (0.95, 1.36) 1.32 (1.06, 1.63) 
4 1.03 (0.87, 1.23) 1.00 (0.76, 1.33) 1.08 (0.91, 1.29) 1.18 (0.95, 1.47) 
5 (most deprived) 1.10 (0.92, 1.30) 0.89 (0.65, 1.21) 1.44 (1.19, 1.75) 1.53 (1.22, 1.93) 
Stage III       
 
     
1 (least deprived) 1.00  
0.15 
1.00  
0.25 
1.00  
<0.001 
1.00  
<0.001 
2 1.03 (0.88, 1.20) 0.99 (0.77, 1.29) 0.99 (0.86, 1.14) 1.06 (0.90, 1.26) 
3 1.02 (0.87, 1.19) 0.94 (0.72, 1.23) 1.01 (0.88, 1.16) 1.09 (0.92, 1.29) 
4 1.13 (0.97, 1.32) 1.09 (0.83, 1.42) 1.12 (0.98, 1.28) 1.23 (1.04, 1.46) 
5 (most deprived) 1.14 (0.96, 1.36) 1.16 (0.88, 1.53) 1.33 (1.16, 1.53) 1.47 (1.23, 1.75) 
Stage IV       
 
     
1 (least deprived) 1.00  
0.58 
1.00  
0.06 
1.00  
0.002 
1.00  
0.01 
2 1.02 (0.93, 1.12) 0.97 (0.85, 1.11) 1.03 (0.88, 1.22) 1.00 (0.83, 1.22) 
3 1.01 (0.92, 1.11) 1.00 (0.87, 1.14) 1.03 (0.87, 1.22) 1.01 (0.84, 1.23) 
4 1.00 (0.91, 1.10) 0.88 (0.77, 1.01) 1.02 (0.86, 1.21) 0.97 (0.80, 1.18) 
5 (most deprived) 1.05 (0.95, 1.16) 0.90 (0.78, 1.04) 1.42 (1.19, 1.70) 1.43 (1.16, 1.77) 
Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio; SES, socioeconomic status. All p-values are of Wald test for trend. Model a: adjusted for sex, age, year of diagnosis, site, histology§, 
tumour grade§, emergency presentation§, chronic and acute comorbidities, obesity (§: multiply imputed). Model b: adjusted for sex, age, year of diagnosis, site, histology, tumour grade, emergency 
presentation, chronic and acute comorbidities. Model c: adjusted for sex, age, year of diagnosis, site, histology§, tumour grade§, emergency presentation§, chronic and acute comorbidities. Model d: 
adjusted for sex, age, year of diagnosis, site, histology, tumour grade, emergency presentation, chronic and acute comorbidities.
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Second analysis (linear regression for days from diagnosis to treatment and its difference by 
SES) 
Among the 45,907 patients (65.8% of total) with colon cancer who received major surgery, 
2,755 patients underwent surgery before the diagnosis (30 days to 1 day before the diagnosis), 
and 14,477 patients underwent surgery within seven days of the date of diagnosis; those patients 
(a total of 17,232, 37.5% of the patients who received major surgery) were removed from the 
analysis. Among the 19,703 patients (51.5% of total) with rectal cancer who received major 
surgery, 432 patients underwent surgery before the diagnosis, and 1,926 patients underwent 
surgery within seven days of the date of diagnosis; in total, 2,358 patients (12.0% of the patients 
who received major surgery) received major surgery emergently. 
Among only colon cancer patients, the deprived groups tended to receive major surgery 
emergently compared with the least deprived group (Table 4.6). An additional analysis revealed 
that the socioeconomic gradient in the receipt of emergency surgery for colon cancer was 
largely confounded by emergency presentation. Of the patients who had an emergency 
presentation, 4,665 (27.2%) and 1,221 (29.0%) had stage IV in colon and rectal cancer, 
respectively. 
Table 4.6 Percentage of patients who received major surgery for the primary lesion as elective 
or emergency (colon and rectal cancer), England 
  SES  
 Total 
(%) 
1 
(least 
deprived) 
2 3 4 5 
(most 
deprived) 
p-value 
Colon cancer        
Elective 28675 
(62.5) 
6594 
(64.3) 
6620 
(64.1) 
6018 
(62.3) 
5361 
(60.6) 
4082 
(59.8) 
<0.001 
Emergency 17232 
(37.5) 
3664 
(35.7) 
3702 
(35.9) 
3637 
(37.7) 
3484 
(39.4) 
2745 
(40.2) 
Rectal cancer        
Elective 17345 
(88.0) 
3804 
(87.8) 
3948 
(88.7) 
3731 
(88.7) 
3370 
(87.1) 
2492 
(87.7) 
0.29 
Emergency 2358 
(12.0) 
529 
(12.2) 
504 
(11.3) 
474 
(11.3) 
501 
(12.9) 
350 
(12.3) 
Abbreviations: SES, socioeconomic status. P-value of chi square test for trend.  
103 
 
For rectal cancer patients, the distribution of the days from diagnosis to treatment was bi-modal 
with a dip at around 100 days. The second peak may be composed of two different patient 
groups: those who had surgery after neoadjuvant therapy and those who had delayed surgery 
without neoadjuvant therapy. Since there was no information available on who had neoadjuvant 
therapy, an interpretation of whether it is a delay is problematical; hence, I did not conduct a 
linear regression analysis for rectal cancer patients. 
Factors associated with time to treatment 
Histological type, emergency presentation and the number of comorbidities mostly influenced 
the time to treatment. Table 4.7 displays the results of the linear regression analysis on the 
number of days from diagnosis to treatment for colon cancer patients. 
When adjusted for all other variables, females had a 3% reduction in time from diagnosis to 
treatment compared with males. In the bivariable analysis, age was associated with time to 
treatment in a quadratic term, but in the multivariable analysis, the association was linear rather 
than quadratic (p=0.93, likelihood ratio test comparing quadratic and linear terms) or 
categorised group. For every 10-year increase in age from the mean age of 72.2, the number of 
the days increased by 2% (β as a coefficient, eβ 1.02 in multivariable regression). A histological 
type of non-adenocarcinoma had a significant longer time to treatment, at more than a 30% 
increase in days compared with adenocarcinoma. Other factors, such as cancer site, stage and 
tumour grade were associated with slightly longer time interval to surgery; increase in the time 
to treatment was no more than 15% depending on the differences in those factors. Sub-group 
analysis separating the descending and sigmoid colon, showed sigmoid colon cancer had more 
than 10% longer time to surgery when compared with the right-sided colon cancer, whereas 
time to treatment was almost the same in right-sided, transverse and descending colon cancer . 
With an emergency presentation, time from diagnosis to treatment was shortened by 
approximately 10% despite the exclusion of patients receiving surgery within seven days of 
diagnosis. The presence of comorbidities also contributed to longer time interval to treatment. 
Notably, patients with three or more acute comorbidities experienced a greater than 20% 
increase in time to treatment. 
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Sensitivity analysis with completed data revealed a similar trend with the same covariates 
included in the multivariable model with imputed data. Obesity was not associated with time to 
treatment in multivariable linear regressions. 
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Table 4.7 Reference number of days from diagnosis to major surgery for primary lesion and ratios using linear regression for colon cancer, England  
Variable Bivariable analysis Multivariable analysis Multivariable sensitivity analysis 
  Multiple imputation (n=28675) Complete cases (n=20825) 
 Days 95% CI  Days** 95% CI  Days** 95% CI  
Reference (geometric mean) days in SES 1 36.4 (35.9, 36.9)  38.5 (37.6, 39.4)  38.3 (37.3, 39.4)  
 eβ* 95% CI p-value† eβ** 95% CI p-value† eβ** 95% CI p-value† 
SES          
1 (least deprived) 1.00 
 
0.94‡ 
1.00  
0.59‡ 
1.00  
0.83‡ 
2 1.01 (0.99, 1.03) 1.00 (0.99, 1.02) 1.00 (0.98, 1.02) 
3 1.01 (0.99, 1.03) 1.01 (0.99, 1.03) 1.01 (0.99, 1.03) 
4 1.02 (1.00, 1.04) 1.02 (1.00, 1.04) 1.02 (1.00, 1.05) 
5 (most deprived) 0.99 (0.97, 1.01) 0.99 (0.97, 1.02) 0.99 (0.96, 1.01) 
Sex 
  
       
Male 1.00 
 
 1.00   1.00   
Female 0.96 (0.95, 0.97) <0.001 0.97 (0.96, 0.98) <0.001 0.97 (0.95, 0.98) <0.001 
Age          
Mean age at diagnosis 72.2 SD 12.6        
Age as linear term (eβ by 10-year increase) 1.01 (1.01, 1.02) <0.001 1.02 (1.01, 1.03) <0.001 1.02 (1.02, 1.03) <0.001 
Age as quadratic term†† ††  0.04†† ††  NA ††  0.93†† 
Year of diagnosis          
2010 1.00      
   
2011 1.01 (1.00, 1.03) 0.13    
   
2012 1.00 (0.98, 1.02) 0.99    
   
2013 1.01 (0.98, 1.04) 0.50    
   
Cancer site 
  
       
Right-sided colon# 1.00 
 
 1.00   1.00   
Transverse colon# 0.99 (0.97, 1.01) 0.23 0.99 (0.97, 1.02) 0.57 1.00 (0.98, 1.03) 0.90 
Left-sided colon# 1.12 (1.11, 1.14) <0.001 1.12 (1.10, 1.13) <0.001 1.12 (1.10, 1.14) <0.001 
   Descending colon 1.04 (1.01, 1.08) <0.001 1.05 (1.01, 1.08) <0.001 1.06 (1.02, 1.10) <0.001 
   Sigmoid colon 1.13 (1.12, 1.15) <0.001 1.13 (1.11, 1.14) <0.001 1.13 (1.11, 1.15) <0.001 
Overlapping site or unspecified 1.08 (1.04, 1.12) <0.001 1.08 (1.04, 1.12) <0.001 1.11 (1.05, 1.16) <0.001 
 
1
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Table 4.7 continued  
 
Bivariable analysis Multivariable analysis Multivariable sensitivity analysis 
  Multiple imputation (n=28675) Complete cases (n=20825) 
 eβ* 95% CI p-value† eβ** 95% CI p-value† eβ** 95% CI p-value† 
Stage          
I 1.00 
 
<0.001‡ 
   1.00  
<0.001‡ 
II 0.85 (0.83, 0.86)    0.87 (0.83, 0.91) 
III 0.86 (0.84, 0.87)    0.90 (0.86, 0.94) 
IV 0.87 (0.85, 0.90)    0.92 (0.87, 0.98) 
Stage§ 
  
       
I 1.00 
 
<0.001‡ 
1.00  
<0.001‡ 
   
II 0.87 (0.85, 0.89) 0.88 (0.85, 0.93)    
III 0.88 (0.86, 0.90) 0.91 (0.87, 0.95)    
IV 0.89 (0.87, 0.91) 0.93 (0.88, 0.98)    
Histology          
Adenocarcinoma 1.00   1.00   1.00   
Adenosquamous and squamous cell carcinoma 1.58 (1.39, 1.79) <0.001 1.77 (1.56, 2.00) <0.001 1.33 (1.13, 1.58) 0.001 
Non-epithelial tumours 1.27 (1.17, 1.39) <0.001 1.37 (1.26, 1.49) <0.001 1.27 (1.14, 1.41) <0.001 
Tumour grade          
Well/moderately differentiated 1.00      1.00   
Poorly/undifferentiated 0.93 (0.91, 0.95) <0.001    0.97 (0.95, 0.99) 0.001 
Tumour grade§          
Well/moderately differentiated 1.00   1.00      
Poorly/undifferentiated 0.94 (0.92, 0.95) <0.001 0.96 (0.94, 0.98) <0.001    
Emergency presentation          
No 1.00      1.00   
Yes 0.89 (0.87, 0.91) <0.001    0.90 (0.88, 0.92) <0.001 
Emergency presentation§          
No 1.00   1.00      
Yes 0.89 (0.87, 0.91) <0.001 0.89 (0.87, 0.91) <0.001    
 
1
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Table 4.7 continued 
Abbreviations: 95% CI, 95% confidence interval; NA, not applicable; SD, standard deviation; SES, socioeconomic status. * Adjusted for SES in all variables. Results of bivariable analysis on histology 
with imputed data and completed data did not differ in an important amount. Thus, results with only imputed data are shown. ** All variables are mutually adjusted. For SES only, days and adjusted 
ratios are shown without interaction between SES and stage. For other variables, interaction between SES and stage is adjusted. # Right-sided colon includes ascending colon, hepatic flexure, caecum 
and appendix. Transverse colon includes transverse colon and splenic flexure. Left-sided colon includes descending colon and sigmoid colon. † P-value of the null hypothesis that the coefficient (β) is 0 
(eβ=1) when all other variables were set at the reference group. ‡ P-value of Wald test for trend. †† When age is put as a quadratic term, in bivariable analysis, log(days) is derived from α(constant) + 
β1(0 in SES=1) + β2(age−mean age) + β3(age−mean age)2. § Multiply imputed.
Variable Bivariable analysis Multivariable analysis Multivariable sensitivity analysis 
  Multiple imputation (n=28675) Complete cases (n=20825) 
 eβ* 95% CI p-value† eβ** 95% CI p-value† eβ** 95% CI p-value† 
Number of chronic comorbidities 
  
 
  
    
0 1.00 
 
<0.001‡ 
1.00 
 
<0.001‡ 
1.00  
<0.001‡ 
1 1.06 (1.04, 1.08) 1.06 (1.04, 1.09) 1.07 (1.05, 1.10) 
2 1.13 (1.07, 1.20) 1.14 (1.08, 1.21) 1.16 (1.08, 1.24) 
3+ 1.08 (0.95, 1.23) 1.11 (0.97, 1.26) 1.10 (0.95, 1.27) 
Number of acute comorbidities 
  
 
  
 
  
 
0 1.00 
 
<0.001‡ 
1.00 
 
<0.001‡ 
1.00 
 
<0.001‡ 
1 1.03 (1.00, 1.05) 1.04 (1.02, 1.06) 1.05 (1.02, 1.08) 
2 1.10 (1.04, 1.17) 1.14 (1.07, 1.21) 1.17 (1.10, 1.26) 
3+ 1.14 (0.97, 1.34) 1.21 (1.03, 1.42) 1.36 (1.12, 1.63) 
Obesity at diagnosis 
  
       
No 1.00 
 
       
Yes 1.07 (1.00, 1.14) 0.04       
1
0
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Time to treatment by SES 
In the bivariable analysis, there was no evidence that the number of days from diagnosis to 
treatment differed by SES. The mean days from diagnosis to treatment was 36.4 (95% CI 35.9, 
36.9) in the least deprived as a reference group (geometric mean of days, reference meaning 
‘intercept’ days in bivariable analysis, Table 4.7). No factors influenced the socioeconomic 
difference in time to treatment by an important amount. 
Stage-specific ratios of time to treatment by SES group are displayed in Table 4.8. Mean 
number of days from diagnosis to treatment in the reference group (the least deprived group) are 
also shown by each stage, which were derived by multivariable models with interaction between 
SES and stage. The mean days from diagnosis to treatment in the reference group ranged from 
34.0 in stage II to 38.5 in stage I after adjusting for all other factors, but the number of days did 
not differ by SES in all stages. There was no evidence of a socioeconomic trend in time to 
treatment in sensitivity analyses with completed data.  
109 
 
Table 4.8 Stage-specific ratios and reference number of days from diagnosis to major surgery 
for primary lesion using multivariable linear regression with interaction between SES and stage 
for colon cancer, England 
Abbreviations: 95% CI, 95% confidence interval; SES, socioeconomic status. All p-values are of Wald test for trend. 
Model a: adjusted for sex, age, site, histology§, tumour grade§, emergency presentation§, chronic and acute 
comorbidities (§: multiply imputed). Model b: adjusted for sex, age, site, histology, tumour grade, emergency 
presentation, chronic and acute comorbidities.  
 Multiple imputationa Complete casesb 
 eβ 95% CI p-value eβ 95% CI p-value 
Stage I 
   
   
SES 
   
   
Reference (days) in SES 1 38.5 (37.0, 40.0)  38.0 (36.5, 39.5)  
1 (least deprived) 1.00  
0.25 
1.00  
0.12 
2 0.99 (0.94, 1.05) 1.02 (0.99, 1.06) 
3 1.01 (0.96, 1.07) 1.03 (1.00, 1.07) 
4 1.01 (0.95, 1.06) 1.05 (1.01, 1.09) 
5 (most deprived) 1.03 (0.98, 1.10) 0.98 (0.94, 1.02) 
Stage II 
  
    
Reference (days) in SES 1 34.0 (33.1, 34.9)  34.1 (33.0, 35.1)  
1 (least deprived) 1.00  
0.64 
1.00  
0.70 
2 1.02 (0.99, 1.06) 1.02 (0.99, 1.06) 
3 1.03 (1.00, 1.07) 1.03 (1.00, 1.07) 
4 1.04 (1.00, 1.08) 1.05 (1.01, 1.09) 
5 (most deprived) 0.99 (0.95, 1.03) 0.98 (0.94, 1.02) 
Stage III 
  
    
Reference (days) in SES 1 35.0 (34.0, 36.0)  35.1 (33.6, 36.7)  
1 (least deprived) 1.00  
0.63 
1.00  
0.84 
2 0.98 (0.95, 1.02) 0.97 (0.94, 1.01) 
3 1.00 (0.96, 1.04) 1.00 (0.96, 1.04) 
4 1.01 (0.97, 1.04) 0.99 (0.96, 1.04) 
5 (most deprived) 1.00 (0.96, 1.04) 0.99 (0.95, 1.04) 
Stage IV 
  
    
Reference (days) in SES 1 35.8 (34.3, 37.3)  37.4 (35.8, 39.1)  
1 (least deprived) 1.00  
0.18 
1.00  
0.05 
2 1.02 (0.97, 1.08) 1.02 (0.96, 1.09) 
3 0.99 (0.93, 1.05) 0.97 (0.91, 1.03) 
4 1.02 (0.96, 1.08) 1.02 (0.96, 1.08) 
5 (most deprived) 0.95 (0.89, 1.01) 0.92 (0.86, 0.98) 
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4.1.3 Summary of findings 
The first analysis demonstrated a socioeconomic difference in receipt of major surgery for the 
primary lesion. A socioeconomic trend favouring the affluent patients was observed for colon 
cancer patients in stage III and rectal cancer patients in stages II to IV. Stage and number of 
chronic comorbidities contributed to a reduction in the socioeconomic gap, but the inequalities 
in receipt of surgery were not completely cancelled. 
The mean time to surgical treatment was approximately 38 days for colon cancer patients. No 
socioeconomic disparities were observed for the time to treatment. Patients with non-
adenocarcinoma, having 3+ acute comorbidities experienced a longer time to treatment than 
patients with adenocarcinoma or those with no acute comorbidities. For rectal cancer patients, a 
group of patients received surgery within 100 days of diagnosis, but there was also a 
considerable number of patients who received surgery after 100 days. 
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4.2 Postoperative 30-day mortality by socioeconomic status 
Chapter 4.1 explored characteristics of patients who were not likely to receive major surgery, 
and whether there were socioeconomic differences in surgery receipt. In Chapter 4.2, I 
restricted the study population to the patients who received surgery to examine whether the 
quality of care varied by SES. Postoperative 30-day mortality is one of the quality measures for 
CRC care [107]. Here, I explored factors associated with postoperative 30-day mortality and 
investigated socioeconomic differences in the mortality. 
4.2.1 Methods 
The analysed population also included cases with urgent operations who had seven days or less 
from the diagnosis to major surgery. Vital status (0 alive, 1 dead) at thirty days from the date of 
major surgery for the primary lesion was set as the outcome. 
I fitted logistic regression with imputed and completed data. An interaction term between SES 
and stage was added as the main interest. Stage, tumour grade and emergency presentation were 
multiply imputed 30 times under the MAR assumption (see Chapter 4.1). As sensitivity 
analyses, multivariable models with completed data were compared with the models with 
imputed data. 
I started with bivariable analyses, adjusting a priori interest variable, SES, for all other variables 
to assess the changes in the association between SES and the outcome. Each variable was also 
retained in the multivariable analysis based on the Wald test (p-value< 0.05) of the bivariable 
analysis. The Wald test was unifiedly used, rather than likelihood ratio test, for both imputed 
and completed data to account for the uncertainty in imputed data [208]. Finally, variables were 
selected by backward elimination. A removed variable was added to the multivariable model 
again as a confounder if a model with the variable changed the effect of SES (OR of the most 
deprived) by more than 10%. Age group and sex were added as a priori confounders. 
As same as Chapter 4.1, for colon cancer, sites were categorised into three groups and sub-
group analysis of the left-sided colon was also conducted.  
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4.2.2 Results 
Of all patients, 45,907 (65.8% of total) with colon cancer and 19,703 (51.5% of total) with 
rectal cancer who received major surgery for the primary lesion were analysed separately. 
Overall, postoperative 30-day mortality was 4.0% for colon cancer and 2.5% for rectal cancer 
with socioeconomic gradients towards higher mortalities in the deprived groups (Table 4.1 and 
Table 4.2). 
Table 4.9 and Table 4.10 display the results of the potential associated factors for postoperative 
death in the bivariable and multivariable logistic regression analyses. To show the overall 
change in the effect of SES, the adjusted ORs of SES in those tables were based on a model 
without interaction between SES and stage. For the rest, adjusted ORs were based on the 
multivariable model with interaction between SES and stage (final model). For the same reason 
in Chapter 4.1, in the sub-group analysis regarding left-sided colon cancer, results of variables 
other than site in the multivariable analyses were omitted. 
Factors associated with postoperative 30-day mortality 
Worse deprivation, increased age, worse tumour grade, emergency presentation and presence of 
acute/chronic comorbidities were associated with postoperative death for both cancers. Site of 
cancer and obesity were associated with a worse outcome only for colon cancer (Table 4.9 and 
Table 4.10). 
Clear socioeconomic trends towards worsening odds in the deprived groups were observed in 
both cancers. Patients aged 80+ had 5 to 7 times higher adjusted odds of postoperative death 
compared with patients under 65. Patients with worse tumour grade had approximately 1.4 
times adjusted odds of postoperative death, and the patients with an emergency presentation had 
a two to threefold increase in adjusted odds compared with the patients in the reference groups. 
For both cancers, the presence of chronic comorbidities increased the adjusted odds of death by 
1.59 to 3.93 times, and acute comorbidities increased the adjusted odds by 1.44 to 7.11 times. 
Transverse colon cancer had 1.3 times higher adjusted odds of death compared with the patients 
with right-sided colon cancer. Both descending and sigmoid colon cancer had similar adjusted 
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odds of death with right-sided colon cancer. Site was not associated with the postoperative 
mortality in rectal cancer. Obesity increased the adjusted odds of death by 1.5 times for colon 
cancer. 
The results of the sensitivity analyses with completed data largely agreed. Among rectal cancer 
patients, tumour grade was not associated with the odds of death. 
Odds ratios of postoperative death by SES 
Table 4.11 displays the results of stage-specific ORs of postoperative death among SES groups 
in each stage when all potential factors were adjusted and an interaction term between SES and 
stage was added in the multivariable logistic regression model. 
The stage-specific ORs provided evidence that the deprived groups had higher odds of death 
than the least deprived group among colon cancer patients with stage II, III and IV and rectal 
cancer patients with stage I. In colon cancer with stage I and rectal cancer with stage II to IV, 
there were similar socioeconomic gradients, but the p-values did not reach a statistical 
significance. All trends of the stage-specific ORs in sensitivity analyses were comparable to 
those of the main analyses using imputed data. 
Bivariable analyses revealed that the socioeconomic gradient towards higher odds of death in 
the deprived groups lessened by around 5 to 10% when stage, emergency presentation or 
number of acute comorbidities were adjusted one at a time; however, no variable cancelled the 
trend completely.
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Table 4.9 Odds ratios of postoperative death within 30 days using logistic regression for colon cancer, England  
Variable Bivariable analysis Multivariable analysis Multivariable sensitivity analysis  
 Multiple imputation (n=45907) Complete cases (n=32903)  
OR* 95% CI p-value† OR** 95% CI p-value† OR** 95% CI p-value† 
SES          
1 (least deprived) 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 
2 1.25 (1.07, 1.45) 1.21 (1.03, 1.42) 1.25 (1.02, 1.53) 
3 1.39 (1.19, 1.61) 1.31 (1.12, 1.53) 1.30 (1.06, 1.59) 
4 1.56 (1.34, 1.81) 1.42 (1.21, 1.66) 1.51 (1.24, 1.84) 
5 (most deprived) 1.79 (1.53, 2.09) 1.63 (1.38, 1.91) 1.57 (1.28, 1.94) 
Sex          
Male 1.00   1.00   1.00   
Female 0.95 (0.87, 1.04) 0.29 0.84 (0.76, 0.93) 0.001 0.87 (0.77, 0.99) 0.04 
Age          
<65 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 65–79 2.99 (2.51, 3.56) 3.04 (2.54, 3.64) 2.68 (2.14, 3.35) 
80–99 7.67 (6.44, 9.13) 6.96 (5.81, 8.34) 6.19 (4.94, 7.75) 
Year of diagnosis          
2010 1.00   1.00   1.00   
2011 0.83 (0.74, 0.93) 0.001 0.85 (0.75, 0.96) 0.008 0.81 (0.68, 0.96) 0.02 
2012 0.79 (0.70, 0.89) <0.001 0.83 (0.73, 0.94) 0.003 0.88 (0.75, 1.03) 0.11 
2013 0.91 (0.75, 1.09) 0.31 0.99 (0.81, 1.20) 0.89 1.00 (0.79, 1.27) 0.98 
Cancer site          
Right-sided colon# 1.00   1.00   1.00   
Transverse colon# 1.28 (1.12, 1.46) <0.001 1.30 (1.13, 1.50) <0.001 1.36 (1.15, 1.63) 0.001 
Left-sided colon# 0.79 (0.71, 0.88) <0.001 1.09 (0.97, 1.23) 0.14 1.09 (0.94, 1.26) 0.25 
   Descending colon 0.95 (0.76, 1.19) <0.001 1.12 (0.88, 1.42) 0.35 1.28 (0.96, 1.71) 0.09 
   Sigmoid colon 0.76 (0.68, 0.86) <0.001 1.08 (0.96, 1.22) 0.91 1.06 (0.91, 1.23) 0.47 
Overlapping site or unspecified 1.94 (1.62, 2.34) <0.001 2.06 (1.69, 2.51) <0.001 1.84 (1.38, 2.47) <0.001 
1
1
4
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Table 4.9 continued  
Variable Bivariable analysis Multivariable analysis Multivariable sensitivity analysis 
  Multiple imputation (n=45907) Complete cases (n=32903) 
 OR* 95% CI p-value† OR** 95% CI p-value† OR** 95% CI p-value† 
Stage          
I 1.00  
<0.001‡ 
   1.00  
0.05‡ 
II 2.31 (1.78, 3.00)    1.59 (0.83, 3.03) 
III 2.09 (1.60, 2.72)    1.30 (0.67, 2.53) 
IV 4.03 (3.09, 5.25)    2.22 (1.13, 4.36) 
Stage§          
I 1.00  
<0.001‡ 
1.00  
<0.001‡ 
   
II 1.00 (0.74, 1.26) 1.67 (0.92, 3.01)    
III 1.02 (0.76, 1.28) 1.61 (0.88, 2.93)    
IV 1.98 (1.72, 2.23) 4.11 (2.25, 7.50)    
Histology          
Adenocarcinoma 1.00         
Adenosquamous/squamous cell carcinoma 1.50 (0.76, 2.94) 0.24       
Non-epithelial tumours 0.74 (0.42, 1.28) 0.28       
Tumour grade          
Well/moderately differentiated 1.00      1.00   
Poorly/undifferentiated 1.69 (1.51, 1.89) <0.001    1.39 (1.20, 1.61) <0.001 
Tumour grade§          
Well/moderately differentiated 1.00   1.00      
Poorly/undifferentiated 0.60 (0.49, 0.71) <0.001 1.39 (1.23, 1.57) <0.001    
 
1
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Table 4.9 continued 
Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio; SES, socioeconomic status. * Adjusted for SES in all variables. Results of bivariable analysis on histology with imputed data and 
completed data did not differ in an important amount. Thus, result with only imputed data are shown. ** All variables are mutually adjusted. For SES only, adjusted ORs are shown without interaction 
between SES and stage. For other variables, interaction between SES and stage is adjusted. # Right-sided colon includes ascending colon, hepatic flexure, caecum and appendix. Transverse colon 
includes transverse colon and splenic flexure. Left-sided colon includes descending colon and sigmoid colon. † P-value of Wald test. ‡ P-value of Wald test for trend. § Multiply imputed.  
Variable Bivariable analysis Multivariable analysis Multivariable sensitivity analysis 
  Multiple imputation (n=45907) Complete cases (n=32903) 
 OR* 95% CI p-value† OR** 95% CI p-value† OR** 95% CI p-value† 
Emergency presentation          
No 1.00      1.00   
Yes 3.99 (3.63, 4.39) <0.001    2.63 (2.32, 2.99) <0.001 
Emergency presentation§          
No 1.00   1.00      
Yes 1.38 (1.29, 1.48) <0.001 2.70 (2.44, 2.99) <0.001    
Number of chronic comorbidities          
0 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 
1 1.90 (1.67, 2.15) 1.59 (1.39, 1.82) 1.75 (1.48, 2.06) 
2 3.34 (2.62, 4.25) 2.61 (2.01, 3.38) 2.89 (2.12, 3.93) 
3+ 3.00 (1.68, 5.35) 1.88 (1.01, 3.51) 2.27 (1.05, 4.89) 
Number of acute comorbidities          
0 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 
1 2.56 (2.29, 2.86) 1.92 (1.71, 2.16) 1.75 (1.50, 2.03) 
2 5.09 (4.18, 6.20) 3.01 (2.43, 3.72) 2.83 (2.16, 3.70) 
3+ 11.05 (7.92, 15.42) 5.98 (4.16, 8.58) 5.30 (3.37, 8.42) 
Obesity at diagnosis          
No 1.00   1.00      
Yes 1.50 (1.10, 2.03) 0.010 1.49 (1.08, 2.06) 0.02    
 
1
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Table 4.10 Odds ratios of postoperative death within 30 days using logistic regression for rectal cancer, England  
Variable Bivariable analysis Multivariable analysis Multivariable sensitivity analysis  
 Multiple imputation (n=19703) Complete cases (n=15401)  
OR* 95% CI p-value† OR** 95% CI p-value† OR** 95% CI p-value† 
SES 
     
 
  
 
1 (least deprived) 1.00 
 
<0.001‡ 
1.00  
0.003‡ 
1.00  
0.003‡ 
2 0.96 (0.71, 1.30) 0.94 (0.69, 1.29) 0.85 (0.57, 1.25) 
3 1.53 (1.16, 2.01) 1.48 (1.11, 1.97) 1.41 (1.00, 1.99) 
4 1.30 (0.97, 1.74) 1.18 (0.87, 1.60) 1.20 (0.83, 1.72) 
5 (most deprived) 1.63 (1.21, 2.20) 1.53 (1.12, 2.09) 1.61 (1.11, 2.33) 
Sex 
     
 
  
 
Male 1.00 
 
 1.00 
 
 1.00 
 
 
Female 0.66 (0.53, 0.80) <0.001 0.61 (0.49, 0.75) <0.001 0.56 (0.43, 0.73) <0.001 
Age 
     
 
  
 
<65 1.00 
 
<0.001‡ 
1.00 
 
<0.001‡ 
1.00 
 
<0.001‡ 65–79 2.72 (2.06, 3.58) 2.55 (1.93, 3.38) 2.23 (1.61, 3.10) 
80–99 8.16 (6.14, 10.85) 6.82 (5.07, 9.16) 5.56 (3.93, 7.87) 
Year of diagnosis 
     
 
  
 
2010 1.00 
  
1.00 
 
 
  
 
2011 0.72 (0.58, 0.91) 0.006 0.76 (0.60, 0.96) 0.02 
  
 
2012 0.82 (0.66, 1.03) 0.09 0.87 (0.69, 1.09) 0.22 
  
 
2013 0.86 (0.60, 1.24) 0.43 0.98 (0.67, 1.42) 0.91 
  
 
Cancer site 
     
 
  
 
Rectosigmoid colon 1.00 
    
 
  
 
Rectum 0.71 (0.58, 0.87) <0.001 
  
 
  
 
Overlapping site or unspecified 0.99 (0.13, 7.33) 1.00 
  
 
  
 
Stage 
     
 
  
 
I 1.00 
 
<0.001‡ 
  
 1.00 
 
0.05‡ 
II 2.47 (1.75, 3.49) 
  
 2.58 (1.09, 6.11) 
III 1.86 (1.31, 2.63) 
  
 1.94 (0.80, 4.69) 
IV 3.09 (2.08, 4.58) 
  
 3.47 (1.31, 9.16) 
Stage§ 
     
 
  
 
I 1.00 
 
<0.001‡ 
1.00 
 
0.002‡ 
  
 
II 2.64 (1.89, 3.68) 2.30 (1.03, 5.17) 
  
 
III 2.16 (1.52, 3.06) 1.91 (0.84, 4.32) 
  
 
IV 5.88 (4.15, 8.34) 4.73 (2.01, 11.11) 
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Table 4.10 continued 
Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio; SES, socioeconomic status. * Adjusted for SES in all variables. Results of bivariable analysis on histology with imputed data and 
completed data did not differ in an important amount. Thus, result with only imputed data are shown. ** All variables are mutually adjusted. For SES only, adjusted ORs are shown without interaction 
between SES and stage. For other variables, interaction between SES and stage is adjusted. † P-value of Wald test. ‡ P-value of Wald test for trend. § Multiply imputed.  
Variable Bivariable analysis Multivariable analysis Multivariable sensitivity analysis   
Multiple imputation (n=19703) Complete cases (n=15401)  
OR* 95% CI p-value† OR** 95% CI p-value† OR** 95% CI p-value† 
Histology          
Adenocarcinoma 1.00 
 
 
  
 
  
 
Adenosquamous/squamous cell carcinoma 1.00 
 
empty 
  
 
  
 
Non-epithelial tumours 0.60 (0.08, 4.30) 0.61 
  
 
  
 
Tumour grade 
  
 
  
 
  
 
Well/moderately differentiated 1.00 
 
 
  
 
  
 
Poorly/undifferentiated 1.51 (1.15, 1.98) 0.003 
  
 
  
 
Tumour grade§ 
  
 
  
 
  
 
Well/moderately differentiated 1.00 
 
 1.00 
 
 
  
 
Poorly/undifferentiated 1.71 (1.32, 2.21) <0.001 1.41 (1.07, 1.85) 0.01 
  
 
Emergency presentation 
  
 
  
 
  
 
No 1.00 
 
 
  
 1.00 
 
 
Yes 4.98 (4.05, 6.13) <0.001 
  
 2.85 (2.14, 3.79) <0.001 
Emergency presentation§ 
  
 
  
 
  
 
No 1.00 
 
 1.00 
 
 
  
 
Yes 4.95 (4.03, 6.09) <0.001 3.11 (2.49, 3.90) <0.001 
  
 
Number of chronic comorbidities 
  
 
  
 
  
 
0 1.00 
 
<0.001‡ 
1.00 
 
<0.001‡ 
1.00 
 
<0.001‡ 
1 2.03 (1.55, 2.65) 1.72 (1.30, 2.28) 1.84 (1.33, 2.56) 
2 4.31 (2.59, 7.18) 3.36 (1.95, 5.79) 3.93 (2.13, 7.24) 
3+ 5.41 (1.61, 18.22) 2.22 (0.61, 8.15) 2.38 (0.51, 11.11) 
Number of acute comorbidities 
  
 
  
 
  
 
0 1.00 
 
<0.001‡ 
1.00 
 
<0.001‡ 
1.00 
 
<0.001‡ 
1 2.42 (1.89, 3.10) 1.62 (1.24, 2.10) 1.44 (1.03, 2.02) 
2 4.14 (2.37, 7.23) 2.29 (1.26, 4.18) 3.20 (1.63, 6.28) 
3+ 13.93 (5.87, 33.08) 6.47 (2.46, 17.00) 7.11 (2.36, 21.46) 
Obesity at diagnosis 
  
 
  
 
  
 
No 1.00 
 
 
  
 
  
 
Yes 1.73 (0.91, 3.29) 0.09 
  
 
  
 
 
1
1
8
 
119 
 
Table 4.11 Stage-specific odds ratios of postoperative death within 30 days using multivariable logistic regression with interaction between SES and stage for colon 
and rectal cancer, England 
Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio; SES, socioeconomic status. All p-values are of Wald test for trend. Model a: adjusted for sex, age, year of diagnosis, site, tumour 
grade§, emergency presentation§, chronic and acute comorbidities, obesity (§: multiply imputed). Model b: adjusted for sex, age, year of diagnosis, site, tumour grade, emergency presentation, chronic 
and acute comorbidities. Model c: adjusted for sex, age, year of diagnosis, tumour grade§, emergency presentation§, chronic and acute comorbidities. Model d: adjusted for sex, age, emergency 
presentation, chronic and acute comorbidities.
 
Colon Rectum 
 Multiple imputationa Complete casesb Multiple imputationc Complete casesd  
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Stage I 
     
       
SES 
     
       
1 (least deprived) 1.00 
 
0.27 
1.00 
 
0.30 
1.00  
0.04 
1.00  
0.007 
2 1.20 (0.58, 2.50) 1.42 (0.65, 3.09) 0.59 (0.19, 1.88) 0.54 (0.16, 1.86) 
3 1.20 (0.56, 2.56) 1.05 (0.45, 2.46) 1.27 (0.51, 3.15) 1.42 (0.54, 3.72) 
4 0.64 (0.25, 1.65) 0.69 (0.25, 1.90) 1.65 (0.68, 3.98) 2.01 (0.78, 5.16) 
5 (most deprived) 2.00 (0.97, 4.14) 2.09 (0.95, 4.58) 1.93 (0.77, 4.81) 2.45 (0.94, 6.39) 
Stage II 
     
       
1 (least deprived) 1.00 
 
<0.001 
1.00 
 
<0.001 
1.00  
0.09 
1.00  
0.05 
2 1.06 (0.78, 1.46) 1.00 (0.72, 1.40) 0.91 (0.50, 1.64) 0.81 (0.42, 1.55) 
3 1.12 (0.82, 1.53) 1.10 (0.78, 1.53) 1.21 (0.69, 2.13) 1.16 (0.64, 2.10) 
4 1.49 (1.11, 2.00) 1.61 (1.17, 2.20) 1.07 (0.60, 1.92) 1.04 (0.57, 1.89) 
5 (most deprived) 1.59 (1.16, 2.18) 1.56 (1.12, 2.18) 1.67 (0.94, 2.96) 1.79 (0.99, 3.22) 
Stage III 
     
       
1 (least deprived) 1.00 
 
0.006 
1.00 
 
0.03 
1.00  
0.35 
1.00  
0.42 
2 1.25 (0.91, 1.73) 1.29 (0.89, 1.86) 0.97 (0.52, 1.81) 0.94 (0.49, 1.81) 
3 1.46 (1.05, 2.02) 1.54 (1.08, 2.21) 1.85 (1.08, 3.16) 1.88 (1.05, 3.37) 
4 1.35 (0.95, 1.91) 1.36 (0.94, 1.98) 1.14 (0.63, 2.08) 1.19 (0.62, 2.27) 
5 (most deprived) 1.62 (1.17, 2.26) 1.54 (1.05, 2.26) 1.23 (0.65, 2.32) 1.16 (0.57, 2.33) 
Stage IV 
     
       
1 (least deprived) 1.00 
 
0.001 
1.00 
 
0.05 
1.00  
0.26 
1.00  
0.46 
2 1.33 (0.98, 1.79) 1.58 (1.07, 2.34) 1.12 (0.56, 2.21) 1.01 (0.43, 2.41) 
3 1.39 (1.03, 1.87) 1.41 (0.95, 2.10) 1.46 (0.75, 2.84) 1.09 (0.47, 2.57) 
4 1.52 (1.13, 2.02) 1.73 (1.18, 2.53) 1.17 (0.61, 2.23) 1.03 (0.43, 2.47) 
5 (most deprived) 1.61 (1.18, 2.19) 1.50 (0.98, 2.29) 1.55 (0.74, 3.23) 1.50 (0.61, 3.68) 
1
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4.2.3 Summary of findings 
Increased age, transverse colon cancer, worse tumour grade, emergency presentation and 
presence of comorbidities were associated with poorer postoperative mortality. 
Among colon cancer patients with stage II to IV and rectal cancer patients with stage I, there 
was evidence that the more deprived groups had higher postoperative mortality than the least 
deprived group when all potential factors were adjusted. A similar socioeconomic gradient was 
also observed among colon cancer patients with stage I and rectal cancer patients with stage II 
to IV, but p-values for trend were high. 
The socioeconomic gradient was reduced but not completely nullified when stage and presence 
of acute comorbidities were taken into account.  
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4.3 Survival by socioeconomic status 
In Chapters 4.1 and 4.2, I explored factors associated with receipt of cancer care and the 
patterns of care by SES. In Chapter 4.3, I investigated general patterns of survival and 
mortality rates by SES without controlling for any other factors. In Chapter 4.4, I explored 
factors associated with survival and displayed socioeconomic differences in survival after the 
potential factors were controlled. 
4.3.1 Methods 
Mortality rates, three-year survival since diagnosis and difference in those figures among SES 
groups were set as the outcomes. I analysed both overall and net survival. 
For net survival, excess hazard ratios (EHRs) of death from CRC can be estimated. Excess 
hazard ratios of death by CRC were derived by comparing the observed overall survival of the 
CRC patients with the expected survival of a similar population (i.e. same sex, age, deprivation 
group and government regions), using lifetables of the background population. Since there are 
no lifetables for 2012 and 2013, the lifetable of 2011 was used to derive net survival for those 
years. 
I used the Royston-Parmar flexible parametric survival model (FPM), which models the basic 
cumulative hazard by restricted cubic spline functions [209]. Advantages of using the FPM over 
a semi-parametric or non-parametric model, such as the Cox regression model or the Kaplan-
Meier method, are that the FPM allows an estimation of the baseline survival function, and the 
FPM enables us to observe the ‘difference’ in hazard and survival graphically [210]. 
Firstly, to apply the restricted cubic splines for the FPM, I modelled the number and positions of 
internal knots for the baseline hazard without any covariates using stpm2. The positions of 
these internal knots were chosen at 90 days, six months and one year since diagnosis based on 
clinical relevance and were compared with the default knots, which were varied from 2 to 5 
degrees of freedom (df). The models were evaluated based on the Akaike information criterion 
(AIC). A model with a smaller AIC is preferred when choosing the number of knots [210]. 
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After selecting a model with a plausible number and positions of knots in the null model, I fitted 
an FPM with a variable SES only. The cumulative hazards were assumed here to be 
proportional among the SES groups (i.e. proportional hazard model [PH] model). Further, I 
assessed the proportional hazard assumption by AIC. I compared the AIC of two models: a 
model with SES acting proportionally and a model with SES treated as a time-varying effect 
(TVE) (i.e. SES interacts with time). For the TVE, the number of internal knots was reduced to 
two [210], positioning at six months and one year since diagnosis. 
The survival curves in the final FPM were graphically compared with survival curves derived 
by the Kaplan-Meier method. The log-cumulative hazard for overall survival was displayed. 
The differences in mortality rate and survival between the least and the most deprived groups 
(subtracting mortality rate/survival of the least deprived from the mortality rate/survival of the 
most deprived) were also estimated by the final FPM for both overall and net survival.  
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4.3.2 Results 
Number and positions of knots in null FPM 
A total of 69,766 colon cancer and 38,267 rectal cancer patients were included. Figure 4.1 and 
Figure 4.2 illustrate the baseline mortality rate and excess mortality rate per 1,000 person-years 
(PYs) for colon cancer. Table 4.12 displays the AIC by number and position of internal knots. 
As shown in the graphs of mortality rate in Figure 4.1 and Figure 4.2, all models with different 
numbers and positions of the knots were similar in both overall and net survival. When 
comparing the AIC of the models, the model with three internal knots positioning at 90 days, six 
months and one year since diagnosis and the model with df 5 (four internal knots positioning at 
20, 40, 60 and 80 centiles of the distribution of uncensored log event-times) showed a relatively 
small AIC. Considering that a smaller number of df is sufficient to understand how data behave 
[211], the model with three internal knots (internal knots positioning at 90 days, six months and 
one year) was chosen for colon cancer. 
The mortality rates and excess mortality rates for rectal cancer displayed in Figure 4.3 and 
Figure 4.4 also showed that all models were similar; however, it was clearer than in the figures 
for colon cancer that the models with df 4 and df 5 show signs of overfitting (curves fluctuating 
at the period of one to two years since diagnosis). From the overfitting figures and AIC (Table 
4.13), the model with three internal knots (internal knots positioning at 90 days, six months and 
one year) was chosen for rectal cancer.  
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Figure 4.1 Mortality rate curves by different degrees of freedom for colon cancer, England 
Abbreviations: 1000 PYs, 1000 person-years; df, degrees of freedom. 
Figure 4.2 Excess mortality rate curves by different degrees of freedom for colon cancer, 
England 
Abbreviations: 1000 PYs, 1000 person-years; df, degrees of freedom. 
Table 4.12 AIC by number and position of knots for colon cancer, England 
Abbreviations: AIC, Akaike information criterion; df, degrees of freedom. The positions of the knots sit on the noted 
centiles of the distribution of uncensored log event-times. 
Number and position of knots AIC 
 Overall survival Net survival 
3 internal knots (at 90 days, 6 months, 1 year) 198576.0 121658.6 
1 internal knot (at 1.5 years) 198710.5 121748.9 
Default 2df (1 internal knot: 50 centiles) 198654.6 121706.2 
Default 3df (2 internal knots: 33, 67 centiles) 198581.5 121667.0 
Default 4df (3 internal knots: 25, 50, 75 centiles) 198593.3 121672.7 
Default 5df (4 internal knots: 20, 40, 60, 80 centiles) 198539.5 121600.5 
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Figure 4.3 Mortality rate curves by different degrees of freedom for rectal cancer, England 
Abbreviations: 1000 PYs, 1000 person-years; df, degrees of freedom. 
Figure 4.4 Excess mortality rate curves by different degrees of freedom for rectal cancer, 
England 
Abbreviations: 1000 PYs, 1000 person-years; df, degrees of freedom. 
Table 4.13 AIC by number and position of knots for rectal cancer, England 
Number and position of knots AIC 
 Overall survival Net survival 
3 internal knots (at 90 days, 6 months, 1year) 93769.2 68131.5 
1 internal knot (at 1.5 year) 93791.7 68150.8 
Default 2df (1 internal knot: 50 centiles) 93789.9 68148.6 
Default 3df (2 internal knots: 33, 67 centiles) 93771.5 68133.8 
Default 4df (3 internal knots: 25, 50, 75 centiles) 93769.4 68131.8 
Default 5df (4 internal knots: 20, 40, 60, 80 centiles) 93742.0 68101.4 
Abbreviations: AIC, Akaike information criterion; df, degrees of freedom. The positions of the knots sit on the noted 
centiles of the distribution of uncensored log event-times.  
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Survival curves and difference in mortality rate, survival by SES 
I added SES to the null model and examined whether HRs among SES groups stayed 
proportional or varied over time. The AIC in Table 4.14 indicates that the model with SES 
treated as a TVE was better in colon cancer, and the model with SES acting proportional was 
better in rectal cancer for both overall and net survival. 
Table 4.14 AIC of FPMs with SES (proportional or TVE), England 
Model AIC 
 Colon cancer Rectal cancer 
 Overall survival Net survival Overall survival Net survival 
     
SES (proportional) 198539.5 121458.5 93553.9 67968.3 
SES (TVE) 198261.9 121422.1 93560.8 67976.5 
Abbreviations: AIC, Akaike information criterion; SES, socioeconomic status; TVE, time-varying effect. 
Figure 4.5 displays the overall survival curves for colon cancer of five SES groups: (a) being 
modelled by FPM with SES treated as TVE and (b) being derived by the Kaplan-Meier method. 
The survival curves modelled by FPM showed a gradient by SES, which did not conflict with 
the curves derived by the Kaplan-Meier method, but rather with smoother lines. There was a 
clear worsening gradient among SES groups from the least deprived to the most deprived in 
both graphs. Since SES interacts with time for colon cancer, the gaps among SES groups in 
terms of (c) log-cumulative hazards and (d) mortality rates narrowed over time. Net survival 
also demonstrated a clear socioeconomic gradient, as shown in Figure 4.6 (a), under a model 
with SES treated as TVE. The gaps among SES groups in excess mortality rates gradually 
diminished. 
Figure 4.7 displays the overall survival curves of five SES groups for rectal cancer. As SES acts 
proportional, the gaps among SES groups in (c) log-cumulative hazards and (d) mortality rates 
were not reduced. Net survival curves and excess mortality rates in Figure 4.8 showed similar 
patterns as for overall survival. 
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Figure 4.5 (a) Overall survival curves by FPM (b) survival curves by Kaplan-Meier method (c) log-cumulative hazards (d) mortality rates by SES group for colon 
cancer, England (SES set as time-varying effect) 
Abbreviations: 1000 PYs, 1000 person-years; FPM, flexible parametric model; SES, socioeconomic status.  
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Figure 4.6 (a) Net survival curves by FPM (b) excess mortality rates by SES group for colon cancer, England (SES set as time-varying effect) 
Abbreviations: 1000 PYs, 1000 person-years; FPM, flexible parametric model; SES, socioeconomic status.  
1
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Figure 4.7 (a) Overall survival curves by FPM (b) survival curves by Kaplan-Meier method (c) log-cumulative hazards (d) mortality rates by SES group for rectal 
cancer, England (SES set as no time-varying effect) 
Abbreviations: 1000 PYs, 1000 person-years; FPM, flexible parametric model; SES, socioeconomic status.  
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Figure 4.8 (a) Net survival curves by FPM (b) excess mortality rates by SES group for rectal cancer, England (SES set as no time-varying effect) 
Abbreviations: 1000 PYs, 1000 person-years; FPM, flexible parametric model; SES, socioeconomic status.
1
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Figure 4.9 graphically demonstrates (a) the HR of the most deprived group when the least 
deprived group is the reference for colon cancer in both overall and net survival, and three 
measures of difference between the least and the most deprived groups derived by the FPM with 
SES treated as TVE. Figure 4.9 (b) displays the difference in the mortality rates per 1,000 PYs, 
(c) survival curves and (d) difference in survival. When no other covariates were adjusted, the 
graphs confirm that both overall and net survival were better in the least deprived group by 
more than 5% at the 3-year point since diagnosis, even with the HR of the most deprived 
approaching 1 (i.e. difference in mortality rate approaching 0) over time. 
For rectal cancer, since the hazard of SES kept proportional throughout, the survival gap 
between the least and the most deprived groups reached more than 10% at the 3-year point since 
diagnosis, as illustrated in Figure 4.10.  
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Figure 4.9 Upper graphs: overall survival, lower graphs: net survival for colon cancer, England. 
(a) Hazard ratio of SES 5 (b) difference in (excess) mortality rate per 1000 PYs (c) (overall/net) 
survival (%) in the most and least deprived groups (d) difference in (overall/net) survival (%) 
between the most and the least deprived groups 
Abbreviations: 1000 PYs, 1000 person-years; SES, socioeconomic status. (a) Reference is SES 1 (least deprived 
group). (b) A positive value means that the mortality is larger in SES 5 (the most deprived group). (d) A negative 
value means that the survival is worse in SES 5.  
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Figure 4.10 Upper graphs: overall survival, lower graphs: net survival for rectal cancer, 
England. (a) Difference in (excess) mortality rate per 1000 PYs (b) (overall/net) survival (%) in 
the most and least deprived groups (c) difference in (overall/net) survival (%) between the most 
and the least deprived groups 
Abbreviations: 1000 PYs, 1000 person-years; SES, socioeconomic status. (a) A positive value means that the 
mortality is larger in SES 5 (the most deprived group). (c) A negative value means that the survival is worse in SES 
5.  
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4.3.3 Summary of findings 
The use of an FPM seemed appropriate, and the number and position of the internal knots 
clinically defined demonstrated a good statistical fit. The graphs estimated by FPMs showed 
that the differences in mortality rates between the least and the most deprived groups in England 
were largest shortly after diagnosis. The mortality rates and excess mortality rates peaked before 
90 days since diagnosis and declined to less than 200 per 1,000 PYs after one year for both 
colon and rectal cancer patients. When not adjusted for any other conditions, the most deprived 
group had lower survival than the least deprived group. The differences in both overall and net 
survival reached approximately 8% for colon cancer and 10% for rectal cancer at the 3-year 
point since diagnosis.  
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4.4 Factors associated with survival and socioeconomic inequalities in 
survival 
Previous sub-chapter (Chapter 4.3) illustrated general patterns of survival by SES, not 
controlling for any other factors. In this sub-chapter, I explored potential factors associated with 
survival and examined whether survival differed by SES after adjusted for the associated 
factors. 
4.4.1 Methods 
Outcome measure 
I conducted three analyses in this sub-chapter. In the first and second analyses, I explored 
potential factors associated with survival and mortality rate ratios (i.e. HR of death) by SES. 
The entry for all survival analyses was the date of diagnosis. In the third analysis, as in Chapter 
4.3, in addition to the mortality rate ‘ratios’, ‘difference’ measures by SES group were 
graphically explored, after adjusting for all potential factors. Three graphical measures were 
presented for each stage for overall and net survival: difference in mortality rates (excess 
mortality rates for net survival) between the least deprived group (SES 1) and the most deprived 
group (SES 5), survival curves of SES 1 and SES 5 and survival difference between the two 
SES groups. 
Analysis strategy 
For deriving factors associated with survival and HRs of SES in the first analysis, I employed 
Cox regression with both imputed and completed data for overall survival. Important variables 
(stage, tumour grade, emergency presentation and histology) were multiply imputed 30 times 
under the MAR assumption (see Chapter 4.1). I conducted bivariable analyses with the main 
effect (SES) for all other variables one at a time, to assess and the confounding effect of each 
variable. Each variable that had strong evidence for association (p<0.05 in the Wald test) with 
the outcome was retained in the multivariable model. Instead of likelihood ratio test, the Wald 
test was unifiedly used for both imputed and completed data to account for the uncertainty in 
imputed data [208]. Variables were further removed by backward elimination. Finally, excluded 
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variables were added back into the model one at a time, and were included in the final 
multivariable model as confounders if the effect of SES in the HR (HR of the most deprived 
group) changed by more than 10%. An interaction term between SES and stage was also added 
as the main interest. Age at diagnosis and sex were included as a priori confounders. 
In the second analysis, I applied the FPM using stpm2. In addition to the advantage of 
visuality in survival differences between groups, the other advantage of using the FPM over a 
semi-parametric model, such as the Cox regression model, is that the FPM easily enables us to 
deal with time-varying effects when the proportional hazard assumption does not hold in the 
Cox regression model. Variable selection of the potential factors associated with survival in the 
FPM was based on multivariable Cox regression analyses in the first analysis [212]. After the 
variable selection, I checked the proportional hazard assumption using Schoenfeld residuals for 
each variable. The identified variables that did not hold the proportional hazard assumption 
were changed to time-varying covariates (TVCs) in the FPM model. When fitting the FPM, 
from the results of Chapter 4.3, positions of the internal knots for the non-TVCs were set at 
three points at 90 days, six months and one year from the date of diagnosis. For the TVCs, the 
number of internal knots was reduced from three (baseline hazard) to two [210]: time points at 
six months and one year from the date of diagnosis. Since imputed data are not technically 
supported in estimations of hazard and survival difference by FPM, the model was built with 
completed data only. Therefore, in this chapter, analyses using imputed data in the first analysis 
were considered sensitivity analyses. After building the FPMs with TVCs for overall survival, I 
adopted the same models for net survival. 
In the third analysis, differences in mortality rates and survival were displayed in figures using 
the results of FPMs in the second analysis for both overall and net survival. 
As in Chapter 4.1 and 4.2, in all analyses in Chapter 4.4, site of colon cancer was categorised 
in three groups, but sub-group analysis (site categorised in four groups: right-sided, transverse, 
descending and sigmoid colon) were also conducted.  
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4.4.2 Results 
First analysis (Cox regression for overall survival and hazard ratios by SES) 
Factors associated with overall survival 
The first analysis using Cox regression included 38,624 colon cancer (55.4% of total) and 
22,630 rectal cancer patients (59.1% of total) with completed data. The sensitivity analysis 
using imputed data included 69,762 colon cancer and 38,267 rectal cancer patients. 
Table 4.15 and Table 4.16 illustrate the results of bivariable and multivariable analyses of Cox 
regression for overall survival. To show the overall change in the effect of SES, the adjusted 
HRs of SES in those tables were based on a model without interaction between SES and stage. 
For the rest, adjusted HRs were based on the multivariable model with interaction between SES 
and stage (final model). As in Chapter 4.1 and 4.2, for the sub-group analysis, results of 
variables except site in the multivariable analyses were omitted. 
All factors except obesity were associated with survival. Adjusted HRs of SES on Table 4.15 
and Table 4.16 confirmed that the socioeconomic gradient in survival remained even after 
controlling for the associated factors. For both colon and rectal cancer patients in completed 
data, there was strong evidence for the association between increased age, increased number of 
comorbidities and higher mortality rates. Patients with worse tumour grades (poorly 
differentiated or undifferentiated tumours) or emergency presentation had a 70 to 80% increase 
in mortality rates compared with the patients with better tumour grades (well or moderately 
differentiated tumours) or those without emergency presentation. Patients who did not receive 
major surgery had a threefold increase in mortality rate compared with the patients who 
received surgery when adjusting for all other variables. Patients with left-sided colon cancer 
(both descending and sigmoid colon cancer) had slightly lower mortality rates than patients with 
right or transverse colon cancer. Mortality rates were lower among patients with rectal cancer 
than patients with rectosigmoid cancer.  
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Hazard ratios of death by SES 
Table 4.17 compares the stage-specific HRs among SES groups in each stage derived by the 
multivariable Cox regression models with interaction between SES and stage using imputed and 
completed data. 
Analyses of completed data suggested a clear socioeconomic gradient towards higher HRs in 
deprived groups for colon cancer with stages II and III, and for rectal cancer at stages I and II, 
even after adjusting for all other factors (Table 4.17). A weak socioeconomic trend was also 
observed for colon cancer at stage I and rectal cancer at stages III and IV. The trend was more 
evident in the sensitivity analyses using imputed data in all stages for both cancers. 
Bivariable analyses implied that stage and emergency presentation confounded the effect of SES 
on survival. The HR of the most deprived group was reduced when those factors were adjusted 
one at a time, but only by less than 10%. Other factors influenced the socioeconomic 
inequalities in survival in a negligible amount in bivariable analyses.
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Table 4.15 Hazard ratios of death using Cox regression for colon cancer, England  
Variable Bivariable analysis Multivariable sensitivity analysis Multivariable analysis 
  Multiple imputation (n=69762) Complete cases (n=38624)  
HR* 95% CI p-value† HR** 95% CI p-value† HR** 95% CI p-value† 
SES          
1 (least deprived) 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 
2 1.08 (1.05, 1.12) 1.04 (1.01, 1.08) 1.03 (0.97, 1.08) 
3 1.15 (1.11, 1.20) 1.10 (1.06, 1.14) 1.05 (0.99, 1.10) 
4 1.26 (1.22, 1.31) 1.17 (1.12, 1.21) 1.13 (1.07, 1.19) 
5 (most deprived) 1.32 (1.27, 1.37) 1.25 (1.20, 1.30) 1.16 (1.09, 1.22) 
Sex         
 
Male 1.00   1.00   1.00   
Female 1.07 (1.05, 1.10) <0.001 0.98 (0.96, 1.01) 0.24 0.93 (0.90, 0.97) <0.001 
Age          
<65 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 65–79 1.37 (1.33, 1.42) 1.57 (1.51, 1.63) 1.46 (1.39, 1.53) 
80–99 3.00 (2.90, 3.09) 2.54 (2.45, 2.64) 2.37 (2.26, 2.50) 
Year of diagnosis          
2010 1.00   1.00   1.00   
2011 0.99 (0.96, 1.02) 0.40 1.06 (1.03, 1.10) <0.001 0.96 (0.92, 1.01) 0.13 
2012 0.96 (0.94, 0.99) 0.02 1.09 (1.05, 1.12) <0.001 0.94 (0.90, 0.98) 0.006 
2013 1.01 (0.96, 1.06) 0.63 1.11 (1.06, 1.18) <0.001 0.94 (0.87, 1.01) 0.08 
Cancer site          
Right-sided colon# 1.00   1.00   1.00   
Transverse colon# 1.03 (0.99, 1.06) 0.17 1.03 (0.99, 1.08) 0.13 1.04 (0.98, 1.09) 0.20 
Left-sided colon# 0.77 (0.75, 0.79) <0.001 0.83 (0.81, 0.86) <0.001 0.82 (0.79, 0.85) <0.001 
   Descending colon 0.83 (0.78, 0.88) <0.001 0.86 (0.80, 0.91) <0.001 0.85 (0.78, 0.93) <0.001 
   Sigmoid colon 0.76 (0.74, 0.78) <0.001 0.83 (0.80, 0.85) <0.001 0.81 (0.78, 0.85) <0.001 
Overlapping site or unspecified 2.21 (2.13, 2.29) <0.001 1.23 (1.18, 1.29) <0.001 1.12 (1.03, 1.21) 0.007 
 
1
3
9
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Table 4.15 continued  
Variable Bivariable analysis Multivariable sensitivity analysis Multivariable analysis  
 Multiple imputation (n=69762) Complete cases (n=38624) 
 HR* 95% CI p-value† HR** 95% CI p-value† HR** 95% CI p-value† 
Stage          
I 1.00  
<0.001‡ 
   1.00  
<0.001‡ 
II 1.85 (1.70, 2.02)    1.70 (1.36, 2.12) 
III 3.53 (3.25, 3.84)    3.39 (2.74, 4.18) 
IV 15.28 (14.10, 16.56)    11.22 (9.16, 13.75) 
Stage§          
I 1.00  
<0.001‡ 
1.00  
<0.001‡ 
   
II 1.91 (1.75, 2.08) 2.04 (1.69, 2.46)    
III 3.50 (3.22, 3.80) 3.75 (3.12, 4.50)    
IV 14.82 (13.65, 16.09) 11.00 (9.26, 13.07)    
Histology          
Adenocarcinoma 1.00   1.00   1.00   
Adenosquamous and squamous cell carcinoma 0.77 (0.63, 0.93) 0.008 0.49 (0.39, 0.63) <0.001 0.83 (0.62, 1.12) 0.23 
Non-epithelial tumours 0.47 (0.42, 0.53) <0.001 0.35 (0.31, 0.40) <0.001 0.68 (0.57, 0.81) <0.001 
Tumour grade          
Well/moderately differentiated 1.00      1.00  
<0.001 
Poorly/undifferentiated 2.23 (2.16, 2.31) <0.001    1.76 (1.69, 1.83) 
Tumour grade§          
Well/moderately differentiated 1.00   1.00      
Poorly/undifferentiated 2.19 (2.11, 2.26) <0.001 1.60 (1.55,1.66) <0.001    
1
4
0
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Table 4.15 continued 
Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio; SES, socioeconomic status. * Adjusted for SES in all variables. Results of bivariable analysis on histology with imputed data and 
completed data did not differ in an important amount. Thus, results with only completed data are shown. ** All variables are mutually adjusted. For SES only, adjusted HRs are shown without 
interaction between SES and stage. For other variables, interaction between SES and stage is adjusted. # Right-sided colon includes ascending colon, hepatic flexure, caecum and appendix. Transverse 
colon includes transverse colon and splenic flexure. Left-sided colon includes descending colon and sigmoid colon. † P-value of Wald test. ‡ P-value of Wald test for trend.  
Variable Bivariable analysis Multivariable sensitivity analysis Multivariable analysis  
 Multiple imputation (n=69762) Complete cases (n=38624) 
 HR* 95% CI p-value† HR** 95% CI p-value† HR** 95% CI p-value† 
Emergency presentation          
No 1.00      1.00   
Yes 2.06 (2.01, 2.12) <0.001    1.85 (1.78, 1.92) <0.001 
Emergency presentation§          
No 1.00   1.00      
Yes 2.19 (2.11, 2.26) <0.001 1.69 (1.64, 1.73) <0.001    
Major surgery for primary lesion          
Received 1.00   1.00   1.00   
Not received 4.91 (4.79 ,5.02) <0.001 2.89 (2.80, 2.98) <0.001 2.92 (2.79, 3.05) <0.001 
Number of chronic comorbidities          
0 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 
1 1.50 (1.45, 1.55) 1.21 (1.17, 1.26) 1.22 (1.15, 1.28) 
2 2.22 (2.09, 2.35) 1.40 (1.30, 1.50) 1.70 (1.53, 1.90) 
3+ 2.65 (2.35, 2.98) 1.53 (1.32, 1.79) 1.51 (1.19, 1.91) 
Number of acute comorbidities          
0 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 
1 1.57 (1.52, 1.62) 1.27 (1.22, 1.31) 1.24 (1.18, 1.30) 
2 2.39 (2.25 ,2.53) 1.45 (1.36, 1.55) 1.56 (1.41, 1.72) 
3+ 3.07 (2.74, 3.45) 1.73 (1.49, 2.00) 2.41 (1.98, 2.93) 
Obesity at diagnosis          
No 1.00         
Yes 0.93 (0.85, 1.03) 0.16       
 
1
4
1
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Table 4.16 Hazard ratios of death using Cox regression for rectal cancer, England  
Variable Bivariable analysis Multivariable sensitivity analysis Multivariable analysis 
  Multiple imputation (n=38267) Complete cases (n=22630) 
 HR* 95% CI p-value† HR** 95% CI p-value† HR** 95% CI p-value† 
SES          
1 (least deprived) 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 
2 1.06 (1.01, 1.12) 1.01 (0.96, 1.07) 0.97 (0.90, 1.04) 
3 1.16 (1.10, 1.22) 1.09 (1.03, 1.15) 1.05 (0.97, 1.13) 
4 1.27 (1.20, 1.33) 1.14 (1.07, 1.20) 1.04 (0.96, 1.12) 
5 (most deprived) 1.43 (1.36, 1.51) 1.23 (1.16, 1.30) 1.16 (1.08, 1.26) 
Sex          
Male 1.00   1.00   1.00   
Female 1.06 (1.03, 1.10) 0.001 0.98 (0.94, 1.01) 0.23 0.91 (0.87, 0.96) <0.001 
Age          
<65 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 65–79 1.49 (1.43, 1.56) 1.63 (1.56, 1.71) 1.60 (1.51, 1.70) 
80–99 3.73 (3.57, 3.90) 2.99 (2.84, 3.14) 2.96 (2.77, 3.17) 
Year of diagnosis          
2010 1.00   1.00   1.00   
2011 0.94 (0.90, 0.98) 0.002 1.02 (0.98, 1.07) 0.33 0.97 (0.91, 1.03) 0.26 
2012 0.87 (0.84, 0.91) <0.001 0.97 (0.93, 1.01) 0.16 0.89 (0.84, 0.95) <0.001 
2013 0.89 (0.83, 0.96) 0.002 1.06 (0.98, 1.15) 0.12 0.93 (0.83, 1.03) 0.15 
Cancer site          
Rectosigmoid junction 1.00   1.00   1.00   
Rectum 0.78 (0.75, 0.81) <0.001 0.81 (0.78, 0.85) <0.001 0.89 (0.84, 0.95) <0.001 
Overlapping site or unspecified 0.93 (0.76, 1.12) 0.43 0.85 (0.67, 1.08) 0.19 0.79 (0.53, 1.20) 0.27 
1
4
2
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Table 4.16 continued  
Variable Bivariable analysis Multivariable sensitivity analysis Multivariable analysis 
  Multiple imputation (n=38267) Complete cases (n=22630) 
 HR* 95% CI p-value† HR** 95% CI p-value† HR** 95% CI p-value† 
Stage          
I 1.00  
<0.001‡ 
   1.00  
<0.001‡ 
II 2.13 (1.94, 2.34)    2.38 (1.87, 3.04) 
III 2.89 (2.66, 3.15)    3.27 (2.62, 4.09) 
IV 12.34 (11.40, 13.36)    10.10 (8.18, 12.48) 
Stage§          
I 1.00  
<0.001‡ 
1.00  
<0.001‡ 
   
II 2.17 (1.99, 2.38) 2.25 (1.83, 2.77)    
III 2.83 (2.61, 3.08) 2.88 (2.39, 3.48)    
IV 11.87 (11.00, 12.81) 8.96 (7.50, 10.70)    
Histology          
Adenocarcinoma 1.00   1.00   1.00   
Adenosquamous and squamous cell carcinoma 0.85 (0.72, 0.99) 0.03 0.60 (0.50, 0.71) <0.001 0.77 (0.61, 0.98) 0.03 
Non-epithelial tumours 0.98 (0.86, 1.13) 0.83 0.77 (0.64, 0.94) 0.01 1.58 (1.27, 1.97) <0.001 
Tumour grade          
Well/moderately differentiated 1.00      1.00   
Poorly/undifferentiated 2.15 (2.05, 2.26) <0.001    1.79 (1.69, 1.90) <0.001 
Tumour grade§          
Well/moderately differentiated 1.00   1.00      
Poorly/undifferentiated 2.09 (1.99, 2.20) <0.001 1.70 (1.61, 1.79) <0.001    
1
4
3
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Table 4.16 continued 
Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio; SES, socioeconomic status. * Adjusted for SES in all variables. Results of bivariable analysis on histology with imputed data and 
completed data did not differ in an important amount. Thus, results with only completed data are shown. ** All variables are mutually adjusted. For SES only, adjusted ORs are shown without 
interaction between SES and stage. For other variables, interaction between SES and stage is adjusted. ‡ P-value of Wald test for trend.  
Variable Bivariable analysis Multivariable sensitivity analysis Multivariable analysis 
  Multiple imputation (n=38267) Complete cases (n=22630) 
 HR* 95% CI p-value† HR** 95% CI p-value† HR** 95% CI p-value† 
Emergency presentation          
No 1.00      1.00   
Yes 3.30 (3.16, 3.44) <0.001    1.81 (1.70, 1.93) <0.001 
Emergency presentation§          
No 1.00   1.00      
Yes 3.38 (3.24, 3.52) <0.001 1.93 (1.84, 2.02) <0.001    
Major surgery for primary lesion          
Received 1.00   1.00   1.00   
Not received 4.82 (4.64, 5.01) <0.001 2.89 (2.77, 3.02) <0.001 2.90 (2.74, 3.06) <0.001 
Number of chronic comorbidities          
0 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 
1 1.62 (1.55, 1.71) 1.31 (1.23, 1.38) 1.38 (1.28, 1.48) 
2 2.46 (2.23, 2.70) 1.58 (1.42, 1.76) 1.87 (1.59, 2.20) 
3+ 3.05 (2.53, 3.66) 1.82 (1.40, 2.37) 2.76 (1.98, 3.84) 
Number of acute comorbidities          
0 1.00  
<0.001‡ 
1.00  
<0.001‡ 
1.00  
<0.001‡ 
1 1.81 (1.73, 1.90) 1.35 (1.28, 1.42) 1.32 (1.22, 1.42) 
2 2.72 (2.46, 3.01) 1.57 (1.39, 1.77) 1.69 (1.42, 2.00) 
3+ 3.60 (2.89, 4.48) 1.93 (1.50, 2.48) 2.12 (1.46, 3.08) 
Obesity at diagnosis          
No 1.00         
Yes 0.92 (0.79, 1.08) 0.30       
1
4
4
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Table 4.17 Stage-specific hazard ratios of death using multivariable Cox regression with interaction between SES and stage for colon and rectal cancer, England 
Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio; SES, socioeconomic status. All p-values are of Wald test for trend. Model a, b, c, d: adjusted for sex, age, site, year of diagnosis, 
histology§, tumour grade§, emergency presentation§, receipt of major surgery, number of chronic and acute comorbidities (§: multiply imputed in Model a, c).
 
Colon Rectum 
 Multiple imputationa Complete casesb Multiple imputationc Complete casesd  
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value 
Stage I             
SES             
1 (least deprived) 1.00  
0.002 
1.00  
0.42 
1.00  
0.007 
1.00  
0.01 
2 1.15 (0.91, 1.44) 1.03 (0.78, 1.36) 1.07 (0.86, 1.34) 1.01 (0.77, 1.33) 
3 1.16 (0.93, 1.46) 1.00 (0.75, 1.32) 1.09 (0.86, 1.37) 1.10 (0.84, 1.44) 
4 1.27 (1.01, 1.59) 1.03 (0.77, 1.37) 1.21 (0.97, 1.51) 1.13 (0.86, 1.49) 
5 (most deprived) 1.47 (1.15, 1.88) 1.16 (0.86, 1.55) 1.36 (1.07, 1.72) 1.43 (1.08, 1.88) 
Stage II             
1 (least deprived) 1.00  
<0.001 
1.00  
<0.001 
1.00  
<0.001 
1.00  
0.002 
2 1.07 (0.96, 1.20) 1.01 (0.88, 1.16) 1.00 (0.85, 1.19) 0.98 (0.80, 1.20) 
3 1.17 (1.04, 1.31) 1.11 (0.97, 1.27) 1.18 (1.00, 1.40) 1.15 (0.94, 1.40) 
4 1.38 (1.23, 1.56) 1.38 (1.21, 1.59) 1.23 (1.04, 1.47) 1.14 (0.93, 1.39) 
5 (most deprived) 1.46 (1.30, 1.64) 1.45 (1.26, 1.67) 1.34 (1.13, 1.59) 1.32 (1.08, 1.63) 
Stage III             
1 (least deprived) 1.00  
<0.001 
1.00  
<0.001 
1.00  
<0.001 
1.00  
0.09 
2 1.14 (1.04, 1.25) 1.17 (1.05, 1.30) 1.02 (0.91, 1.16) 0.98 (0.85, 1.13) 
3 1.14 (1.04, 1.25) 1.11 (0.99, 1.23) 1.15 (1.03, 1.29) 1.07 (0.93, 1.24) 
4 1.21 (1.10, 1.33) 1.18 (1.06, 1.32) 1.23 (1.09, 1.39) 1.12 (0.97, 1.29) 
5 (most deprived) 1.37 (1.25, 1.51) 1.32 (1.19, 1.48) 1.20 (1.07, 1.36) 1.07 (0.92, 1.25) 
Stage IV             
1 (least deprived) 1.00  
<0.001 
1.00  
0.29 
1.00  
<0.001 
1.00  
0.05 
2 1.01 (0.96, 1.06) 0.97 (0.90, 1.04) 1.00 (0.92, 1.08) 0.95 (0.85, 1.05) 
3 1.08 (1.02, 1.13) 1.01 (0.94, 1.08) 1.04 (0.96, 1.13) 1.00 (0.90, 1.11) 
4 1.11 (1.06, 1.17) 1.04 (0.97, 1.12) 1.07 (0.99, 1.16) 0.95 (0.86, 1.06) 
5 (most deprived) 1.17 (1.10, 1.24) 1.00 (0.93, 1.09) 1.20 (1.10, 1.31) 1.13 (1.02, 1.26) 
 
1
4
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Second analysis (Flexible parametric model for overall/net survival and hazard ratios/excess 
hazard ratios by SES) 
The variables in the first analysis using Cox regression were applied to the FPM in the second 
analysis for overall and net survival to address variables violating the proportional hazard 
assumption. 
To identify TVCs, I checked the proportional hazard assumption in each variable of the 
multivariable Cox regression models derived in the first analysis. In both cancers, the 
proportional hazard assumption was held among SES groups after adjusting for covariates in the 
Cox regression models. In colon cancer, the assumption was violated for nine variables: sex, age 
at diagnosis, site, stage, histology, tumour grade, emergency presentation, receipt of major 
surgery and number of acute comorbidities. Those nine variables were included as TVCs in the 
FPM for overall survival. Histology was changed to non-TVC for net survival since the FPM 
did not converge if histology was treated as a TVC. 
In rectal cancer, the proportional hazard assumption was violated for five variables: age at 
diagnosis, site, histology, tumour grade and emergency presentation. Those five variables were 
included as TVCs in the FPM for both overall and net survival. 
Factors associated with survival 
Hazard ratios of the non-TVCs in the FPM for overall survival showed close agreement with 
HRs in the Cox regression models (see Table 4.15 vs Table 4.18 and Table 4.16 vs Table 4.19). 
There was generally a clear socioeconomic gradient with higher hazards in the deprived groups 
for both cancers, for both overall and net survival (Table 4.18 and Table 4.19). As observed in 
the previous analyses, chronic comorbidities were consistently associated with increased 
mortality rates also for net survival (Table 4.18 and Table 4.19). 
For the TVCs, HRs and EHRs change over time. Table 4.20 and Table 4.21 illustrate the point 
estimates of the HRs and EHRs for the TVCs at 90 days, six months and one year since 
diagnosis. For both cancers, the effect of age on hazard decreased over time. Emergency 
presentation had a waxing effect on hazard for both cancers under the overall and net survival 
settings. Regarding the site of cancer, HR and EHR of sigmoid colon cancer were lower than 
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right-sided colon cancer at 90 days from diagnosis; however, HR and EHR of descending colon 
cancer also decreased to that of sigmoid colon cancer over the time. Rectal cancer continuously 
had lower mortality rates than rectosigmoid cancer. However, the hazard of rectal cancer 
increased over time, suggesting that the increased mortality rates after six months could be due 
to the local recurrence, which often occurs in rectal cancer. When comparing the HRs and EHRs 
of the stages, EHRs expanded substantially in stage IV. The inflations imply that the reference 
group of patients with stage I rarely died from cancer. The effect of tumour grade on HRs/EHRs 
changed over time, but the worse grades (poorly differentiated or undifferentiated tumours) 
persistently had double the rate of that in the better grades (well or moderately differentiated 
tumours) after adjusting for other factors. The effects of major surgery and acute comorbidities 
on HRs/EHRs changed over time only among colon cancer patients but were both highest in the 
first period (90 days since diagnosis).  
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Table 4.18 Hazard ratios (overall survival) and excess hazard ratios (net survival) of death using 
multivariable FPM with TVCs for colon cancer, England 
Variable Overall survival Net survival 
 HR* 95% CI EHR* 95% CI 
SES     
1 (least deprived) 1.00  1.00  
2 1.03 (0.97, 1.09) 1.01 (0.95, 1.08) 
3 1.05 (0.99, 1.11) 1.01 (0.94, 1.07) 
4 1.13 (1.07, 1.19) 1.09 (1.02, 1.16) 
5 (most deprived) 1.16 (1.09, 1.23) 1.09 (1.01, 1.16) 
Sex TVC  TVC  
Age TVC  TVC  
Year of diagnosis     
2010 1.00  1.00  
2011 0.97 (0.92, 1.01) 0.95 (0.90, 1.00) 
2012 0.95 (0.90, 0.99) 0.95 (0.90, 1.00) 
2013 0.94 (0.87, 1.01) 0.93 (0.85, 1.02) 
Cancer site TVC  TVC  
Stage TVC  TVC  
Histology     
Adenocarcinoma TVC  1.00  
asc/scc   0.78 (0.56, 1.10) 
Non-epithelial tumours   0.73 (0.60, 0.89) 
Tumour grade TVC  TVC  
Emergency presentation TVC  TVC  
Major surgery for primary lesion TVC  TVC  
Number of chronic comorbidities     
0 1.00  1.00  
1 1.22 (1.15, 1.28) 1.22 (1.14, 1.30) 
2 1.69 (1.51, 1.89) 1.78 (1.55, 2.04) 
3+ 1.48 (1.17, 1.88) 1.40 (1.04, 1.89) 
Number of acute comorbidities TVC  TVC  
Abbreviations: 95% CI, 95% confidence interval; asc, adenosquamous cell carcinoma; EHR, excess hazard ratio; HR, 
hazard ratio; scc, squamous cell carcinoma; SES, socioeconomic status; TVC, time-varying covariate. * All variables 
are mutually adjusted. For SES only, adjusted HRs/EHRs are shown without interaction between SES and stage. For 
other variables, interaction between SES and stage is adjusted.  
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Table 4.19 Hazard ratios (overall survival) and excess hazard ratios (net survival) of death using 
multivariable FPM with TVCs for rectal cancer, England 
Variable Overall survival Net survival 
 HR* 95% CI EHR* 95% CI 
SES     
1 (least deprived) 1.00  1.00  
2 0.97 (0.90, 1.04) 0.95 (0.87, 1.04) 
3 1.05 (0.97, 1.13) 1.02 (0.93, 1.12) 
4 1.04 (0.96, 1.12) 0.99 (0.90, 1.09) 
5 (most deprived) 1.16 (1.08, 1.26) 1.10 (1.00, 1.21) 
Sex     
Male 1.00  1.00  
Female 0.92 (0.87, 0.96) 0.97 (0.91, 1.03) 
Age TVC  TVC  
Year of diagnosis     
2010 1.00  1.00  
2011 0.96 (0.91, 1.02) 0.99 (0.92, 1.07) 
2012 0.89 (0.84, 0.95) 0.91 (0.85, 0.98) 
2013 0.94 (0.84, 1.04) 1.01 (0.89, 1.15) 
Cancer site TVC  TVC  
Stage     
I 1.00  1.00  
II 2.21 (1.74, 2.82) 6.17 (3.01, 12.64) 
III 2.45 (1.96, 3.06) 10.04 (5.02, 20.10) 
IV 7.93 (6.43, 9.79) 35.63 (17.95, 70.73) 
Histology TVC  TVC  
Tumour grade TVC  TVC  
Emergency presentation  TVC  TVC  
Major surgery for primary lesion     
Received 1.00  1.00  
Not received 2.89 (2.74, 3.05) 3.65 (3.39, 3.92) 
Number of chronic comorbidities     
0 1.00  1.00  
1 1.37 (1.27, 1.48) 1.38 (1.26, 1.52) 
2 1.86 (1.58, 2.18) 2.00 (1.64, 2.43) 
3+ 2.70 (1.94, 3.76) 3.21 (2.16, 4.76) 
Number of acute comorbidities     
0 1.00  1.00  
1 1.31 (1.21, 1.41) 1.35 (1.23, 1.49) 
2 1.69 (1.43, 2.01) 1.79 (1.46, 2.20) 
3+ 2.12 (1.46, 3.08) 2.41 (1.57, 3.72) 
Abbreviations: 95% CI, 95% confidence interval; EHR, excess hazard ratio; HR, hazard ratio; SES, socioeconomic 
status; TVC, time-varying covariate. * All variables are mutually adjusted. For SES only, adjusted HRs/EHRs are 
shown without interaction between SES and stage. For other variables, interaction between SES and stage is adjusted.
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Table 4.20 Point estimates of hazard ratios (overall survival) and excess hazard ratios (net survival) of death for time-varying covariates at 90 days, 6 months and 1 
year since diagnosis using multivariable FPM with TVCs and interaction between SES and stage for colon cancer, England  
Variable Overall survival Net survival 
 90 days 6 months 1 year 90 days 6 months 1 year  
HR 95% CI HR 95% CI HR 95% CI EHR 95% CI EHR 95% CI EHR 95% CI 
SES Proportional hazard assumption holds Proportional hazard assumption holds 
Sex             
Male 1.00  1.00  1.00  1.00  1.00  1.00  
Female 0.96 (0.91, 1.02) 0.94 (0.88, 1.00) 0.93 (0.88, 0.98) 1.00 (0.93, 1.07) 0.98 (0.90, 1.06) 0.97 (0.91, 1.04) 
Age             
<65 1.00  1.00  1.00  1.00  1.00  1.00  
65–79 1.67 (1.54, 1.82) 1.50 (1.38, 1.64) 1.41 (1.31, 1.52) 1.57 (1.44, 1.72) 1.36 (1.20, 1.54) 1.19 (1.07, 1.33) 
80–99 2.65 (2.42, 2.89) 2.42 (2.20, 2.66) 2.31 (2.14, 2.50) 2.15 (1.94, 2.39) 1.76 (1.49, 2.09) 1.40 (1.19, 1.66) 
Year of diagnosis Proportional hazard assumption holds Proportional hazard assumption holds 
Cancer site             
Right-sided colon# 1.00  1.00  1.00  1.00  1.00  1.00  
Transverse colon# 1.15 (1.06, 1.25) 1.09 (1.00, 1.20) 1.02 (0.94, 1.11) 1.13 (1.03, 1.25) 1.10 (0.97, 1.24) 1.01 (0.90, 1.13) 
Left-sided colon# 0.77 (0.72, 0.82) 0.73 (0.68, 0.79) 0.78 (0.73, 0.82) 0.73 (0.67, 0.79) 0.67 (0.59, 0.75) 0.72 (0.66, 0.78) 
   Descending colon 0.93 (0.81, 1.08) 0.72 (0.59, 0.88) 0.74 (0.64, 0.84) 0.90 (0.76, 1.07) 0.65 (0.48, 0.89) 0.67 (0.55, 0.82) 
   Sigmoid colon 0.74 (0.69, 0.80) 0.73 (0.68, 0.79) 0.78 (0.73, 0.83) 0.71 (0.65, 0.77) 0.67 (0.59, 0.75) 0.72 (0.67, 0.79) 
Overlapping site or unspecified 1.23 (1.09, 1.39) 1.05 (0.90, 1.23) 1.01 (0.89, 1.14) 1.21 (1.05, 1.39) 1.02 (0.82, 1.26) 0.95 (0.80, 1.13) 
Stage             
I 1.00  1.00  1.00  1.00  1.00  1.00  
II 1.78 (1.34, 2.36) 1.79 (1.37, 2.35) 1.78 (1.39, 2.28) 2.79 (1.44, 5.40) 2.74 (1.38, 5.42) 3.21 (1.63, 6.32) 
III 2.53 (1.92, 3.33) 3.53 (2.72, 4.58) 3.95 (3.12, 5.02) 5.13 (2.70, 9.73) 7.86 (4.05, 15.23) 11.10 (5.74, 21.45) 
IV 8.45 (6.49, 11.01) 12.63 (9.81, 16.26) 14.02 (11.14, 17.64) 19.20 (10.19, 36.18) 32.33 (16.77, 62.34) 45.81 (23.84, 88.05) 
1
5
0
 
 
151 
 
Table 4.20 continued 
Variable Overall survival Net survival 
 90 days 6 months 1 year 90 days 6 months 1 year 
 HR 95% CI HR 95% CI HR 95% CI EHR 95% CI EHR 95% CI EHR 95% CI 
Histology       Changed to proportional hazard 
Adenocarcinoma 1.00  1.00  1.00        
asc/scc 1.14 (0.71, 1.84) 0.95 (0.55, 1.62) 0.80 (0.49, 1.30)       
Non-epithelial tumours 0.98 (0.74, 1.29) 0.74 (0.54, 1.03) 0.61 (0.46, 0.80)       
Tumour grade             
Well/moderately differentiated 1.00  1.00  1.00  1.00  1.00  1.00  
Poorly/undifferentiated 2.02 (1.89, 2.15) 2.31 (2.16, 2.48) 2.01 (1.90, 2.13) 2.21 (2.05, 2.38) 2.63 (2.36, 2.94) 2.23 (2.07, 2.41) 
Emergency presentation              
No 1.00  1.00  1.00  1.00  1.00  1.00  
Yes 1.73 (1.59, 1.89) 1.81 (1.68, 1.95) 1.86 (1.76, 1.97) 1.72 (1.50, 1.97) 1.87 (1.69, 2.08) 1.97 (1.82, 2.13) 
Major surgery for primary lesion             
Received 1.00  1.00  1.00  1.00  1.00  1.00  
Not received 3.83 (3.55, 4.13) 3.58 (3.33, 3.84) 2.91 (2.72, 3.11) 4.20 (3.81, 4.63) 3.88 (3.53, 4.25) 3.02 (2.75, 3.32) 
Number of chronic comorbidities Proportional hazard assumption holds Proportional hazard assumption holds 
Number of acute comorbidities             
0 1.00  1.00  1.00  1.00  1.00  1.00  
1 1.26 (1.16, 1.36) 1.14 (1.03, 1.25) 1.16 (1.08, 1.24) 1.24 (1.12, 1.36) 1.11 (0.96, 1.28) 1.14 (1.03, 1.26) 
2 1.61 (1.40, 1.86) 1.44 (1.20, 1.74) 1.42 (1.23, 1.64) 1.57 (1.33, 1.85) 1.44 (1.12, 1.84) 1.39 (1.14, 1.70) 
3+ 2.35 (1.81, 3.05) 1.73 (1.19, 2.52) 1.88 (1.46, 2.42) 2.41 (1.75, 3.30) 1.70 (0.99, 2.94) 2.04 (1.46, 2.86) 
Abbreviations: 95% CI, 95% confidence interval; asc, adenosquamous carcinoma; EHR, excess hazard ratio; HR, hazard ratio; SES, socioeconomic status; scc, squamous cell carcinoma. # Right-sided 
colon includes ascending colon, hepatic flexure, caecum and appendix. Transverse colon includes transverse colon and splenic flexure. Left-sided colon includes descending colon and sigmoid colon.   
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Table 4.21 Point estimates of hazard ratios (overall survival) and excess hazard ratios (net survival) of death for time-varying covariates at 90 days, 6 months and 1 
year since diagnosis using FPM with TVCs and interaction between SES and stage for rectal cancer, England 
Variable Overall survival Net survival 
 90 days 6 months 1 year 90 days 6 months 1 year  
HR 95% CI HR 95% CI HR 95% CI EHR 95% CI EHR 95% CI EHR 95% CI 
SES Proportional hazard assumption holds Proportional hazard assumption holds 
Sex Proportional hazard assumption holds Proportional hazard assumption holds 
Age 
            
<65 1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
65–79 1.86 (1.63, 2.13) 1.74 (1.56, 1.93) 1.59 (1.44, 1.76) 1.75 (1.51, 2.02) 1.59 (1.42, 1.79) 1.41 (1.27, 1.57) 
80–99 3.09 (2.69, 3.55) 3.07 (2.74, 3.44) 3.01 (2.71, 3.34) 2.43 (2.07, 2.85) 2.39 (2.09, 2.73) 2.21 (1.95, 2.51) 
Year of diagnosis Proportional hazard assumption holds Proportional hazard assumption holds 
Cancer site 
            
Rectosigmoid junction 1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
Rectum 0.82 (0.73, 0.93) 0.88 (0.80, 0.98) 0.91 (0.83, 1.00) 0.80 (0.70, 0.92) 0.85 (0.75, 0.95) 0.86 (0.77, 0.96) 
Overlapping site or unspecified 0.51 (0.12, 2.08) 0.81 (0.31, 2.11) 0.67 (0.29, 1.54) 0.42 (0.07, 2.40) 0.75 (0.25, 2.27) 0.70 (0.28, 1.75) 
Stage Proportional hazard assumption holds Proportional hazard assumption holds 
Histology 
            
Adenocarcinoma 1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
asc/scc 0.96 (0.62, 1.48) 1.09 (0.78, 1.53) 0.93 (0.64, 1.37) 0.99 (0.62, 1.56) 1.10 (0.76, 1.58) 0.91 (0.60, 1.37) 
Non-epithelial tumours 1.72 (1.22, 2.42) 1.40 (0.92, 2.13) 1.25 (0.86, 1.81) 1.71 (1.20, 2.44) 1.47 (0.95, 2.26) 1.36 (0.93, 2.00) 
Tumour grade 
            
Well/moderately differentiated 1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
Poorly/undifferentiated 1.96 (1.74, 2.20) 2.17 (1.98, 2.39) 2.00 (1.82, 2.19) 2.10 (1.84, 2.38) 2.34 (2.10, 2.60) 2.16 (1.95, 2.40) 
Emergency presentation  
            
No 1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
Yes 1.63 (1.39, 1.92) 1.57 (1.38, 1.79) 1.63 (1.47, 1.81) 1.57 (1.27, 1.95) 1.64 (1.41, 1.91) 1.78 (1.58, 2.00) 
Major surgery for primary lesion Proportional hazard assumption holds Proportional hazard assumption holds 
Number of chronic comorbidities Proportional hazard assumption holds Proportional hazard assumption holds 
Number of acute comorbidities Proportional hazard assumption holds Proportional hazard assumption holds 
Abbreviations: 95% CI, 95% confidence interval; asc, adenosquamous carcinoma; EHR, excess hazard ratio; HR, hazard ratio; SES, socioeconomic status; scc, squamous cell carcinoma 
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Hazard ratios and excess hazard ratios of death by SES 
The adjusted HRs estimated by the multivariable FPMs with TVCs and interaction between SES 
and stage agreed with the figures estimated by the multivariable Cox regression models (see 
Table 4.17 and Table 4.22). As seen in the Cox regression models using completed data, there 
was a gradient towards higher HRs among deprived groups for colon cancer patients with stage 
I, II and III, and rectal cancer patients with stage I, II, III and IV. A similar trend was also 
confirmed for EHRs in net survival. 
Table 4.22 Stage-specific hazard ratios (overall survival) and excess hazard ratios (net survival) 
of death using multivariable FPM with TVCs and interaction between SES and stage for colon 
and rectal cancer, England 
Abbreviations: 95% CI, 95% confidence interval; EHR, excess hazard ratio; HR, hazard ratio; SES, socioeconomic 
status. Model a, b: adjusted for sexT, ageT, year of diagnosis, siteT, stageT, histologyT*, tumour gradeT, emergency 
presentationT, major surgeryT, chronic and acuteT comorbidities (T: time-varying covariate. * Histology is time-
varying covariate only in Model a). Model c, d: adjusted for sex, ageT, year of diagnosis, siteT, stage, histologyT, 
tumour gradeT, emergency presentationT, major surgery, chronic and acute comorbidities.  
 Colon Rectum 
 Overall survivala Net survivalb Overall survivalc Net survivald 
 HR 95% CI EHR 95% CI HR 95% CI EHR 95% CI 
Stage I         
SES         
1 (least deprived) 1.00  1.00  1.00  1.00  
2 1.03 (0.78, 1.36) 1.11 (0.49, 2.51) 1.01 (0.77, 1.33) 1.33 (0.57, 3.11) 
3 1.00 (0.75, 1.32) 0.65 (0.23, 1.85) 1.11 (0.85, 1.45) 1.36 (0.58, 3.20) 
4 1.03 (0.77, 1.38) 1.04 (0.44, 2.47) 1.14 (0.87, 1.50) 1.31 (0.54, 3.14) 
5 (most deprived) 1.17 (0.87, 1.57) 1.46 (0.64, 3.31) 1.44 (1.10, 1.90) 1.96 (0.84, 4.54) 
Stage II         
1 (least deprived) 1.00  1.00  1.00  1.00  
2 1.01 (0.88, 1.16) 0.95 (0.74, 1.22) 0.98 (0.80, 1.20) 0.89 (0.64, 1.23) 
3 1.11 (0.97, 1.28) 1.01 (0.78, 1.31) 1.15 (0.95, 1.40) 1.14 (0.85, 1.54) 
4 1.37 (1.20, 1.57) 1.53 (1.21, 1.94) 1.14 (0.93, 1.39) 1.15 (0.85, 1.56) 
5 (most deprived) 1.44 (1.25, 1.66) 1.57 (1.23, 2.00) 1.33 (1.08, 1.63) 1.40 (1.03, 1.90) 
Stage III         
1 (least deprived) 1.00  1.00  1.00  1.00  
2 1.17 (1.05, 1.30) 1.16 (1.02, 1.33) 0.98 (0.85, 1.13) 0.97 (0.80, 1.16) 
3 1.11 (1.00, 1.23) 1.06 (0.93, 1.22) 1.07 (0.93, 1.24) 1.04 (0.86, 1.25) 
4 1.19 (1.07, 1.33) 1.12 (0.98, 1.29) 1.12 (0.97, 1.30) 1.12 (0.93, 1.34) 
5 (most deprived) 1.33 (1.19, 1.48) 1.28 (1.11, 1.47) 1.07 (0.92, 1.25) 1.03 (0.85, 1.25) 
Stage IV         
1 (least deprived) 1.00  1.00  1.00  1.00  
2 0.97 (0.90, 1.04) 0.97 (0.90, 1.04) 0.95 (0.86, 1.06) 0.95 (0.85, 1.06) 
3 1.01 (0.93, 1.08) 0.99 (0.92, 1.07) 1.00 (0.90, 1.11) 0.99 (0.89, 1.11) 
4 1.05 (0.97, 1.13) 1.04 (0.96, 1.12) 0.96 (0.86, 1.07) 0.93 (0.83, 1.04) 
5 (most deprived) 1.01 (0.93, 1.09) 0.98 (0.90, 1.07) 1.13 (1.01, 1.26) 1.08 (0.96, 1.21) 
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Third analysis (Graphical figures of measures of difference by SES) 
From the FPMs fitted in the second analysis, I estimated three measures of difference in graphs: 
hazard/excess hazard difference between the least and the most deprived groups, survival curves 
of the two groups and survival difference between the two groups (Figure 4.11 to Figure 4.22). 
For all figures, results were shown by each sex and stage. Year of diagnosis was set at 2010, age 
group at under 65 years old, cancer site at right-sided colon in colon cancer and rectosigmoid 
junction in rectal cancer, histology of adenocarcinoma, tumour grade of well/moderately 
differentiated tumours, no emergency presentation, received major surgery and having no 
chronic or acute comorbidities. 
For colon cancer, the hazard difference marked positive values in all stages; the most deprived 
group had a larger mortality rate than the least deprived group. In stages II and III, the 
difference hit a sharp peak around 20 per 1,000 PYs at the very beginning, but in stage III, the 
figure again demonstrated a gradual increase over time (Figure 4.11). As expected from the 
hazard difference, the least deprived group had higher overall survival than the most deprived 
group in all stages (Figure 4.12). The gap in overall survival was largest in stage III, reaching 
approximately 5% at the 3-year point (Figure 4.13). The excess hazard difference showed 
similar patterns to the hazard difference but marked below 0 in stage IV (Figure 4.14). As the 
excess mortality rate of the most deprived was lower than that of the least deprived group in 
stage IV, the net survival of the most deprived group was slightly better than the least deprived 
group in this stage (Figure 4.15). The difference in net survival was largest in stage III, reaching 
around 4% at the 3-year point (Figure 4.16). 
For rectal cancer, the hazard difference marked positive values in all stages as for colon cancer 
but was largest in stage IV (Figure 4.17). The difference in overall survival in stage IV extended 
to 4% at the 3-year point, followed by 3% in stage II (Figure 4.18 and Figure 4.19). The patterns 
of the excess hazard difference were comparable to that of the hazard difference. In stages I and 
III, the gap was almost null, whereas more than 5/1,000 PYs of the difference was observed in 
stages II and IV (Figure 4.20). The most deprived group had worse net survival than the least 
155 
 
deprived group in all stages (Figure 4.21); however, the gap expanded no more than 3% for all 
stages. Only in stage II, the 95% CI of the gap remained below 0 throughout (Figure 4.22). 
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Figure 4.11 Hazard difference between the least and the most deprived groups for colon cancer, England 
(A) Stage I, male (B) stage I, female (C) stage II, male (D) stage II, female  
A B 
D C 
←
d
ep
ri
ve
d
 b
et
te
r 
ǀ a
ff
lu
en
t 
b
et
te
r→
 
←
d
ep
ri
ve
d
 b
et
te
r 
ǀ a
ff
lu
en
t 
b
et
te
r→
 
←
d
ep
ri
ve
d
 b
et
te
r 
ǀ a
ff
lu
en
t 
b
et
te
r→
 
←
d
ep
ri
ve
d
 b
et
te
r 
ǀ a
ff
lu
en
t 
b
et
te
r→
 
1
5
6
 
 
157 
 
Figure 4.11 continued (hazard difference between the least and the most deprived groups for colon cancer, England) 
(E) Stage III, male (F) stage III, female (G) stage IV, male (H) stage IV, female 
Abbreviations: 1000 PYs, 1000 person-years.  
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Figure 4.12 Overall survival of the least deprived group (SES 1, solid line) and the most deprived group (SES 5, dotted line) for colon cancer, England 
(A) Stage I, male (B) stage I, female (C) stage II, male (D) stage II, female  
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Figure 4.12 continued (overall survival of the least deprived (SES 1, solid line) and the most deprived (SES 5, dotted line) for colon cancer, England) 
(E) Stage III, male (F) stage III, female (G) stage IV, male (H) stage IV, female 
Abbreviations: SES, socioeconomic status.  
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Figure 4.13 Difference in overall survival between the least and the most deprived groups for colon cancer, England 
(A) Stage I, male (B) stage I, female (C) stage II, male (D) stage II, female  
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Figure 4.13 continued (difference in overall survival between the least and the most deprived groups for colon cancer, England) 
(E) Stage III, male (F) stage III, female (G) stage IV, male (H) stage IV, female  
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Figure 4.14 Excess hazard difference between the least and the most deprived groups for colon cancer, England 
(A) Stage I, male (B) stage I, female (C) stage II, male (D) stage II, female  
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Figure 4.14 continued (excess hazard difference between the least and the most deprived groups for colon cancer, England) 
(E) Stage III, male (F) stage III, female (G) stage IV, male (H) stage IV, female 
Abbreviations: 1000 PYs, 1000 person-years.  
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Figure 4.15 Net survival of the least deprived group (SES 1, solid line) and the most deprived group (SES 5, dotted line) for colon cancer, England 
(A) Stage I, male (B) stage I, female (C) stage II, male (D) stage II, female  
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Figure 4.15 continued (net survival of the least deprived group [SES 1, solid line] and the most deprived group [SES 5, dotted line] for colon cancer, England) 
(E) Stage III, male (F) stage III, female (G) stage IV, male (H) stage IV, female 
Abbreviations: SES, socioeconomic status.  
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Figure 4.16 Difference in net survival between the least and the most deprived groups for colon cancer, England 
(A) Stage I, male (B) stage I, female (C) stage II, male (D) stage II, female  
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Figure 4.16 continued (difference in net survival between the least and the most deprived groups for colon cancer, England) 
(E) Stage III, male (F) stage III, female (G) stage IV, male (H) stage IV, female  
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Figure 4.17 Hazard difference between the least and the most deprived groups for rectal cancer, England 
(A) Stage I, male (B) stage I, female (C) stage II, male (D) stage II, female  
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Figure 4.17 continued (hazard difference between the least and the most deprived groups) for rectal cancer, England 
(E) Stage III, male (F) stage III, female (G) stage IV, male (H) stage IV, female 
Abbreviations: 1000 PYs, 1000 person-years.  
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Figure 4.18 Overall survival of the least deprived group (SES 1, solid line) and the most deprived group (SES 5, dotted line) for rectal cancer, England 
(A) Stage I, male (B) stage I, female (C) stage II, male (D) stage II, female
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Figure 4.18 continued (overall survival of the least deprived group [SES 1, solid line] and the most deprived group [SES 5, dotted line] for rectal cancer, England) 
(E) Stage III, male (F) stage III, female (G) stage IV, male (H) stage IV, female 
Abbreviations: SES, socioeconomic status.  
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Figure 4.19 Difference in overall survival between the least and the most deprived groups for rectal cancer, England 
(A) Stage I, male (B) stage I, female (C) stage II, male (D) stage II, female  
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Figure 4.19 continued (difference in overall survival between the least and the most deprived groups for rectal cancer, England) 
(E) Stage III, male (F) stage III, female (G) stage IV, male (H) stage IV, female  
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Figure 4.20 Excess hazard difference between the least and the most deprived groups for rectal cancer, England 
(A) Stage I, male (B) stage I, female (C) stage II, male (D) stage II, female  
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Figure 4.20 continued (excess hazard difference between the least and the most deprived groups) for rectal cancer, England 
(E) Stage III, male (F) stage III, female (G) stage IV, male (H) stage IV, female 
Abbreviations: 1000 PYs, 1000 person-years.  
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Figure 4.21 Net survival of the least deprived group (SES 1, solid line) and the most deprived group (SES 5, dotted line) for rectal cancer, England 
(A) Stage I, male (B) stage I, female (C) stage II, male (D) stage II, female  
B 
D 
A 
C 
 
1
7
6
 
177 
 
Figure 4.21 continued (net survival of the least deprived group [SES 1, solid line] and the most deprived group [SES 5, dotted line] for rectal cancer, England) 
(E) Stage III, male (F) stage III, female (G) stage IV, male (H) stage IV, female 
Abbreviations: SES, socioeconomic status.  
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Figure 4.22 Difference in net survival between the least and the most deprived groups for rectal cancer, England 
(A) Stage I, male (B) stage I, female (C) stage II, male (D) stage II, female  
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Figure 4.22 continued (difference in net survival between the least and the most deprived groups for rectal cancer, England) 
 (E) Stage III, male (F) stage III, female (G) stage IV, male (H) stage IV, female 
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4.4.3 Summary of findings 
Increased age, worse tumour grade, emergency presentation, increased number of acute/chronic 
comorbidities and non-receipt of major surgery were associated with worse survival. 
Socioeconomic inequalities in survival were observed, but stage and emergency presentation 
decreased the gap to some extent. Non-receipt of surgery and increased number of acute 
comorbidities affected survival especially shortly after diagnosis for colon cancer. Emergency 
presentation had a waxing effect on survival. In Cox regression analyses, the socioeconomic 
trend towards higher HRs in the deprived groups was clear among colon cancer patients with 
stages II and III, and rectal cancer patients with stages I and II. There was also a weak trend for 
colon cancer with stage I and rectal cancer with stages III and IV. 
In addition to the relative measures (HRs), I provided absolute measures (differences) in 
mortality rate and survival. The hazard difference and survival difference between the least and 
the most deprived groups were estimated using the FPM incorporating TVCs for overall and net 
survival. The survival difference between the least and the most deprived groups was noticeable 
among colon cancer patients with stages II and III, and rectal cancer patients with stages I, II 
and IV.  
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4.5 Mediation analysis 
Chapter 4.1 demonstrated that there was a socioeconomic gradient favouring the affluent in 
receipt of major surgery, particularly for rectal cancer with stage II to IV, when potential 
confounders were adjusted. Chapter 4.4 illustrated a survival gap between the least and the 
most deprived groups, particularly for colon cancer with stage II and III and rectal cancer with 
stage I, II and IV, under the overall survival setting. 
In this sub-chapter, I combined these two analyses and proceeded with a mediation analysis to 
understand the potential magnitude of the effect of inequalities in cancer care on socioeconomic 
inequalities in survival at several time points. 
4.5.1 Methods 
Outcome measure 
The outcome measure was conditional mortalities set at three time points: 90 days, six months 
and one year since diagnosis. The main interest was to see the magnitude of the effect of 
socioeconomic inequalities in stage distribution, emergency presentation and surgical treatment 
on the conditional mortalities. Those three variables were treated as mediators having NIE, and 
the magnitude of the effects of the mediators was derived as ‘proportion mediated’ (NIE out of 
TCE) in mediation analysis. Details of the definitions are described in Chapter 3. 
Analysis strategy 
All results were derived in ratios in log-odds of death by five SES groups using g-computation, 
which employs Monte Carlo simulations. The TCE is the sum of effects that SES has on the 
log-odds of death after all variables are fitted in the designed model. The NIE of SES is the 
effect of SES on the log-odds of death, mediated by stage plus chronic and acute comorbidities 
in Figure 4.23 for example. ‘Proportion mediated’ measures how much effect of the TCE is 
mediated through the effect of NIEs. 
Figure 4.23, Figure 4.24 and Figure 4.25 are the DAGs of the three conducted analyses. The 
first mediation analysis focuses on the effect of the socioeconomic inequalities in stage 
distribution on the inequalities in conditional mortality at 90 days, six months and one year. The 
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second mediation analysis focuses on the effect of the socioeconomic inequalities in emergency 
presentation on the inequalities in conditional mortalities at the three time points. The third 
mediation analysis focuses on the effect of socioeconomic inequalities in treatment (binary 
outcome yes/no of the receipt of major surgery for the primary lesion) on the inequalities in 
conditional mortalities at the three time points. 
In the first analysis, stage was defined as a mediator, affecting socioeconomic inequalities in 
conditional mortalities at several time points. In addition, chronic and acute comorbidities were 
defined as mediators affected by SES and affecting conditional mortalities but were not directly 
associated with the stage (Figure 4.23). The NIE in this DAG is the effect of the three mediators 
measured en bloc. In the second analysis, a variable of the main interest, emergency 
presentation, was added to the first mediation model (Figure 4.24). The NIE in this DAG is the 
effect of the four mediators measured en bloc. Then, in the third analysis, a variable of the main 
interest, receipt of major surgery, was added to the second model (Figure 4.25). Emergency 
presentation, stage and comorbidities were treated as post-exposure confounders; they were 
affected by SES and affected both the variable ‘treatment’ and the outcome of conditional 
mortalities. 
The difference in PM, between the first and second mediation models, indicates the magnitude 
of the effect of emergency presentation on the inequalities in survival status. The difference in 
PM, between the second and third mediation models, indicates the magnitude of the effect of 
receipt of major surgery on the inequalities in survival status. 
In all analyses, sex, age and year of diagnosis were defined as baseline confounders. Age was 
treated as a continuous variable having a spline function after centred around the mean. As in 
the previous analyses, SES was categorised into five groups, stage into four, and comorbidities 
into four groups, with 0 indicating no comorbidities and +3 indicating three or more 
comorbidities. 
To separate the effect of the main interest on the outcome at several duration of time, 
conditional mortalities were coded binary (0 alive, 1 dead) at three time points at 90 days, six 
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months and one year. Patients who died before 90 days from diagnosis were coded 1 at 90 days 
mortality and were not included in the conditional mortality at the next time period (i.e. six 
months). Patients who survived more than 90 days were coded 0 or 1 in the conditional 
mortality at six months, depending on their vital status at six months from diagnosis. Similarly, 
patients who survived more than six months were included in the conditional mortality at one 
year. 
Bootstrap was conducted 1,000 times using Monte Carlo simulation in each analysis with the 
outcome of conditional mortality at 90 days, six months and one year. Stage information was 
missing at approximately 30% for both colon and rectal cancer. Emergency presentation was 
missing at 9.8% for colon, and 6.7% for rectal cancer. Stage and emergency presentation were 
therefore imputed 30 times by single stochastic imputation using chained equations within the 
g-computation. 
Figure 4.23 DAG of the first mediation analysis 
Chronic/acute comorbidities and stage were the mediators. Age, sex and year of diagnosis were the baseline 
confounders.  
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Figure 4.24 DAG of the second mediation analysis 
Chronic/acute comorbidities, emergency presentation and stage were the mediators. Age, sex and year of diagnosis 
were the baseline confounders. 
Figure 4.25 DAG of the third mediation analysis 
Treatment (binary outcome: received major surgery for the primary lesion yes/no) was the mediator. Chronic/acute 
comorbidities, emergency presentation and stage worked as post-exposure confounders, which were affected by SES 
and affected treatment and conditional mortality. Age, sex and year of diagnosis were the baseline confounders.  
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4.5.2 Results 
The ORs of death among SES groups at three time points are displayed in Figure 4.26 and 
Figure 4.27. The TCE and NIE with stage (denoted as St) show the results of the first analysis, 
stage and emergency presentation (denoted as St & EmPr) the second analysis, and stage, 
emergency presentation and treatment (denoted as St & EmPr & Tx) the third analysis. 
The three mediation analyses modelled clear slopes by SES in ORs of the TCEs. For colon 
cancer, the slopes of the TCE slightly flattened over time, while for rectal cancer, the slopes did 
not level out throughout. For both cancers, NIEs in all time points showed no clear 
socioeconomic trends for the first and second analyses; however, the NIEs in ORs of all SES 
groups marked over 1 in the third analysis. 
The PMs by the mediators (NIE divided by TCE in the log-odds scale of SES 5 when odds of 
SES 1 were set at the reference of 1) are illustrated in Figure 4.28. In the first mediation 
analysis, stage (and comorbidities) mediated the effect of SES on survival status over 20% at all 
three time points for both cancers. For rectal cancer, stage and comorbidities explained the 
increased odds of death in the most deprived group by more than 30%. 
When emergency presentation was modelled as an additional mediator in the second analysis, 
the proportion, which the model explains the effect of SES on the survival status, improved at 
all time points for both cancers. The largest improvement in PM was observed at six months 
since diagnosis of rectal cancer with +20%, followed by the same time point with +17% for 
colon cancer. However, surgical treatment less contributed to the inequalities in survival status. 
When treatment was modelled as an additional mediator in the third mediation analysis, the 
proportion, which the model explains the effect of SES on the survival status, showed little 
improvement or rather reduction, especially in rectal cancer. For rectal cancer, the third analysis 
with treatment explained approximately 30% of the inequalities in survival status at all time 
points. For colon cancer, the third analysis with treatment explained over 50% of the 
inequalities in survival status at six months and one year but remained below 30% at 90 days 
since diagnosis. 
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Figure 4.26 Total causal effect and natural indirect effect in odds ratios of death at 90 days, 6 months, 1 year since diagnosis for colon cancer, England  
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Figure 4.26 continued 
Abbreviations: EmPr, emergency presentation; NIE, natural indirect effect; SES, socioeconomic status; St, stage; TCE, total causal effect; Tx, treatment.  1
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Figure 4.27 Total causal effect and natural indirect effect in odds ratios of death at 90 days, 6 months, 1 year since diagnosis for rectal cancer, England  
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Figure 4.27 continued 
Abbreviations: EmPr, emergency presentation; NIE, natural indirect effect; SES, socioeconomic status; St, stage; TCE, total causal effect; Tx, treatment. 1
8
9
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Figure 4.28 Proportion mediated in three mediation analyses with mediators of stage, stage and 
emergency presentation, and stage, emergency presentation and surgical treatment for colon 
(upper graph) and rectal cancer (lower graph), England 
Abbreviations: EmPr, emergency presentation; St, stage; Tx, treatment.  
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4.5.3 Summary of findings 
Socioeconomic inequalities in stage distribution, comorbidities and emergency presentation 
explained the socioeconomic inequalities in survival status by at least 20% in both colon and 
rectal cancer. Stage, comorbidities, emergency presentation and treatment inequalities greatly 
contributed to the socioeconomic inequalities in survival status by more than 50% for colon 
cancer after six months since diagnosis, but these factors explained the inequalities in survival 
status by only 30% in the early timeline for both cancers. 
Results of the 90-day conditional mortality revealed that the known factors (stage, 
comorbidities, emergency presentation and receipt of surgical treatment) played a relatively 
minor role in socioeconomic inequalities in survival status for both cancers in the early timeline. 
Regarding conditional mortality at six months, the effect of emergency presentation increased 
PM by 20% compared to a model with stage and comorbidities as mediators. The results mean 
that the survival gap could further be reduced by 20%, if emergency presentation were equalised 
between the most and the least deprived groups, in addition to 30% of the gap being cancelled 
by equalising the distribution of stage and comorbidities between the two groups. No further 
improvement in PM in the third analysis means that the additional effect of equalising the 
percentage in receipt of surgery on reducing the gap in survival status deemed to be small, 
especially for rectal cancer patients. For colon cancer patients, as demonstrated in Chapter 4.1, 
the percentage in receipt of surgery was relatively equalised among SES groups; this is 
considered to be the reason the PM in the third model did not improve from the second 
mediation model.  
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4.6 Discussion 
4.6.1 Socioeconomic inequalities in receipt of surgery and postoperative mortality 
For colon cancer, receipt of major surgery and time to treatment did not differ among SES 
groups, but postoperative mortality was worse among the deprived groups in stages II to IV. 
The differences in postoperative mortality among SES groups have three potential reasons. 
Firstly, quality of care might be different (i.e. different types of hospital or difference in the 
characteristics of hospitals) among SES groups. For instance, lower SES groups may be treated 
in hospitals that have a smaller number of ICU beds, a smaller number of medical staff or 
unspecialised doctors. Secondly, some biological factors (e.g. factors at the molecular level) 
may exist, which could also be associated with SES but were not measured. However, it is 
unlikely that biological factors would affect such short-term postoperative mortality. Thirdly, 
some behavioural factors, which are closely related to both SES and mortality, may exist [213]. 
Potential examples include smoking status, nutrition status, progression of the CRC stage after 
diagnosis and existence of family or social care. If a patient smokes or in low nutrition status, 
the patient is likely to have major postoperative complications such as respiratory complications 
or leakage [213-215]. Stage of CRC could have progressed more among lower SES groups 
compared with the least deprived group while awaiting treatment. Although there was no 
difference in time from diagnosis to treatment for colon cancer, the time from recognition of 
symptoms to diagnosis could be longer in the deprived groups because of differences in health-
seeking behaviour; time to diagnosis, otherwise called the ‘appraisal interval’ and ‘help-seeking 
interval’ [177], was not incorporated in this analysis. If a patient has no family members or 
carers after discharge and experiences complications, late readmission or aggravated 
complications can be expected. 
For rectal cancer with stages II to IV, the deprived groups were less likely to receive major 
surgery. Although there was a socioeconomic trend towards worse postoperative mortality 
among the deprived groups, evidence was relatively weak compared with that of colon cancer. 
These facts suggest that once patients receive surgery, the quality of care provided seems to be 
uniform (i.e. the quality of hospitals may not vary) regardless of SES group. Some rectal cancer 
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patients may require neoadjuvant therapy, such as CRT or SCPRT. Through the therapy 
courses, patients might have been selected before undergoing surgery for a few potential 
reasons. If a patient could not attend the neoadjuvant therapy because of low access to facilities, 
this could also affect the further treatment choices. This accessibility might be related to SES 
due to geographical distance or job inflexibility [92, 148, 216]. Alternatively, adherence to 
treatment may be low in deprived groups [213, 217]. Another reason for the selection of 
surgical treatment could be related to performance status. Lastly, patients who were able to care 
for a stoma by themselves or family members might be more likely to be selected for surgery. 
To conclude, the results presented in Chapter 4.1 and Chapter 4.2 indicate that colon cancer 
patients receive surgery equally, but the quality of care (surgical and postoperative care) may 
vary among SES groups, possibly across the hospitals. Rectal cancer patients might be selected 
for surgery based on unmeasured factors, but patients from different SES groups seem to 
receive a standardised quality of care. The unmeasured factors could be related to receipt of 
neoadjuvant therapy, access issues or behavioural factors, which may also vary among SES 
groups. 
Careful interpretation is needed for the analyses in Chapter 4.1. The outcome in Chapter 4.1 is 
a binary variable of whether receiving major surgery for the primary lesion. Among patients 
with either colon or rectal cancer with stage I or IV, not receiving major surgery does not 
necessarily mean inappropriate care. For some patients with stage I, having only an endoscopic 
resection (e.g. EMR or ESD) can be a sufficient treatment option intending cure. However, there 
was no information on whether the stage I patients had unfavourable histological findings, and 
data regarding why major surgery for the primary lesion was not performed were mostly 
missing. 
Similarly, for patients with stage IV, there was little information on why the major surgery was 
not performed. In stage IV, indication for major surgery for the primary lesion largely depends 
on clinical factors (performance status, the severity of obstruction or bleeding symptoms, 
whether the patient reacted to chemotherapy aiming conversion therapy and extent of metastasis 
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to other organs), which are not fully captured in the population data. Neither palliative intent nor 
curative intent was clear among stage IV patients. 
Misclassification of the outcome could occur because of the aforementioned reasons; thus, at 
this point, the results of Chapter 4.1 and Chapter 4.2 may only be interpretable with certainty 
for CRC patients with stage II or III, who have a potential for cure if treated appropriately. 
4.6.2 Socioeconomic inequalities in survival and their mediators 
In Chapter 4.2, higher prevalence of emergency presentation and urgent operation (surgery 
within seven days of diagnosis) in the deprived groups was observed among colon cancer 
patients. The fact suggests that, in addition to improving the quality of postoperative care, 
reducing emergency presentation may also reduce the survival gap among SES groups. In fact, 
since 2012, significant efforts have been made to standardise and improve the quality of care for 
those undergoing emergency laparotomy [218, 219]. 
In Chapter 4.4, the FPM estimated that the HRs of emergency presentation increased over time 
in both cancers. Mediation analyses also suggested that the survival gap, especially after six 
months of diagnosis, was mediated at around 20% by the inequalities in emergency 
presentation. Over 27% of the emergency presenters were in stage IV (Chapter 4.1.2). Some 
emergency presentations may be inevitable [220]. Although factors associated with emergency 
presentation are known to include a higher stage [220], the fact that emergency presentation 
affected survival after six months, independent of stage, suggests that emergency presentation 
may also be associated with other biological factors, behavioural factors or access issues. 
Potential biological factors include tumour grade, site or symptoms. Emergency presenters had 
fewer recorded ‘red flag symptoms’ than non-emergency presenters [220, 221]. However, no 
studies have explored the association between those factors and SES. In this thesis, no 
association was found between tumour grade and SES. Although the GP consultation pattern 
was shown to be the same among emergency presenters and non-emergency presenters [221], 
behavioural factors and healthcare access may not only affect the mode of presentation and 
receipt of surgery, but overall interactions between the patient and the healthcare system: receipt 
of neoadjuvant therapy, adjuvant therapy or attendance at follow-up. For colon cancer, the 
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hazard difference between SES 1 and SES 5 marked the first peak shortly after diagnosis but 
continued widening in stage III after six months from diagnosis. The figures in Chapter 4.4 
refer to the patients who did not have emergency presentation, but those figures also support the 
existence of unmeasured factors related to survival (e.g. receipt of adjuvant therapy or 
attendance at follow-up after surgery). 
For rectal cancer patients, despite the gap in receipt of surgery, mediation analyses confirmed 
that the survival gap, particularly observed in stage II, was mediated by inequalities in 
emergency presentation but less so through inequalities in receipt of surgical treatment. The 
combined results imply that even if surgical treatment is provided with an equal percentage to 
all SES groups, the survival gap may not be reduced. The aforementioned potential unmeasured 
factors may partly mediate the remaining pathway in socioeconomic inequalities in survival, but 
not through the differences in emergency presentation, comorbidities, stage and receipt of 
surgical treatment. 
4.6.3 Insights into factors associated with receipt of surgery, postoperative 
mortality and survival 
As illustrated in Table 4.1 and Table 4.2, a socioeconomic gradient towards a worse stage 
among lower SES groups was observed only for rectal cancer. These findings are in line with a 
previous study in Denmark [222] and may be symptom-related. Colon cancer patients may have 
vague symptoms that are confused with other benign conditions equally for all SES groups. On 
the other hand, rectal cancer patients may have rectal bleeding, which is more obvious and 
easier to be aware of; however, diagnosis can be delayed in the lower SES groups because of 
their health-seeking behaviour or poor communication with GPs. As Sinding et al. (2014) noted 
[11], patients with a louder voice (i.e. more affluent patients) may attract the attention of GPs 
more easily than less privileged patients. 
Chapter 4.2 and Chapter 4.4 revealed that the different effects of colon cancer site on 
postoperative mortality and survival. Transverse colon cancer had higher odds of postoperative 
death than cancer of the right-sided colon, while long-term survival was similar between the two 
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sites. One potential reason for the higher postoperative mortality in transverse colon cancer may 
be a higher probability of leakage in the transverse colon than in the right-sided colon due to 
anatomical structure related to the blood supply. 
In colon cancer, as cancer locates more distal, odds of not receiving surgery increased; right-
sided colon cancers were more selected to surgery for some reasons. Stage advantaged sigmoid 
colon cancer for the postoperative 30-day mortality. Sigmoid colon cancer had lower hazard of 
death systemically than right-sided colon cancer. Descending colon cancer had the same hazard 
of death as the right-sided colon cancer at 90 days from diagnosis. For longer-term survival 
beyond 90 days, the hazard of death for both descending and sigmoid colon cancer was 
systemically lower than right-sided colon cancer. The difference between the descending and 
sigmoid colon, in terms of 90-day survival, may be influenced by uncontrolled confounding. 
Rectal cancer had more than twice the odds of not receiving surgery when compared with 
rectosigmoid cancer, but survival was 10–20% better in rectal cancer than rectosigmoid cancer, 
both at 90 days and 6 months from diagnosis. One potential reason for observing the difference 
in survival between the two sites is covering stoma; for a patient without a defunctioning stoma, 
leakage may become fatal. In contrast, the postoperative 30-day mortality was not different 
between the two sites (in Chapter 4.2); site was not associated with the short-term mortality in 
rectal cancer. This disagreement of the results in short-term postoperative mortality (30 days) 
and survival in the longer term (90 days from diagnosis and more) is unclear. As described as 
one of the potential problems in data acquisition in Chapter 1.3.9, data regarding complication 
rates and stoma rates were missing in approximately 40%. Thus, failure-to-rescue rates were not 
able to be analysed. More detailed clinical information may be needed to investigate further for 
the explanations. 
When the results of colon and rectal cancer were compared, colon cancer had higher emergency 
presentations, but patients received surgery equally by SES. Colon cancer patients had a clearer 
socioeconomic gradient in postoperative mortality. To combine all these results, whether or not 
specialists managed a patient may be a possible explanation for the inequalities in postoperative 
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mortality in colon cancer. Treatment by non-specialists may reduce disparities in receipt of 
surgery, but especially for emergency cases, postoperative mortality may be worse than the 
specialists’ management. 
Regarding long-term survival, left-sided colon cancer had a lower mortality rate than cancers of 
the right-sided colon. The results agree with other studies [223, 224], and this difference could 
be associated with biological factors. Cancer with BRAF mutations, which are often associated 
with right-sided colon cancer, may have resulted in lower survival than cancer with KRAS 
mutations, which is often seen in left-sided colon cancer. 
This is the first study that differentiates comorbidities in chronic and acute phases. Analyses on 
receipt of surgery and postoperative morality revealed that chronic and acute comorbidities 
influence those outcomes to different degrees. The presence of chronic comorbidities was 
associated with over 4.5 times higher odds of not receiving surgery compared with having no 
chronic comorbidities, whereas the presence of acute comorbidities was associated with less 
than 2.5 times higher odds of not receiving surgery compared with having no acute 
comorbidities. In contrast, up to a sevenfold increase in odds of postoperative death was 
observed in patients with acute comorbidities compared with patients without acute 
comorbidities. Up to a fourfold increase in odds of postoperative death was observed in patients 
with chronic comorbidities compared with the patients without chronic comorbidities. These 
results indicate that chronic comorbidities have a more significant influence on receipt of 
surgery, but acute comorbidities have a more significant influence on postoperative 30-day 
mortality. 
In the analyses described in Chapter 4.2 and Chapter 4.4, postoperative mortality was higher 
in obese patients than patients with BMI<30 among colon cancer patients, but obesity was not 
associated with survival. Previous studies have suggested that obesity is associated with 
postoperative complications such as leakage, which could lead to higher mortality rates [225-
227]. However, hypoalbuminemia, which suggests long-term malnutrition, is also associated 
with leakage, and body weight loss of more than 10% is associated with both leakage and higher 
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postoperative mortality [215, 225, 228]; the effect of those factors may outweigh the effect of 
obesity on survival. When measuring surgical outcomes, postoperative complications and 
quality of treatment (30-day mortality in this thesis, others include recurrence) should be 
addressed separately.  
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Chapter 5: Colorectal cancer in Osaka, Japan 
In Chapter 5, I explored factors associated with receipt of major surgery and survival and 
investigated whether socioeconomic inequalities in care and survival existed among patients 
registered at OUH, Japan. 
5.1. Factors associated with receipt of major surgery and socioeconomic 
inequalities in receipt of surgery 
The first analysis examined factors associated with not receiving major surgery for the primary 
lesion as the first definitive treatment. The second analysis explored whether there was any time 
difference in receiving major surgery among SES groups. 
5.1.1 Methods 
Study population 
Of the patients with CRC registered with hospital-based cancer registry data at OUH, the 
residents of Osaka Prefecture were included in the analysis. Patients were diagnosed with colon 
or rectal cancer between 2012 and 2015 and followed up until the end of July 2018. The 
inclusion criteria were primary CRC of any histological type and age at diagnosis younger than 
100 years old. Tis (carcinoma in situ) was excluded from the analysis. 
Outcome measure 
The outcome in the first analysis was set as a binary measure (0 yes, 1 no) of whether a patient 
received major surgery for the primary lesion. I explored factors associated with receipt of 
surgery and investigated whether it differed by SES group. 
I extracted the date and type of operation procedure of the first major surgery from the DPC 
data and supplemented the hospital-based cancer registry data. In the analysis of the patients in 
England, extraction of the date of major surgery for the primary lesion was restricted from 30 
days before diagnosis to 180 days after diagnosis. To capture all treatment information, 
especially for patients with rectal cancer, no such time restriction was set for the analysis in 
OUH. 
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As in the England context, the first analysis was extended to the second analysis to examine 
factors associated with time to treatment and whether it varied by SES group. The outcome for 
the second analysis was the number of days from diagnosis to the first definitive surgery among 
patients who have received major surgery for the primary lesion. 
Analysis strategy 
In the first analysis, I fitted logistic regression with a priori exposure of SES. To derive days 
from diagnosis to treatment in the second analysis, I applied linear regression as in Chapter 4.1. 
As the number of days from diagnosis to treatment was right-skewed, the outcome was log-
transformed. After the log-transformation, the outcome became normally distributed. 
Because of sparse data, stage was categorised into two groups: non-metastatic stages (localised, 
positive regional lymph nodes and invasion to adjacent organs) and with distant metastases. Site 
was categorised into colon and rectum. The number of comorbidities was also categorised into 
two groups (0 and ≥1). In Japan, as seen in Table 5.1, most patients who come to university 
hospitals are referred from clinics at the primary care level. Therefore, referral routes were 
categorised into two groups, i.e. referral from other clinics/hospitals and others. Obesity at 
diagnosis was not included in this analysis, as there were only eleven overweight patients with 
BMI ≥30 in total. Histology, tumour grade and emergency presentation were excluded from this 
analysis for the same reason. 
Clinical information such as emergency presentations, comorbidities, use of ICU and ADL was 
extracted from the episodes of the first definitive treatment recorded in the DPC data and linked 
to the hospital-based cancer registry data. Of all patients registered with the hospital-based 
cancer registry, 25% was missing DPC information. 
Stage and clinical information of interest (comorbidities, ADL and Brinkman index) were 
missing: in 16.5% of patients for stage, and 24.1% for clinical information. These variables 
were imputed 25 times with chained equations. Distributions of the imputed stage (non-
metastasis or metastasis), comorbidities (0 or 1 and more), ADL and Brinkman index (binary: 0 
or more than 0) are shown in Appendix 10. The covariates used for the imputation included sex, 
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age group, SES group, cancer site, receipt of major surgery for the primary lesion (binary: 0 yes, 
1 no), vital status (dead or alive) at the end of follow-up and Nelson-Aalen estimator. 
To explore whether the models and results were robust, I conducted sensitivity analyses for both 
the first and second analyses, using data with complete cases only. 
For all analyses, I started from bivariable analyses with a priori interest variable, SES, to assess 
the changes in the association between SES and the outcome, i.e. the confounding effect of each 
variable. Each variable was also retained in the multivariable analysis based on the Wald test (p-
value< 0.05) of the bivariable analysis, since the likelihood ratio test in each of the imputed 
dataset does not incorporate uncertainty [208]. Variables were finally selected by backward 
elimination. A removed variable was added to the multivariable model again as a confounder if 
a model with the variable changed the effect of SES (e.g. OR of the most deprived group in the 
first analysis) by more than 10%. Age group and sex were added as a priori confounders. An 
interaction term between SES and stage was added as the main interest. 
5.1.2 Results 
There were 710 patients with colon or rectal cancer in total. The baseline characteristics of the 
patients with colon or rectal cancer are shown in Table 5.1. Nearly 40% had cancer in the 
rectosigmoid junction or rectum. Over 50% of patients were males, and the median age of the 
patients at OUH (66.8 years) was lower than that of the patients in England (median age of 
patients in England: 73.9 for colon, 70.8 for rectal cancer). 
There were much fewer patients from the most deprived group (11.3% of total) than from the 
least deprived group (38.7%). There was no clear trend by SES for most characteristics except 
the median age at diagnosis; the most deprived group was approximately four years younger 
than the least deprived group. Stage information was missing for 16.5% of patients, without a 
socioeconomic trend in the missingness. Stage distribution neither had a clear trend among SES 
groups. Overall, 70% were diagnosed at other clinics or hospitals before the consultation at 
OUH. In total, 443 patients (62.4%) received major surgery for the primary lesion without 
differences by SES groups. Only one patient in the second SES group died within 30 days of the 
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major surgery; thus, the postoperative 30-day mortality at OUH was 0.23%. Of the total number 
of patients, 4.1% received neoadjuvant therapy. After a consultation at OUH, around 20% were 
referred to other hospitals for treatment. 
Regarding information from DPC data, emergency presentation (unplanned or emergency 
hospitalisation) at the first definitive treatment was seen in less than 4% of patients, with no 
gradient among SES groups. There was no socioeconomic gradient in the number of 
comorbidities, ADL, Brinkman index or obesity. Around 40% of the total patients had 
comorbidities. The overall mean BMI was 21.6. Use of ICU was 4.5% of the total patients who 
received major surgery for the primary lesion; the ICU use was mostly confined to the patients 
who underwent other major surgeries for the comorbidities during the same hospitalisation 
episode. Of the 20 patients who were admitted to the ICU, two patients with oesophageal 
cancer, one with pancreatic cancer and one with gastric cancer received major surgery for the 
simultaneous cancer and underwent surgery for CRC in the same episode.
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Table 5.1 Baseline characteristics of patients with colon or rectal cancer at Osaka University Hospital, Japan  
 
Total number SES 
1st 
(least deprived) 
2nd 3rd 4th 5th 
(most deprived) 
Total number 710 275 135 121 99 80 
(%) 100 38.7 19.0 17.0 13.9 11.3 
Median age at diagnosis 66.8 65.7 65.8 66.0 68.6 70.0 
IQR 58.8–74.1 58.2–73.7 57.7–73.1 54.9–72.8 63.3–73.2 61.9–75.8 
Female (%) 303 (42.7) 106 (38.6) 65 (48.2) 49 (40.5) 47 (47.5) 36 (45.0) 
Death at the end of follow-up (%) 188 (26.5) 70 (25.5) 30 (22.2) 40 (33.1) 29 (29.3) 19 (23.8) 
Year of diagnosis (%) 
      
2012 161 (22.7) 64 (23.3) 35 (25.9) 28 (23.1) 18 (18.2) 16 (20.0) 
2013 176 (24.8) 71 (25.8) 29 (21.5) 28 (23.1) 24 (24.2) 24 (30.0) 
2014 173 (24.4) 66 (24.0) 41 (30.4) 28 (23.1) 22 (22.2) 16 (20.0) 
2015 200 (28.2) 74 (26.9) 30 (22.2) 37 (30.6) 35 (35.4) 24 (30.0) 
Cancer site (%) 
      
Right-sided colon 151 (21.3) 61 (22.2) 31 (23.0) 18 (14.9) 20 (20.2) 21 (26.3) 
Transverse colon 48 (6.8) 18 (6.6) 6 (4.4) 12 (9.9) 3 (3.0) 9 (11.3) 
Left-sided colon 218 (31.0) 85 (30.9) 32 (23.7) 42 (34.7) 37 (37.4) 22 (27.5) 
Rectosigmoid junction or rectum 268 (37.8) 103 (37.5) 59 (43.7) 45 (37.2) 35 (35.4) 26 (32.5) 
Overlapping site 25 (3.5) 8 (2.9) 7 (5.2) 4 (3.3) 4 (4.0) 2 (2.5) 
Stage at diagnosis (%) 
      
Localised 364 (51.3) 141 (51.3) 82 (60.7) 48 (39.7) 51 (51.5) 42 (52.5) 
Positive regional lymph nodes 67 (9.4) 28 (10.2) 10 (7.4) 14 (11.6) 5 (5.1) 10 (12.5) 
Invasion to adjacent organs 41 (5.8) 18 (6.6) 2 (1.5) 9 (7.4) 9 (9.1) 3 (3.8) 
Distant metastasis 121 (17.0) 49 (17.8) 19 (14.1) 26 (21.5) 15 (15.2) 12 (15.0) 
Missing 117 (16.5) 39 (14.2) 22 (16.3) 24 (19.8) 19 (19.2) 13 (16.3) 
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Table 5.1 continued  
 
Total number SES 
1st 
(least deprived) 
2nd 3rd 4th 5th 
(most deprived) 
Histology (%)       
Adenocarcinoma 648 (91.3) 247 (89.8) 122 (90.4) 113 (93.4) 90 (90.9) 76 (95.0) 
Adenosquamous cell, squamous cell carcinoma 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Non-epithelial tumours 27 (3.8) 14 (5.1) 7 (5.2) 0 (0.0) 4 (4.0) 2 (2.5) 
Missing 35 (4.9) 14 (5.1) 6 (4.4) 8 (6.6) 5 (5.1) 2 (2.5) 
Tumour grade (%) 
      
Well/moderately differentiated 595 (84.5) 227 (82.6) 111 (82.2) 99 (81.8) 86 (86.9) 72 (90.0) 
Poorly differentiated/undifferentiated 12 (1.7) 6 (2.2) 3 (2.2) 2 (1.7) 0 (0.0) 1 (1.3) 
Missing 97 (13.8) 42 (15.3) 21 (15.6) 20 (16.5) 13 (13.1) 7 (8.8) 
Route to OUH (%)   
    
Referral from other clinics/hospitals 578 (81.4) 228 (82.9) 112 (83.0) 95 (78.5) 76 (76.8) 67 (83.8) 
Self-referral 38 (5.4) 16 (5.8) 8 (5.9) 7 (5.8) 6 (6.1) 1 (1.3) 
Followed up for other diseases in OUH 80 (11.3) 27 (9.8) 12 (8.9) 14 (11.6) 15 (15.2) 12 (15.0) 
Screening 8 (1.1) 2 (0.7) 3 (2.2) 3 (2.5) 0 (0.0) 0 (0.0) 
Health check-up 3 (0.4) 1 (0.4) 0 (0.0) 1 (0.8) 1 (1.0) 0 (0.0) 
Others 3 (0.4) 1 (0.4) 0 (0.0) 1 (0.8) 1 (1.0) 0 (0.0) 
Place of diagnosis (%)       
OUH 210 (29.6) 77 (28.0) 41 (30.4) 39 (32.2) 33 (33.3) 20 (25.0) 
Other clinics or hospitals 500 (70.4) 198 (72.0) 94 (69.6) 82 (67.8) 66 (66.7) 60 (75.0) 
Treatment (%)       
Received open major surgery for primary lesion at OUH 42 (5.9) 13 (4.7) 5 (3.7) 11 (9.1) 8 (8.1) 5 (6.3) 
Received laparoscopic major surgery for primary lesion at OUH 401 (56.5) 150 (54.6) 83 (61.5) 62 (51.2) 56 (56.6) 50 (62.5) 
Treatment/follow-up at OUH (no record of major surgery) 123 (17.3) 54 (19.6) 26 (19.3) 19 (15.7) 16 (16.2) 8 (10.0) 
Referral to other hospitals for treatment 137 (19.3) 56 (20.4) 18 (13.3) 28 (23.1) 19 (19.2) 16 (20.0) 
No visit to OUH after diagnosis 7 (1.0) 2 (0.7) 3 (2.2) 1 (0.8) 0 (0.0) 1 (1.3) 
Postoperative 30-day mortality (%)* 1 (0.2) 0 (0.0) 1 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 
Received neoadjuvant therapy (%) 29 (4.1) 12 (4.4) 6 (4.4) 6 (5.0) 1 (1.0) 4 (5.0) 
2
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Table 5.1 continued 
Abbreviations: ADL, activities of daily living; BMI, body mass index; DPC, diagnostic procedure combinations; ICU, intensive care unit; IQR, interquartile range; OUH, Osaka University Hospital; 
SES, socioeconomic status. * Denominator is the number of patients who received major surgery for the primary lesion (n=443). ** The same percentage is missing for all variables below, except the 
use of ICU.
 
Total number SES 
1st 
(least deprived) 
2nd 3rd 4th 5th 
(most deprived) 
From linked DPC data       
Linked to hospital-based cancer registry data 539 (75.9) 204 (74.2) 105 (77.8) 90 (74.4) 76 (76.8) 64 (80.0) 
No hospital episodes linked** 171 (24.1) 71 (25.8) 30 (22.2) 31 (25.6) 23 (23.2) 16 (20.0) 
Emergency presentation (%)   
    
Planned hospitalisation 514 (72.4) 194 (70.6) 104 (77.0) 83 (68.6) 70 (70.7) 63 (78.8) 
Unplanned or emergency hospitalisation 25 (3.6) 10 (3.6) 1 (0.7) 7 (5.8) 6 (6.1) 1 (1.3) 
Use of ICU (%)*  
     
No 407 (91.9) 150 (92.0) 80 (90.9) 71 (97.2) 59 (92.2) 47 (85.5) 
Yes 20 (4.5) 7 (4.3) 3 (3.4) 1 (1.4) 2 (3.1) 7 (12.7) 
Number of acute comorbidities (%)  
     
0 406 (57.2) 163 (59.3) 80 (59.3) 64 (52.9) 55 (55.6) 44 (55.0) 
1 97 (13.7) 30 (10.9) 24 (17.8) 17 (14.1) 13 (13.1) 13 (16.3) 
2 30 (4.2) 9 (3.3) 1 (0.7) 7 (5.8) 7 (7.1) 6 (7.5) 
3+ 6 (0.9) 2 (0.7) 0 (0.0) 2 (1.7) 1 (1.0) 1 (1.3) 
Obesity at diagnosis (BMI>30) (%) 11 (1.6) 2 (0.7) 2 (1.5) 2 (1.7) 3 (3.0) 2 (2.5) 
Brinkman index>0 (%) 210 (29.6) 76 (27.6) 44 (32.6) 39 (32.2) 27 (27.3) 24 (30.0) 
Modified ADL (%)  
     
Completely independent 268 (37.8) 107 (38.9) 60 (44.4) 36 (29.8) 33 (33.3) 32 (40.0) 
Need support 271 (50.3) 97 (35.3) 45 (33.3) 54 (44.6) 43 (43.4) 32 (40.0) 
2
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First analysis (logistic regression for receipt of major surgery and odds ratios by SES) 
In total, 442 patients (62.4%) received major surgery for the primary lesion (Table 5.1). 
The first analysis using logistic regression included all 710 patients with imputed data. In 
sensitivity analysis using completed data, 480 patients (67.6% of total) were included. 
Table 5.2 demonstrates the results of bivariable and multivariable analyses of logistic regression 
for receipt of surgery. To show the overall change in the effect of SES, the adjusted ORs of SES 
in those tables were based on a model without interaction between SES and stage. For the rest, 
adjusted ORs were based on the multivariable model with interaction between SES and stage 
(final model). 
Factors associated with receipt of major surgery 
The adjusted ORs among the SES groups in Table 5.2 show that there is no evidence that the 
deprived groups are failing to receive major surgery. Rather, there was a socioeconomic 
gradient favouring deprived groups in receipt of surgery. Sensitivity analysis using completed 
data also showed the same results but with a bias towards even better receipt of surgery for the 
deprived groups. 
Older patients had the same odds of receiving surgery as young patients. Female patients were 
more likely to receive surgery than male patients, but this was not statistically significant. 
Presence of comorbidities was not associated with receipt of surgery, but patients with 
comorbidities tended to have lower odds of not receiving surgery. Neither year of diagnosis nor 
cancer site (colon or rectum) was related to receipt of surgery. Patients with history of smoking 
were more likely to receive surgery than patients without a smoking history, but the variable 
was finally not included in the multivariable model. Patients not referred from clinics were 50% 
more likely to receive major surgery at OUH than patients referred from clinics. The majority 
were followed up at OUH for other diseases, followed by self-referral. Sensitivity analysis 
showed that the referral route was not associated with receipt of surgery. Instead, patients with 
lower ADL (i.e. needing support in ADL) were more likely to receive major surgery at OUH 
than patients with fit for ADL.
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Table 5.2 Odds ratios of not receiving major surgery for primary lesion using logistic regression for colorectal cancer, Osaka University Hospital, Japan  
Variable Bivariable analysis Multivariable analysis Multivariable sensitivity analysis 
  Multiple imputation (n=710) Complete cases (n=480) 
 OR* 95% CI p-value† OR** 95% CI p-value† OR** 95% CI p-value† 
SES          
1 (least deprived) 1.00  
0.16‡ 
1.00  
0.19‡ 
1.00  
0.08‡ 
2 0.78 (0.51, 1.19) 0.79 (0.49, 1.27) 0.57 (0.26, 1.23) 
3 0.96 (0.62, 1.48) 0.80 (0.49, 1.32) 0.58 (0.25, 1.31) 
4 0.80 (0.49, 1.28) 0.87 (0.51, 1.49) 0.51 (0.20, 1.34) 
5 (most deprived) 0.66 (0.39, 1.12) 0.66 (0.36, 1.18) 0.53 (0.20, 1.33) 
Sex          
Male 1.00   1.00  
0.10 
1.00  
0.16 
Female 0.95 (0.70, 1.29) 0.74 0.74 (0.52, 1.06) 0.66 (0.36, 1.19) 
Age          
<60 1.00  
0.54‡ 
1.00  
0.96‡ 
1.00  
0.38‡ 60–69 0.82 (0.55, 1.22) 0.89 (0.57, 1.39) 0.93 (0.44, 1.90) 
70–99 0.87 (0.60, 1.28) 1.00 (0.65, 1.53) 1.34 (0.65, 2.77) 
Year of diagnosis          
2012 1.00         
2013 0.73 (0.47, 1.14) 0.17       
2014 1.04 (0.67, 1.61) 0.88       
2015 0.93 (0.61, 1.43) 0.75       
Cancer site          
Colon 1.00         
Rectum 1.05 (0.77, 1.44) 0.75       
Stage          
No metastasis 1.00      1.00   
Metastasis 6.81 (4.40, 10.55) <0.001    5.13 (2.12, 12.41) <0.001 
Stage§          
No metastasis 1.00   1.00      
Metastasis 6.58 (4.22, 10.27) <0.001 6.07 (3.10, 11.91) <0.001    
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Table 5.2 continued 
Variable Bivariable analysis* Multivariable analysis Multivariable sensitivity analysis 
  Multiple imputation (n=710) Complete cases (n=480) 
 OR 95% CI p-value† OR** 95% CI p-value† OR** 95% CI p-value† 
Route          
Referral from clinics/hospitals 1.00   1.00      
Others 0.51 (0.33, 0.78) 0.002 0.47 (0.29, 0.75) 0.002    
Comorbidities          
0 1.00         
1+ 0.68 (0.40, 1.15) 0.15       
Comorbidities§          
0 1.00         
1+ 0.77 (0.46, 1.28) 0.31       
Modified ADL          
Completely independent 1.00      1.00   
Need support 0.50 (0.32, 0.80) 0.004    0.44 (0.24, 0.81) 0.008 
Modified ADL§          
Completely independent 1.00         
Need support 0.65 (0.35, 1.20) 0.16       
Brinkman index          
0 1.00         
>0 0.65 (0.41, 1.03) 0.066       
Brinkman index§          
0 1.00         
>0 0.63 (0.39, 1.01) 0.055       
Abbreviations: 95% CI, 95% confidence interval; ADL, activities of daily living; OR, odds ratio; SES, socioeconomic status. * Adjusted for SES in all variables. **All variables are mutually adjusted. 
For SES only, adjusted ORs are shown without interaction between SES and stage. For other variables, interaction between SES and stage is adjusted. † P-value of Wald test. ‡ P-value of Wald test for 
trend. § Multiply imputed.
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Receipt of major surgery by SES 
The stage-specific ORs, when interaction between SES and stage was added, are shown in Table 
5.3. Although evidence is weak (p=0.09), there was a socioeconomic gradient in receipt of 
surgery in the non-metastatic stages favouring the deprived groups. The adjusted OR of the 
most deprived group on non-receipt of surgery was 0.47 (95% CI 0.22, 1.00) with imputed data. 
No clear trend was seen in the metastatic stage. Similar socioeconomic trends were seen in 
sensitivity analyses using completed data. 
In the bivariable analysis, stage enhanced the effect of SES on the odds of non-receipt of 
surgery by more than 10%. 
Table 5.3 Stage-specific oddds ratios of not receiving major surgery for primary lesion using 
multivariable logistic regression with interaction between SES and stage for colorectal cancer, 
Osaka University Hospital, Japan 
 
Multiple imputationa Complete casesb 
 OR 95% CI p-value OR 95% CI p-value 
No metastasis 
      
SES 
      
1 (least deprived) 1.00 
 
0.09 
1.00 
 
0.08 
2 0.80 (0.46, 1.40) 0.55 (0.22, 1.36) 
3 0.80 (0.43, 1.48) 0.45 (0.15, 1.37) 
4 0.86 (0.45, 1.62) 0.45 (0.15, 1.39) 
5 (most deprived) 0.47 (0.22, 1.00) 0.12 (0.02, 0.90) 
Metastasis 
  
 
  
 
1 (least deprived) 1.00 
 
0.60 
1.00 
 
0.28 
2 0.74 (0.28, 1.99) 0.67 (0.17, 2.60) 
3 0.85 (0.34, 2.12) 0.93 (0.27, 3.23) 
4 0.90 (0.28, 2.87) 0.75 (0.12, 4.68) 
5 (most deprived) 2.17 (0.45, 10.39) 7.06 (0.68, 73.05) 
Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio; SES, socioeconomic status. All p-values are of 
Wald test for trend. Model a: adjusted for sex, age, stage (imputed), route. Model b: adjusted for sex, age, stage, 
modified ADL (activities of daily living). 
Further analysis of the 267 patients who did not receive major surgery showed that 72 patients 
(27.0%) had localised stage, 76 (28.5%) had distant metastasis and 96 (36.0%) had missing 
stage information. Among them, the least deprived group was more likely to have a localised 
stage (p=0.008, Wald test for trend), which may not require major surgical treatment. Moreover, 
137 patients (51.3%) of the total cases who did not receive surgery at OUH were referred to 
other hospitals for treatment: twenty-nine cases (40.0%) of the patients with localised, 36 cases 
(47.4%) of the patients with a metastatic stage. The records showed no socioeconomic trend for 
referral or other treatment plans (treatment at OUH, follow-up at OUH or no visit). Of the 23 
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patients who had stages with the potential for cure (positive regional lymph nodes or invasion to 
adjacent organs) but did not receive surgery at OUH, 16 patients were referred to other hospitals 
for treatment. Another six patients were recorded as treated or followed up at OUH. Those 
developed metastatic disease (e.g. obstructive jaundice due to metastasis from CRC) or had 
severe comorbidities (e.g. acute subdural haemorrhage, primary malignancy in other organs). 
One patient in SES 2 did not appear to OUH visit after diagnosis. Patients with colon cancer 
were more likely to be referred to other hospitals compared with patients with rectal cancer 
(p<0.001, chi square test). The presence of comorbidities or ADL were not associated with 
referral. 
An additional analysis, in which not only major surgery but also minor surgery (endoscopic 
resection for the localised stage) was defined as a success in receiving treatment, showed a 
similar socioeconomic gradient towards higher treatment receipt in the more deprived groups 
for the non-metastatic stage.  
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Second analysis (linear regression for days from diagnosis to treatment and its difference by 
SES) 
The study population in the second analysis was firstly restricted to 443 patients who received 
major surgery for the primary lesion. A total of 102 patients died without receiving major 
surgery. Half of the 102 patients had a metastatic stage, and stage was missing for the remaining 
30%, but there was no socioeconomic trend for stage distribution and stage missingness. Of the 
443 patients who received major surgery, seven patients who underwent surgery within seven 
days of the date of diagnosis (four patients from SES 1, one each from SES 3, 4 and 5) were 
excluded from the analysis. An eventual total of 394 patients were included in the linear 
regression analysis for time to treatment. 
Eleven patients received major surgery after more than 180 days from diagnosis. Of the eleven 
patients, nine had neoadjuvant chemotherapy. No patients were diagnosed, underwent surgery 
and died on the same day. 
The results of mean days to treatment and the ratios using linear regression are shown in Table 
5.4. When not adjusting for other conditions but SES, the mean days from diagnosis to 
treatment was 41.8 (95% CI 37.7, 46.4) for the least deprived group (reference days for the 
reference group in bivariable analysis, Table 5.4). When potential associated factors with the 
time length were adjusted in multivariable analysis, the mean days to treatment were 41.5 (95% 
CI 36.6, 47.2) for the reference group (least deprived group, male, mean age 65.7 years, colon 
cancer). There was no evidence that the more deprived groups experienced delays compared 
with the least deprived group. 
When the association of age and the number of days was analysed in bivariable analysis, age 
was better associated in quadratic term than the linear term or categorised groups (likelihood 
ratio test p<0.05). However, in a multivariable regression model, age was associated with the 
number of days linearly. No patients were missing comorbidities or Brinkman index and days 
from diagnosis to treatment (outcome) at the same time; therefore, the results were identical in 
the analyses using imputed and completed data. 
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In a multivariable regression model, other than SES and a priori confounders (age and sex), the 
site of cancer showed evidence of an association with time to treatment. When other covariates 
were set as reference (SES 1, male, mean 65.7 years), patients with rectal cancer experienced 
36% longer (95% CI 19%, 54%) time to treatment than patients with colon cancer. There was 
no evidence that the delay was associated with other potential factors, such as stage, referral 
route, number of comorbidities, ADL or Brinkman index. 
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Table 5.4 Reference number of days from diagnosis to major surgery for primary lesion and 
ratios using linear regression for colorectal cancer, Osaka University Hospital, Japan 
Abbreviations: 95% CI, 95% confidence interval; ADL, activities of daily living; SD, standard deviation; SES, 
socioeconomic status. * Adjusted for SES in all variables. † P-value of the null hypothesis that the coefficient (β) is 0 
(eβ=1) when all other variables were set as the reference group. ‡ P-value for linear trend. †† When age is put as a 
quadratic term, in bivariable analysis, log(days) is derived from α(constant) + β1(0 in SES=1) + β2(age−mean age) + 
β3(age−mean age)2. P-value of likelihood ratio test comparing linear and quadratic models. § Multiply imputed. §§ 
No patients were missing comorbidities or Brinkman index and days from diagnosis to treatment (outcome) at the 
same time, therefore the results of the analysis using multiply imputed data were identical to the results of the 
analysis using complete cases.
 
Bivariable analysis Multiple regression 
  Complete cases (n=394) 
 Days 95% CI  Days 95% CI  
Reference (geometric mean) days in SES 1 41.8 (37.7, 46.4)  41.5 (36.6, 47.2)  
 eβ* 95% CI p-value† eβ 95% CI p-value† 
SES 
      
1 (least deprived) 1.00 
 
0.97‡ 
1.00 
 
0.92‡ 
2 1.08 (0.91, 1.29) 1.06 (0.90, 1.26) 
3 1.02 (0.84, 1.23) 1.01 (0.84, 1.21) 
4 0.89 (0.73, 1.08) 0.90 (0.75, 1.09) 
5 (most deprived) 1.10 (0.89, 1.35) 1.10 (0.90, 1.35) 
Sex 
      
Male 1.00 
 
 1.00 
 
 
Female 0.89 (0.79, 1.02) 0.09 0.91 (0.81, 1.03) 0.51 
Age 
      
Mean age at diagnosis 65.7 SD 11.9 
  
 
 
Age as linear term (10-year increase) 0.97 (0.91, 1.03) 0.29 0.98 (0.92, 1.03) 0.38 
Age as quadratic term ††  0.02†† ††  0.01†† 
Year of diagnosis 
      
2012 1.00 
     
2013 1.08 (0.91, 1.29) 0.39 
   
2014 1.03 (0.85, 1.24) 0.76 
   
2015 1.03 (0.86, 1.24) 0.75 
   
Cancer site 
      
Colon 1.00 
 
 1.00 
 
 
Rectum 1.35 (1.19, 1.54) <0.001 1.36 (1.19, 1.54) <0.001 
Stage 
      
No metastasis 1.00 
 
 
   
Metastasis 1.11 (0.89, 1.39) 0.36 
   
Stage§ 
      
No metastasis 1.00 
 
 
   
Metastasis 1.11 (0.89, 1.38) 0.36 
   
Route       
Referral from clinics/hospitals 1.00      
Others 1.02 (0.88, 1.19) 0.77    
Number of acute comorbidities§§       
0 1.00      
1+ 1.12 (0.98, 1.30) 0.11    
Modified ADL       
Completely independent 1.00      
Need support 0.92 (0.81, 1.05) 0.21    
Modified ADL§       
Completely independent 1.00      
Need support 0.92 (0.81, 1.04) 0.20    
Brinkman index§§       
0 1.00      
>0 1.11 (0.98, 1.27) 0.10    
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5.1.3 Summary of findings 
Among the patients with non-metastatic stages, there was weak evidence that the more deprived 
groups had lower odds of not receiving major surgery; however, the majority of the non-
recipients had localised or metastatic stage. The more affluent non-recipients were likely to have 
a localised stage. Of the non-recipients, 51% were referred to other hospitals for treatment, and 
patients with colon cancer were more likely to be referred compared with patients with rectal 
cancer. No socioeconomic gradient in receipt of surgery was observed for patients with the 
metastatic stage. The multivariable logistic regression model with imputed data and the model 
with completed data varied, meaning that the models may not be robust. At OUH, patients not 
referred from other clinics or hospitals (the majority were followed up at OUH for other 
diseases) or with lower ADL were more likely to receive surgery than the patients referred 
through clinics or with fit ADL. 
The mean time to treatment at OUH was approximately 40 days and was consistent through the 
different SES groups. Patients with rectal cancer experienced a longer time from diagnosis to 
treatment than patients with colon cancer. 
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5.2 Survival by socioeconomic status 
This analysis investigated general patterns of survival and mortality rates by SES without 
controlling for any other factors. 
5.2.1 Methods 
Outcome measure 
Mortality rates and the difference in survival among SES groups were set as the outcomes. 
Firstly, to estimate mortality rates, the number and positions of the knots in a model of the 
baseline hazard were explored. 
Analysis strategy 
Since there is no lifetable for deriving net survival for the patient population in this analysis, I 
analysed overall survival only. I fitted the Royston-Parmar FPM, which models basic 
cumulative hazard by restricted cubic spline functions. I modelled the number and positions of 
the internal knots for the baseline hazard without any covariates. The number and positions of 
the internal knots were set in the same ways as in Chapter 4.3 and were compared with the 
default knots, which varied from 2 to 5 df. A model with the smallest AIC was selected. 
After selecting a model with a plausible number and positions of the knots, I estimated the 
survival curves for each SES group not adjusting for other covariates. I compared the curves 
derived by the FPM and the survival curves derived by the Kaplan-Meier method but used the 
AIC to determine how SES acts (proportional or time-varying). The difference in mortality rate 
per 1,000 PYs and the difference in survival between SES 1 and SES 5 were estimated by the 
FPM.  
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5.2.2 Results 
Number and positions of knots in null FPM 
Figure 5.1 shows the mortality rate per 1,000 PYs modelled by the FPM changing the number 
and position of the knots. Table 5.5 shows the AIC by the number and position of the knots. 
From the wavy figures in the models with three internal knots, df 4 and df 5 (Figure 5.1) and the 
AIC in Table 5.5, models with three or more internal knots were likely to be overfitted. The 
smallest AIC suggests that the model with one internal knot at 1.5 years from the time of 
diagnosis is the best model. 
Not only the number of the knots in the model but also the shapes of the mortality rates in Japan 
differed considerably from that in England; the figure of the mortality rate in England showed a 
concave shape, whereas that in Japan showed a convex shape, peaking around six months from 
diagnosis. 
Figure 5.1 Mortality rate for colorectal cancer, Osaka University Hospital, Japan 
Abbreviations: 1000 PYs, 1000 person-years; df, degrees of freedom.  
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Table 5.5 AIC by number and position of knots for colorectal cancer, Osaka University 
Hospital, Japan 
Abbreviations: AIC, Akaike information criterion; df, degrees of freedom. The positions of the knots sit on the noted 
centiles of the distribution of uncensored log event-times. 
Survival curves and difference in mortality rate, survival by SES 
Figure 5.2 shows survival curves derived by (a) FPM with SES treated as proportional, and (b) 
the Kaplan-Meier method. It is apparent that the graph (a) disagrees with the graph (b), meaning 
that the assumption of the proportional hazard among SES groups in the FPM may not be 
suitable. The survival curves of the most and the least deprived groups cross each other in the 
Kaplan-Meier graph. The crossed curves indicate that the effect of SES interacts with time. 
Therefore, SES was treated as a TVE having an internal knot at 1.5 years from diagnosis using 
FPM in the graph (c). Graph (c) agrees with the curves derived by the Kaplan-Meier method in 
the graph (b). However, as shown in Table 5.6, the AIC of the FPM with SES treated as 
proportional was smaller than that of the FPM with TVE. The log- cumulative hazards and 
mortality rates by five SES groups, when SES is treated as proportional, are shown in Figure 5.2 
(d) and (e). The curves of the mortality rate for the least and the most deprived groups run 
closely together, and there is no ordered gradient by SES group. 
Table 5.6 AIC of FPMs with SES (proportional or TVE), Osaka University Hospital, Japan 
Model AIC 
SES (proportional) 1078.0 
SES (TVE) 1084.7 
Abbreviations: AIC, Akaike information criterion; SES, socioeconomic status; TVE, time-varying effect. 
Number and position of knots AIC 
3 internal knots (at 90 days, 6 months, 1 year) 1080.6 
1 internal knot (at 1.5 years) 1078.1 
Default 2df (1 internal knot: 50 centiles) 1078.1 
Default 3df (2 internal knots: 33, 67 centiles) 1080.0 
Default 4df (3 internal knots: 25, 50, 75 centiles) 1080.1 
Default 5df (4 internal knots: 20, 40, 60, 80 centiles) 1082.7 
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Figure 5.2 (a) Overall survival curves by FPM (SES as proportional) (b) survival curves by Kaplan-Meier method (c) survival curves by FPM (SES treated as time-
varying effect) for colorectal cancer, Osaka University Hospital, Japan  
2
1
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Figure 5.2 continued. (d) Log-cumulative hazards (e) mortality rates by SES group for colorectal cancer, Osaka University Hospital, Japan (SES treated as 
proportional) 
Abbreviations: 1000 PYs, 1000 person-years; SES, socioeconomic status.
2
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Figure 5.3 visualises the differences in mortality rate and survival. All graphs show that there is 
no strong evidence of a difference in survival between the least and the most deprived groups 
throughout time until the 3-year point from diagnosis. 
Figure 5.3 (a) Difference in mortality rate per 1000 PYs (b) overall survival (%) in the most and 
least deprived groups (c) difference in overall survival (%) between the most and the least 
deprived groups for colorectal cancer, Osaka University Hospital, Japan 
Abbreviations: 1000 PYs, 1000 person-years. (a) Difference between the least and the most deprived groups. (c) A 
positive value means that the most deprived group has better survival than the least deprived group. 
5.2.3 Summary of findings 
When no potential related factors were adjusted, there was no clear socioeconomic trend in 
overall survival. The hazard of death appeared proportional by SES; however, the graphs show 
that the difference between the most and the least deprived groups, in terms of mortality rate 
and survival, is close to zero.  
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5.3 Factors associated with survival and socioeconomic inequalities in 
survival 
In Chapter 5.2, general patterns of survival by SES group was demonstrated, without adjusting 
for any other factors. In this sub-chapter, I explored factors associated with survival and 
examined whether survival varied by SES after adjusted for the associated factors. 
5.3.1 Methods 
Outcome measure 
As with the analyses of the England data (Chapter 4.4), I conducted three analyses in this sub-
chapter. In the first and second analysis, I explored mortality rate ratios (i.e. HR of death) by 
SES and potential factors associated with survival. In the third analysis, measures of difference 
by SES group were presented graphically. The entry for all the survival analyses was the date of 
diagnosis. Three graphical measures were presented by each stage for overall survival: 
difference in mortality rates between the least deprived group (SES 1) and the most deprived 
group (SES 5), survival curves of the SES 1 and the SES 5 and survival difference of the two 
SES groups. Since there is no lifetable by SES for deriving net survival for Osaka Prefecture, I 
analysed overall survival only. 
Analysis strategy 
Firstly, I fitted Cox regression to explore associated factors for survival. Both imputed and 
completed data were used for the Cox regression analysis. I started with bivariable analysis for 
all potential factors one at a time with the main effect (SES) included. The variables which had 
strong evidence for association (at p<0.05 significance level at the Wald test) with the outcome 
were retained to a multivariable model. Variables were further removed by backward 
elimination. An interaction term between SES and stage was added as the main interest. 
Secondly, for each variable in the final multivariable Cox regression model with completed 
data, I tested the proportional hazard assumption based on Schoenfeld residuals. If a variable did 
not hold the proportional hazard assumption, I next fitted an FPM with the same variables 
selected in the final Cox regression model and treated the variable as a TVC. As in Chapter 
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4.4, Cox regression analysis using imputed data was considered as a sensitivity analysis. 
Histology, tumour grade, emergency presentation and obesity were excluded from this analysis 
because of insufficient observations in each group. Age at diagnosis and sex were included as a 
priori confounders. In the FPM, the positions of the knots for both SES and non-TVCs were set 
at a time point of 1.5 years since diagnosis only. If there were any TVCs in the multivariable 
FPM, the knot was also set at 1.5 years since diagnosis. 
Lastly, in the third analysis, differences in mortality rate and overall survival were shown with 
figures using the multivariable FPM fitted in the second analysis. 
5.3.2 Results 
First analysis (Cox regression for overall survival and hazard ratios by SES) 
The first analysis using Cox regression included 480 patients in completed data and 710 patients 
in imputed data. Table 5.7 presents the HRs in bivariable and multivariable analyses. To show 
the overall change in the effect of SES, the adjusted HRs of SES in those tables were based on a 
model without interaction between SES and stage. For the rest, adjusted HRs were based on the 
multivariable model with interaction between SES and stage (final model). 
Factors associated with survival 
Table 5.7 demonstrated no clear trend in the adjusted HRs of SES. Male, older age, metastatic 
stage, presence of comorbidities and low ADL were associated with worse survival in 
completed data. The adjusted mortality rate for female patients was half that of male patients. 
Stage and ADL confounded the effect of sex on survival. Patients aged 70+ had more than 
double the adjusted mortality rate compared with patients under 60 years old. Patients with 
comorbidities had double the adjusted mortality rate that of patients with no comorbidities. 
Patients with low ADL had more than 2.5 times higher adjusted mortality rate compared with 
the patients with fit ADL. The route was not associated with survival. Receipt of surgery was 
not associated with survival in completed data, but sensitivity analysis showed that patients who 
did not receive surgery had more than a twofold increase in the hazard of death compared with 
patients who received surgery. 
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Table 5.7 Hazard ratios of death using Cox regression for colorectal cancer, Osaka University Hospital, Japan  
Variable Bivariable analysis Multivariable sensitivity analysis Multivariable analysis 
  Multiple imputation (n=710) Complete cases (n=480)  
HR* 95% CI p-value HR** 95% CI p-value HR** 95% CI p-value 
SES 
         
1 (least deprived) 1.00 
 
0.53 
1.00 
 
0.62 
1.00 
 
0.54 
2 0.66 (0.41, 1.08) 0.77 (0.46, 1.27) 0.83 (0.42, 1.63) 
3 1.36 (0.90, 2.05) 1.29 (0.83, 2.02) 1.19 (0.65, 2.19) 
4 1.18 (0.74, 1.87) 1.25 (0.75, 2.07) 1.09 (0.54, 2.17) 
5 (most deprived) 0.89 (0.52, 1.55) 0.88 (0.50, 1.56) 0.56 (0.23, 1.36) 
Sex 
  
 
  
 
  
 
Male 1.00 
 
 1.00 
 
 1.00 
 
 
Female 0.90 (0.65, 1.23) 0.51 0.68 (0.48, 0.96) 0.03 0.56 (0.34, 0.93) 0.02 
Age 
  
 
  
 
  
 
<60 1.00 
 
<0.001 
1.00 
 
0.003 
1.00 
 
0.005 60–69 1.38 (0.88, 2.17) 1.27 (0.78, 2.09) 1.44 (0.70, 2.98) 
70–99 2.10 (1.38, 3.18) 1.93 (1.21, 3.07) 2.46 (1.22, 4.96) 
Year of diagnosis 
  
 
  
 
  
 
2012 1.00 
 
 
  
 
  
 
2013 0.72 (0.46, 1.12) 0.15 
  
 
  
 
2014 1.13 (0.74, 1.74) 0.57 
  
 
  
 
2015 1.40 (0.89, 2.19) 0.14 
  
 
  
 
Cancer site 
  
 
  
 
  
 
Colon 1.00 
 
0.85 
  
 
  
 
Rectum 1.03 (0.75, 1.41)  
  
 
  
 
Stage 
  
 
  
 
  
 
No metastasis 1.00 
 
 
  
 1.00 
 
 
Metastasis 6.37 (4.49, 9.05) <0.001 
  
 6.81 (3.36, 13.79) <0.001 
Stage§ 
  
 
  
 
  
 
No metastasis 1.00 
 
 1.00 
 
 
  
 
Metastasis 6.70 (4.81, 9.33) <0.001 5.91 (3.42, 10.21) <0.001    
2
2
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Table 5.7 continued 
Variable Bivariable analysis Multivariable sensitivity analysis Multivariable analysis 
  Multiple imputation (n=710) Complete cases (n=480) 
 HR* 95% CI p-value HR** 95% CI p-value HR** 95% CI p-value 
Route 
         
Referral from clinics/hospitals 1.00 
 
 
      
Others 1.10 (0.76, 1.59) 0.62 
      
Major surgery for primary lesion 
  
 
      
Received 1.00 
 
 1.00 
 
 
   
Not received 3.63 (2.65, 4.97) <0.001 2.45 (1.69, 3.57) <0.001 
   
Number of acute comorbidities 
  
 
  
 
   
0 1.00 
 
 
  
 1.00 
 
 
1+ 1.59 (1.04, 2.42) 0.03 
  
 1.99 (1.24, 3.19) 0.004 
Number of acute comorbidities§ 
  
 
  
 
  
 
0 1.00 
 
 
  
 
  
 
1+ 1.34 (0.89, 2.01) 0.16 
  
 
  
 
Modified ADL 
  
 
  
 
  
 
Completely independent 1.00 
 
 
  
 1.00 
 
 
Need support 2.77 (1.75, 4.36) <0.001 
  
 2.59 (1.54, 4.33) <0.001 
Modified ADL§ 
  
 
  
 
  
 
Completely independent 1.00 
 
 1.00 
 
 
  
 
Need support 2.28 (1.36, 3.80) 0.002 2.47 (1.51, 4.02) <0.001 
  
 
Brinkman index 
  
 
  
 
  
 
0 1.00 
 
 
  
 
   
>0 1.07 (0.72, 1.61) 0.73 
  
 
   
Brinkman index§ 
  
 
  
 
   
0 1.00 
 
 
  
 
   
>0 0.98 (0.67, 1.44) 0.94 
      
Abbreviations: 95% CI, 95% confidence interval; ADL, activities of daily living; HR, hazard ratio; SES, socioeconomic status. * Adjusted for SES in all variables. **All variables are mutually adjusted. 
For SES only, adjusted HRs are shown without interaction between SES and stage. For other variables, interaction between SES and stage is adjusted. † P-value of Wald test. ‡ P-value of Wald test for 
trend. § Multiply imputed.
 
2
2
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Hazard ratios of death by SES 
Analyses of completed data demonstrated no clear socioeconomic gradient in the adjusted HRs 
(Table 5.8). A gradient towards increased HRs in the deprived groups was found only for non-
metastatic stages with imputed data but with a high p-value for trend. 
Bivariable analyses implied that ADL confounded the effect of SES on survival. The HR of the 
most deprived group was reduced by 15% when ADL was adjusted. Other factors influenced the 
socioeconomic inequalities in survival in a negligible magnitude in bivariable analyses. 
Table 5.8 Stage-specific hazard ratios using multivariable Cox regression with interaction 
between SES and stage for colorectal cancer, Osaka University Hospital, Japan 
 
Multiple imputationa Complete casesb 
 HR 95% CI p-value HR 95% CI p-value 
No metastasis 
      
SES 
      
1 (least deprived) 1.00 
 
0.24 
1.00 
 
0.77 
2 0.85 (0.40, 1.84) 0.78 (0.32, 1.88) 
3 1.14 (0.53, 2.45) 0.72 (0.29, 1.83) 
4 1.35 (0.65, 2.83) 1.03 (0.43, 2.49) 
5 (most deprived) 1.47 (0.67, 3.23) 0.82 (0.30, 2.24) 
Metastasis 
  
 
  
 
1 (least deprived) 1.00 
 
0.72 
1.00 
 
0.55 
2 0.72 (0.36, 1.43) 0.92 (0.32, 2.61) 
3 1.38 (0.77, 2.47) 1.87 (0.82, 4.26) 
4 1.18 (0.58, 2.37) 1.11 (0.35, 3.51) 
5 (most deprived) 0.54 (0.21, 1.36) 0.21 (0.03, 1.65) 
Abbreviations: HR, hazard ratio; SES, socioeconomic status. All p-values are of Wald test for trend. Model a: 
adjusted for sex, age, stage (imputed), major surgery, modified ADL (activities of daily living). Model b: adjusted for 
sex, age, stage, comorbidities, modified ADL.  
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Second analysis (Flexible parametric model for overall survival and hazard ratios by SES) 
The first analysis using multivariable Cox regression with completed data was next applied to 
an FPM in the second analysis to address variables violating the proportional hazard 
assumption. 
To identify TVCs, I checked the proportional hazard assumption in each variable of the 
multivariable Cox regression model derived in the first analysis. The proportional hazard 
assumption was violated only for SES. SES was treated as a TVE (time-varying ‘effect’ but not 
time-varying ‘covariate’ as SES is the main interest) in the FPM. Other variables, namely sex, 
age group, stage, comorbidities and ADL did not interact with time. 
Factors associated with survival 
As seen in the left column of Table 5.9, adjusted HRs of the non-TVCs in the FPM showed 
close agreement with the adjusted HRs in the Cox regression models (see also Table 5.7). There 
was no clear socioeconomic gradient, but patients who were male, in the older age groups, with 
metastatic stage, with comorbidities or with low ADL had a higher adjusted hazard of death 
compared with patients with the reference characteristics. 
Hazard ratios of death by SES 
The right columns of Table 5.9 show the point estimates of the adjusted HRs for SES at one 
year and 1.5 years since diagnosis when SES was treated as a TVE. In non-metastatic stages, 
when compared with the least deprived group, the hazard of death was smaller in the most 
deprived group at the 1-year point, but it increased at 1.5 years since diagnosis. In the metastatic 
stage, the most deprived group consistently had a lower hazard of death than the least deprived 
group. 
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Table 5.9 Hazard ratios of death and point estimates of stage-specific hazard ratios (overall survival) for time-varying effect at 1 year and 1.5 years since diagnosis 
using multivariable FPM with TVE and interaction between SES and stage for colorectal cancer, Osaka University Hospital, Japan 
Abbreviations: 95% CI, 95% confidence interval; ADL, activities of daily living; HR, hazard ratio; SES, socioeconomic status. * All variables are mutually adjusted. For SES only, adjusted HRs are 
shown without interactions between SES and time, SES and stage. For other variables, interactions between SES and time, SES and stage are adjusted. ** All variables are mutually adjusted with 
interactions between SES and time, SES and stage. HRs of SES are stage-specific.
Variable   Point estimate of time-varying effect 
   No metastasis Metastasis 
   1 year 1.5 years 1 year 1.5 years 
 HR* 95% CI HR** 95% CI HR** 95% CI HR** 95% CI HR** 95% CI 
SES           
1 (least deprived) 1.00  1.00  1.00  1.00  1.00  
2 0.83 (0.43, 1.64) 1.18 (0.41, 3.41) 0.64 (0.24, 1.71) 1.21 (0.37, 3.91) 0.66 (0.20, 2.11) 
3 1.21 (0.66, 2.21) 0.56 (0.20, 1.59) 0.66 (0.26, 1.69) 1.59 (0.65, 3.87) 1.87 (0.79, 4.43) 
4 1.10 (0.55, 2.19) 1.16 (0.42, 3.22) 0.65 (0.23, 1.83) 1.04 (0.29, 3.73) 0.58 (0.15, 2.21) 
5 (most deprived) 0.57 (0.24, 1.38) 0.90 (0.18, 4.63) 1.76 (0.55, 5.64) 0.22 (0.02, 2.33) 0.43 (0.05, 3.61) 
Sex   Proportional hazard assumption holds Proportional hazard assumption holds 
Male 1.00          
Female 0.54 (0.33, 0.89)         
Age   Proportional hazard assumption holds Proportional hazard assumption holds 
<60 1.00          
60–69 1.41 (0.69, 2.89)         
70–99 2.31 (1.16, 4.63)         
Stage   Proportional hazard assumption holds Proportional hazard assumption holds 
No metastasis 1.00          
Metastasis 7.01 (3.46, 14.23)         
Comorbidities   Proportional hazard assumption holds Proportional hazard assumption holds 
0 1.00          
1+ 1.92 (1.19, 3.07)         
Modified ADL   Proportional hazard assumption holds Proportional hazard assumption holds 
Completely independent 1.00          
Need support 2.66 (1.59, 4.47)         
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Third analysis (Graphical figures of measures of difference by SES) 
From the FPM fitted in the second analysis, I estimated three measures of difference in graphs: 
difference in mortality rate between the least and the most deprived groups, survival curves of 
the two groups and survival difference between the two groups (Figure 5.4 to Figure 5.6). For 
all figures, results were shown by each sex and stage. Age group was set at under 60 years old, 
with no acute comorbidities and with fit ADL. 
The hazard difference fluctuated around zero with wide 95% CIs in non-metastatic stages, 
whereas in metastatic stage, the difference was generally below zero throughout; the most 
deprived group had a lower mortality rate than the least deprived group for the metastatic stage 
only (Figure 5.4). As expected from the hazard difference, the survival curves of the least and 
the most deprived groups crossed at around the 1.5-year point, showing little difference between 
the two (Figure 5.5). The gap in overall survival between the two groups was estimated to be 
less than 1% for non-metastatic stages throughout. Overall survival was better in the most 
deprived group in the metastatic stage, with the difference reaching over 10% at the 3-year point 
since diagnosis; however, its lower 95% CI was on the boundary of 0% most of the time (Figure 
5.6). 
5.3.3 Summary of findings 
Male, older age, presence of comorbidities and low ADL were associated with worse survival. 
The socioeconomic gradient in the HRs of death was not clear; however, the FPM, which 
treated SES as a TVE, estimated a favourable survival in the most deprived group for the 
metastatic stage.
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Figure 5.4 Hazard difference between the least and most deprived groups for colorectal cancer, Osaka University Hospital, Japan 
(A) Non-metastatic stages, male (B) non-metastatic stages, female (C) metastatic stage, male (D) metastatic stage, female 
Abbreviations: 1000 PYs, 1000 person-years.  
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Figure 5.5 Overall survival of the least deprived group (SES 1, solid line) and the most deprived group (SES 5, dotted line) for colorectal cancer, Osaka, Japan 
(A) Non-metastatic stages, male (B) non-metastatic stages, female (C) metastatic stage, male (D) metastatic stage, female 
Abbreviations: SES, socioeconomic status.  
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Figure 5.6 Difference in overall survival between the least and the most deprived groups for colorectal cancer, Osaka, Japan 
(A) Non-metastatic stages, male (B) non-metastatic stages, female (C) metastatic stage, male (D) metastatic stage, female
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5.4 Discussion 
5.4.1 Socioeconomic inequalities in receipt of surgery 
Patients with CRC at OUH were generally less deprived and the characteristics of the patients, 
including stage, did not vary among SES groups. There was weak evidence that the deprived 
groups were more likely to receive major surgery in non-metastatic stages; however, an 
additional analysis confirmed that patients who did not receive surgery at OUH mostly had 
localised or metastatic stage. Among the patients who did not receive surgery at OUH, the 
affluent groups were more likely to have a localised stage. Records on treatment plan reinforced 
the evidence that patients, who did not receive surgery at OUH, were referred to other hospitals 
or received some treatment/follow-up at OUH. Patients with a potential for cure, who did not 
receive major surgery and were followed up at OUH, developed metastasis to other organs after 
diagnosis or had severe comorbidities. To conclude, it is likely that, except the patients who 
failed to attend, all patients with CRC at OUH, irrespective of their SES, received stage-
appropriate care. 
As seen in England, time to treatment did not vary by SES. In a particular setting like a teaching 
hospital in the present analysis, patients who were already followed up for other diseases before 
diagnosis of CRC, may be prioritised to continue CRC treatment at the same hospital. Further 
analysis showed that patients who were not referred from clinics had lower ADL (p<0.001, chi 
square test). 
The mean time from diagnosis to treatment at OUH was slightly longer than that observed in 
England. The finding is in line with a previous study, which showed a longer time to treatment 
in teaching hospital settings [153]. Patients with rectal cancer may have a longer time to 
treatment since the assessment of stage and resectability in rectal cancer requires additional 
diagnostic tests (e.g. MRI, ERUS). The present analysis also showed that some patients who 
received surgery more than 180 days after diagnosis mostly had neoadjuvant therapy. In 
England, the distribution of days in time to treatment for rectal cancer showed a truncated figure 
when surgery information was restricted to 180 days since diagnosis. When analysing time to 
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surgical treatment, especially for rectal cancer, information on surgical treatment may need to 
be captured for a longer period. 
In Chapter 2, I described the characteristics of the healthcare system in Japan is that specialists 
exist in the primary care level. As we can see, 70% of the patients were diagnosed as CRC in 
other clinics or hospitals before consultation at OUH. The fact reflects that diagnosis is mainly 
made in the primary care level. Referral to other hospitals also reflects the healthcare system in 
Japan, which offers free movement among institutions. To avoid possibly longer waiting times 
in teaching hospitals, patients that do not require complex treatment strategies or highly 
advanced surgical techniques, such as colon cancer cases, may be likely to be referred to non-
teaching hospitals. 
However, considering that large proportion of CRC patients in Osaka Prefecture are treated in 
non-teaching hospitals, patients coming to OUH (both referrals from other clinics/hospitals and 
self-referral) are likely to have caused selection bias in the study population. There are no 
referral criteria for PCPs of which patients to refer to OUH; thus, referral to OUH largely 
depends on a patient’s preference. In addition to the unique settings of teaching hospitals, when 
investigating socioeconomic inequalities in survival, data from a single hospital may not be 
suitable, as a selection bias occurs in that situation. 
5.4.2 Socioeconomic inequalities in survival 
The difference in overall survival for non-metastatic stages was almost null. Overall survival 
was estimated to be better in the most deprived group for the metastatic stage only but with very 
wide 95% CIs. 
The two findings for non-metastatic stages: no socioeconomic difference in receipt of care, and 
no difference in survival, suggest that no conclusion can be drawn from this analysis. Using the 
situation of a randomised controlled trial for example; in the OUH setting, the baseline 
characteristics being similar among SES groups means that the characteristics are matched 
among SES groups, but intervention has only one arm (i.e. equal treatment for all SES groups). 
If there is no other arm for comparison (e.g. unequal treatment for different SES groups), we 
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cannot conclude that the outcome, equal survival among SES groups, is due to the intervention 
(equal treatment). 
The potential reasons for not observing inequalities can be related to statistical problems. The 
number of patients was small, and the patients were heavily skewed to a higher SES in a single 
institution. The wide CIs in all analyses also imply that the statistical power for detecting the 
difference in important characteristics may be weak. The data in the present study were from a 
single institution, but a previous study that reported socioeconomic inequalities in survival used 
population-based data from multiple institutions [2]. 
Although patients at OUH might have selection bias, within the selected population, both care 
and survival were equally achieved by SES. Within-hospital variation of care is unlikely; 
however, inter-hospital variation may exist. Indubitably, stage may also be one of the potential 
contributors for observing the inequalities. 
5.4.3 Strengths and limitations 
The strength of the analysis at OUH is that important clinical information, such as stage, 
comorbidities, BMI, Brinkman index and ADL was available for more than 70% of the total 
cases. Information on surgery was recorded not only for CRC but also for other diseases. ADL 
and detailed information on surgery and comorbidities enabled identification of the clinical 
characteristics of the patients. 
This analysis, which includes the most recent years, also presented that most of the surgery was 
laparoscopic rather than open, and that ICU use was mostly limited to the patients with severe 
comorbidities, which required major surgeries. Neoadjuvant therapy use at OUH was low, being 
approximately 10% of all rectal cancer cases. 
One limitation is the size and specific characteristics of the study population. The data were 
from one university hospital in an affluent area. The results of the analysis on receipt of surgery 
showed the specific features of teaching hospitals, where patients with low ADL or who are 
being followed up for other diseases were more likely to receive surgery at the same hospital. 
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Since the population is not representative of the whole population in Osaka Prefecture, the 
patterns of receipt of cancer care and survival may be not applicable to the general population. 
Another limitation may be the use of DPC data. Unlike HES data in England, DPC is a costing 
data similar to diagnosis-related groups. Comorbidities might not be recorded in DPC if no costs 
for the comorbidities were incurred in the hospital episode. Thus, misclassification of the 
comorbidities may occur. 
Lastly, I could not analyse net survival because there are no lifetables based on SES. Future 
studies should include more patients from multiple institutions and investigate net survival.  
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Chapter 6: Discussion 
6.1 Main findings 
This study demonstrated socioeconomic gaps in survival graphically, over time by each stage, 
using multivariable FPM incorporating comorbidities. The results in Chapter 4 revealed that, 
among patients with stage II and III, who have a potential for cure, a survival gap existed for 
both cancers in England. 
Surgical treatment was relatively equally received in patients with colon cancer. However, 
higher postoperative mortality in the deprived groups suggests that the quality of care received 
may have varied by SES. 
To the best of our knowledge, this study employed mediation analysis for the first time to 
examine the magnitude of the effect of patient, tumour and treatment factors on survival 
inequalities in CRC. Although treatment was not received equally among different SES groups 
in rectal cancer, results of the mediation analyses imply that intervening on the inequalities in 
receipt of surgical treatment may not reduce the survival inequalities. Disparities in the 
distribution of stage, comorbidities and emergency presentation played an essential role in the 
survival inequalities. However, for both cancers, around 50% of the survival inequalities remain 
unexplained. 
For Japan, this study assessed the socioeconomic differences in receipt of care and survival at 
one of DCHs. Disease stage, comorbidities, surgical treatment and survival were equally 
distributed among SES groups within a single hospital, which provides an inconclusive answer 
for the inequalities in survival observed previously. 
6.2 Strengths and limitations 
All analyses were based on routinely collected data, such as cancer registry data, HES or DPC. 
The use of national cancer registry data linked with clinical information from HES provided an 
overall picture of how patient factors (age, sex and comorbidities), tumour factors (site, stage, 
histology and tumour grade) and healthcare system factors interact and affect survival at the 
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national level. For Japan, this study investigated the mechanism of socioeconomic inequalities 
in survival incorporating detailed clinical factors using DPC data. 
The analyses in England included important tumour factors, i.e. not only stage but also tumour 
grade and histology. One limitation is that the difference by SES, in terms of some histological 
types (mucinous, signet-cell carcinoma vs other adenocarcinomas), was not explored. This was 
because some CRC were recorded without detailed histological information (e.g. neoplasm, 
carcinoma) in both countries. These histological types (around 10% of total colon cancer and 
5% of total rectal cancer cases in England, and 5% of total cases in Japan) were grouped into 
adenocarcinoma; thus, misclassification may exist. 
The time to treatment did not vary among different SES groups for colon cancer in England. 
The truncated distribution in time to treatment for rectal cancer suggests that some patients may 
have received surgery after 180 days. The data in Japan supported the prolonged time to 
treatment in patients with rectal cancer who received neoadjuvant therapy. Because of the high 
use in neoadjuvant therapy, treatment options and timeline for rectal cancer may be complex 
and challenging to capture, particularly in the European countries. There is evidence that the 
delay in adjuvant therapy is related to poorer survival [229, 230]. However, there is mixed 
evidence on whether other delays affect survival [176]. As Walter et al. (2012) suggested, the 
definition of ‘delay’ is not clearly defined, and time to treatment should be measured in time 
intervals (e.g. days) to make studies comparable [177]. Further research is needed to explore 
which kind of intervals, and to what extent it matters to survival. 
Regarding the time from diagnosis to treatment, the advantage of using linear regression is that 
the actual figures of the days can be derived. Some studies obtained HRs using Cox regression 
for examining socioeconomic difference in time to treatment [133, 156, 157, 159]; however, the 
assumption in such a regression is that all patients will have the outcome (in time to treatment 
analysis, the outcome is receipt of surgery) if followed up long enough after the right-truncation 
in time. The assumption is, in reality, not correct; some patients will receive treatment, but some 
will not, or will die before receiving treatment. Cure models can be used [231], or death can be 
treated as a competing risk for treatment [232]; however, for the patients who died before 
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receiving treatment, it will never be known whether they had or had not been planning to 
receive treatment before their death. Therefore, I derived the outcome in days by linear 
regression rather than HRs by Cox regression. Hazard ratios are not easily clinically 
interpretable, and the results in the present study provide the average day to treatment, which is 
meaningful clinically and for public health. 
When analysing time to treatment, patients who received urgent operation were removed. I 
defined ‘urgent operation’ as the surgery performed within seven days of diagnosis. The cut-off 
days defined may be arbitrary; however, while the patients who received surgery within three 
days of diagnosis exceeded 25% of all patients who received surgery, the patients who received 
surgery four to seven days from the date of diagnosis included 2.1% for colon cancer patients in 
England. Therefore, the cut-off days for the definition of urgent operation are considered to 
make little change in the results. 
I extracted data on comorbidities based on Charlson comorbidity index but separated acute and 
chronic comorbidities. I assumed that the two variables (acute/chronic) on comorbidity reflect 
correctly the health status of the patients. Information on some key comorbidities may be 
missing differentially by deprivation because the index does not capture severity for some 
comorbidities. However, it would then reinforce the hypothesis of inequalities in care by SES in 
the healthcare system. One can notice that, after adjusting for individual factors, difference in 
probability of receiving surgery by SES weakened (but there is a strong gradient by 
comorbidity); these results by SES would be difficult to explain if the information on 
comorbidity was biased. The disadvantage of lack of information on severity of comorbidities 
might have been affected the results of analysis in this thesis though it is assumed that 
distinguishing acute and chronic comorbidities improved collection of information on 
performance status. How chronicity and severity of the comorbidities affect socioeconomic 
inequalities in cancer care and survival would be important to investigate in further studies. 
Comorbidities were categorised in four groups with counted numbers, and only the trend among 
the groups was explored with the Wald test. Th categorisation may lose power regarding dose-
response effect [233]; thus, splines or fractional polynomials could be further sought. The 
239 
 
benefit of fractional polynomials is that estimation of the dose-response effect, confounding the 
effect of SES on an outcome, can be estimated in a smoothed line. However, the number of 
comorbidities would never take a non-discrete number, and less than 1% of patients had three or 
more comorbidities. The present analyses aimed to identify the association between 
comorbidities and outcomes but not the prediction of the outcomes. For those reasons, there will 
be no benefit seeking splines or fractional polynomials in the dose-response effect of the 
comorbidities. For predicting outcomes, assessment of individual comorbidity and clinical data 
with more detailed information would be appropriate [234-237]. 
The difference in HRs and survivals between the least and the most deprived groups was 
estimated using FPM. Previous studies used Cox regressions to explore associated factors and 
derive HRs by SES. For clinical and public health perspective, measures of difference may be 
more useful to describe socioeconomic inequalities. The estimations derived by FPM may be 
biased since the estimations can be used only for completed data but not for imputed data (i.e. 
FPM currently does not support multiply imputed data). Regarding the data from England, 
55.4% of total patients with colon cancer and 59.1% of patients with rectal cancer were 
analysed using FPM. For data in Japan, 67.6% of total patients were analysed. However, 
sensitivity analysis enabled the estimation of bias; considering the results of sensitivity analyses 
using imputed data in Cox regression, particularly for England, the socioeconomic differences 
in mortality rate and survival may be underestimated. 
Lastly, ecological measures, i.e. IMD for England and ADI for Japan, were used to define SES. 
We are aware that the ecological measures may differ from the individual level of deprivation, 
and misclassification may exist. The misclassification may lead to either of underestimation 
(e.g. dilution effect [238]) or overestimation of the observed inequalities in treatment and 
survival, as seen in a previous study in Japan [239]. ADI was built using an approach similar to 
EDI (European Deprivation Index). ADI and IMD are not comparable. However, when 
measuring inequalities in cancer survival at the population level, it was demonstrated that the 
most important element was the size of the area how the indices are defined, rather than the type 
of measure [238]. 
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6.3 Future studies 
Multilevel analysis was not used for the data from England, which is one of the limitations of 
this study. Data of hospitals were not available at around 10%. Multilevel imputation could not 
be conducted since the hospital information is likely to be missing systematically. Considering 
both surgeons and hospital facilities may influence the postoperative outcomes, using hospital 
rather than Trust as the cluster level is likely to be more appropriate, particularly for surgical 
treatment; however, the multilevel imputation model may contain interactions and become 
complex, which leads to convergence problems [240]. The lack of considering the random 
effect is also problematic in mediation analysis. For instance, the effect of a mediator on an 
outcome (e.g. surgical treatment as a mediator and 90-day mortality as an outcome) is likely to 
differ by hospital. However, the consistency assumption underlying the mediation analysis does 
not allow such difference (random effect) among hospitals [241]. In that case, categorising 
hospitals by volume or specialisation [141, 242-244], and including the variable as a mediator-
outcome confounder affected by exposure may be applied in future research (Figure 6.1). 
Figure 6.1 DAG including important unmeasured factors 
Hospital type can be categorised by hospital volume or specialist type. 
As discussed in Chapter 4.6, the results for England implied several unmeasured confounders. 
Important factors related to both SES and receipt of treatment could be a patient’s preference or 
health-seeking behaviour. If preference is the reason for a patient not choosing care, no 
judgement can be made to deem it unfair. However, the clear socioeconomic gradient in 
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emergency presentation and survival suggests that the situation is caused systematically. 
Persistent inequalities are seen in those figures in England [245, 246], also suggesting that the 
situation may have some room for improvement. Health-seeking behaviour may influence time 
to diagnosis or mode of presentation [111, 220]. Some previous studies suggest that the distance 
or time to hospital, rather than SES, is associated with inequalities in receipt of cancer care 
[118, 149, 154]. In Japan, patients in the low SES group cited distance as one reason for the 
delay in seeking healthcare [92]. When it comes to the inequalities in receipt of cancer care, it is 
essential to distinguish between disparities in geographical access to treatment and disparities in 
quality of treatment [111]. Information on performance status or ASA grade was also missing in 
the data from England. As seen in the analyses in Japan, performance status (measured as ADL) 
may influence survival independently from comorbidities. Although ADL and comorbidities 
apparently represent similar meanings of the general condition of a patient, the collinearity of 
the two variables was only 13.8%. 
Other important unmeasured treatment factors are the use of neoadjuvant and adjuvant therapy. 
The patient pathway map and literature review in Chapter 2 demonstrated growing evidence of 
inequalities in every step of cancer care in CRC. In addition to the receipt of surgical treatment, 
investigating socioeconomic variations in the use of chemotherapy or radiotherapy, in relation 
to survival, would be of interest for CRC. For colon cancer in England, the survival gap was 
most significant in stage III (Chapter 4.4.2). On the contrary, for rectal cancer, the survival gap 
was smallest in stage III. These results indicate that the use of chemotherapy, for colon cancer, 
may also have influenced the survival inequalities, and the rectal cancer patients who underwent 
surgery might be the selected groups of patients, who have received neoadjuvant therapy. 
Lastly, in relation to the 30-day postoperative mortality, further details for the quality of 
postoperative care were not explored in this thesis because of large proportion of missingness in 
postoperative complications and stoma procedure.  
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6.4 Recommendations for England and Japan 
Findings of this thesis and supplemental information are summarised in Table 6.1. 
Table 6.1 Summary of findings and general statistics in England and Japan 
 
England Japan 
Localised (stage I)  Colon 8.6% 
Rectum 16.6% 
51.3% (OUH, colon and rectum) 
25.7% (DCHs, colon and rectum, 
UICC stage, 2008)* 
Distance metastasis (stage IV) Colon 22.5% 
Rectum 19.0% 
17.0% (OUH) 
20.1% (DCHs, colon and rectum, 
UICC stage, 2008)* 
Emergency presentation Colon 24.5% 
Rectum 11.1% 
3.6% (OUH) 
No data nationwide 
England: all figures are from analyses in this thesis. Japan: figures in upper lines are from analyses in this thesis. 
Figures in lower lines are from national statistics. * Source: Cancer Statistics in Japan ’16 [247]. Data provided from 
296 DCHs. 
In England, when compared with Japan, Table 6.1 demonstrates that, the percentage of the 
patients diagnosed with a localised stage is much smaller than in Japan, and a substantial 
percentage of the patients present emergently. The fact may suggest barriers in access to both 
diagnosis and treatment. 
For the patients with emergency presentations, firstly, triaging the vital emergency (e.g. 
obstruction and perforation) cases is necessary. Patients without vital emergency should then 
return to the normal patient pathway. In both vital and non-vital emergency cases, patients 
should have safe operations and managed by specialist surgeons. To improve the quality of care, 
two ways may be selected: centralisation of specialised-team hospitals: or to keep the 
distribution of hospitals and aim to improve the quality of care as a whole. The first choice may 
be easier and less costly. However, geographical access may be hampered; thus, socioeconomic 
inequalities may become worse. Considering that colon cancer is common and large number is 
expected nationwide, the latter choice may reduce socioeconomic inequalities in cancer care 
access, and then survival. Also, screening uptake may have effect on reducing emergency 
presentation [248]. In future studies, relationship among SES, screening uptake, emergency 
presentation and survival should be investigated.  
For Japan, information at the prefecture or national level was not able to obtain in this study. 
Therefore, existence of socioeconomic inequalities in both cancer care and survival was unclear 
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and yet to be studied. Not only from DCHs but also non-DCHs, data are needed to be examined 
for inequalities. Linkage of other databases, such as national clinical database, may be effective 
to capture the disparities in clinical management. National clinical database includes detailed 
information on comorbidities, surgery (procedure, operation time and amount of blood loss) and 
complications of each case. Further studies and recommendations may include topics as 
follows.  
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❖ Future studies and recommendations for England 
• Future studies 
• Triage of emergency presentations: identification of vital emergency cases and 
non-vital emergency cases. 
• Identification of reason for socioeconomic inequalities in postoperative mortality 
especially for colon cancer cases (e.g. operation by specialists or non-specialists). 
• Assessment of quality of postoperative care by SES: exploration of stoma rates, 
complication rates, failure to rescue rates by SES. 
• Further assessment of receipt of treatment: exploration of receipt of chemotherapy, 
radiotherapy by SES. 
• Collection of individual data on screening uptake and emergency presentation to 
examine the relationship between screening uptake and accessibility to diagnosis 
in different SES. 
• Recommendations 
• Reduction of emergency presentation 
• Promote safer surgery operated by specialist surgeons to reduce the survival gap 
between the least and the most deprived patients. 
❖ Future studies and recommendations for Japan 
• Future studies 
• Assessment of quality of postoperative care by SES: linkage of national cancer 
registry data, DPC data and nationwide clinical database. 
• Recommendations 
• Collection of data at the prefectural or national level not only from DCHs but also 
from non-DCHs to capture differential access to cancer care.  
245 
 
An important point in the healthcare system is that the funding and resources in healthcare are 
not public good (public good: a service or a good, which is non-excludable and non-rival in 
consumption). If we pursue the goal of ‘equity in a health outcome’, it may mean that someone 
improves but some others decrease their health. We are also aware that socioeconomic 
inequalities in a health outcome are often seen, but not all of them are ‘inequity’, which is 
considered unfair [249]. Priority should be set for solving the inequalities [249]. Needless to 
say, the mechanism of how the socioeconomic inequalities in health (in this thesis, cancer 
survival) occur, may involve multifactorial pathways, with complex interactions between the 
healthcare system and biological, behaviour, lifestyle and environmental factors of a patient, but 
not a single dominant pathway [250, 251]. Although the proportion of the patients diagnosed 
without symptoms is small, reports suggest that socioeconomic inequalities in screening 
participation exist in both countries [252-254]. The difference in up-stream factors (e.g. lifestyle 
and behavioural/environmental factors) is not easily modifiable. However, understanding the 
potential mechanisms and magnitude of the healthcare effect on survival inequalities would 
provide insight into which level of change can be made in the healthcare systems and into what 
aspects efforts should be expended. 
The WHO guideline on referral policy recommends that the potential for curative therapy 
should be assessed at the primary care level [255]. It also mentions the pointlessness of referring 
advanced-stage patients to major hospitals, since these patients may only be offered palliative 
care. Colorectal cancer has a good chance for cure if diagnosed, treated and followed up 
appropriately and in a timely manner; therefore, there is a good reason for prioritising reduction 
of the socioeconomic gap in CRC survival. This thesis aims to understand the role of the 
healthcare system and the potential for improving equity further by amending healthcare access. 
The access has already been greatly ensured by the UHC, and it is expected to be modifiable by 
minor changes in the present system. 
6.5 Conclusion 
In England, socioeconomic inequalities in survival existed for CRC patients with the stages of 
potential for cure. Reducing emergency presentation for both colon and rectal cancer and 
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improving postoperative care for colon cancer may reduce the survival inequalities. For rectal 
cancer, further study is needed to understand the mechanism of the survival inequalities. 
In Japan, further investigation with a larger population is needed to capture the survival 
inequalities and understand its mechanism.  
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Appendix 2 Histology grouping 
Modification from sources: WHO Classification of Tumours Pathology and Genetics of Tumours of the Digestive 
System 4th edition (2010) and Japanese Classification of Colorectal Carcinoma 8th edition (2013). 
* Goblet cell carcinoid of appendix was categorised as a sub-type of adenocarcinoma (epithelial tumour) in Japanese 
Classification of Colorectal Carcinoma 8th edition. 
** Endocrine cell tumours (carcinoid tumour and endocrine cell carcinoma) in Japanese Classification of Colorectal 
Carcinoma 8th edition were classified as one of the NET in WHO Classification of tumours of the colon and rectum 
4th edition.  
Histological group 
 
Adenocarcinoma papillary adenocarcinoma (pap) 
tubular adenocarcinoma (tub) 
medullary carcinoma (med) 
poorly differentiated adenocarcinoma (por) 
mucinous adenocarcinoma (muc) 
signet-ring cell carcinoma (sig) 
undifferentiated carcinoma 
villous adenocarcinoma 
tubulovillous adenocarcinoma 
neoplasm 
carcinoma 
Adenosquamous and squamous 
cell carcinoma 
adenosquamous carcinoma (asc) 
squamous cell carcinoma (scc) 
mixed types of epithelial tumours 
goblet cell carcinoid of appendix* 
Non-epithelial tumour and others adenocarcinoid tumour 
carcinoid tumour** 
endocrine cell carcinoma** 
neuroendocrine tumour (NET: WHO) 
carcinoid tumour of appendix 
non-epithelial tumour (mesenchymal tumour) 
lymphoma 
malignant melanoma 
others 
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Appendix 3 Operation code and name for colon cancer, England 
OPCS code 
H04.1 Proctocolectomy NEC, Panproctocolectomy and Ileostomy 
H04.2 Panproctocolectomy and anastomosis of ileum to anus and creation of pouch HFQ 
H04.3 Panproctocolectomy and anastomosis of ileum to anus NEC 
H04.8 Other specified total excision of colon and rectum 
H04.9 Panproctocolectomy NEC, Total excision of colon and rectum, unspecified-  
H05.1 Total colectomy and anastomosis of ileum to rectum 
H05.2 Total colectomy and ileostomy and creation of rectal fistula HFQ 
H05.3 Total colectomy and ileostomy NEC 
H05.8 Total excision of colon, other specified 
H05.9 Total excision of colon, Unspecified 
H06.1 Extended right hemicolectomy and end to end anastomosis 
H06.2 Extended right hemicolectomy and anastomosis of ileum to colon 
H06.3 Extended right hemicolectomy and anastomosis NEC 
H06.4 Extended right hemicolectomy and ileostomy HFQ 
H06.8 Other specified extended excision of right hemicolon 
H06.9 Extended excision of Right hemicolon, unspecified, excision of Right colon and surrounding tissue 
H07.1 Right hemicolectomy and end to end anastomosis of ileum to colon, Ileocaecal resection 
H07.2 Right hemicolectomy and side to side anastomosis of ileum to transverse colon,  
H07.3 Right hemicolectomy and anastomosis NEC  
H07.4 Right hemicolectomy and ileostomy HFQ 
H07.8 Other specified other excision of right hemicolon 
H07.9 Other excision of right hemicolon, unspecified; Right hemicolectomy NEC 
H08.1 Transverse colectomy and end to end anastomosis 
H08.2 Transverse colectomy and anastomosis of ileum to colon 
H08.3 Transverse colectomy and anastomosis NEC 
H08.4 Transverse colectomy and ileostomy HFQ 
H08.5 Transverse colectomy and exteriorisation of bowel NEC (CODE COLOSTOMY SPERATELY) 
H08.8 Other specified excision of transverse colon 
H08.9 Excision of transverse colon, unspecified 
H09.1 Left hemicolectomy and end to end anastomosis of colon to rectum 
H09.2 Left hemicolectomy and end to end anastomosis of colon to colon 
H09.3 Left hemicolectomy and anastomosis NEC 
H09.4 Left hemicolectomy and ileostomy HFQ 
H09.5 Left hemicolectomy and exteriorisation of bowel NEC (CODE COLOSTOMY SEPERATELY) 
H09.8 Excision of left hemicolon, Other specified 
H09.9 Left hemicolectomy NEC, Excision of left hemicolon, Unspecified 
H10.1 Sigmoid colectomy and end to end anastomosis of ileum to rectum 
H10.2 Sigmoid colectomy and anastomosis of colon to rectum 
H10.3 Sigmoid colectomy and anastomosis NEC 
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Appendix 3 continued (Operation code and name for colon cancer, England) 
H10.4 Sigmoid colectomy and ileostomy HFQ 
H10.5 Sigmoid colectomy and exteriorisation of bowel NEC 
H10.8 Other specified excision of sigmoid colon 
H10.9 Unspecified excision of sigmoid colon 
H11.1 Colectomy and end to end anastomosis of colon to colon NEC 
H11.2 Colectomy and side to side anastomosis of ileum to colon NEC 
H11.3 Colectomy and anastomosis NEC 
H11.4 Colectomy and ileostomy NEC 
H11.5 Colectomy and exteriorisation of bowel (CODE COLOSTOMY SEPERATELY) 
H11.8 Other excision of colon, other specified 
H11.9 Hemicolectomy NEC; Colectomy NEC, Other excision of colon, unspecified;  
H29.1 Subtotal excision of colon and rectum and creation of colonic pouch and anastomosis of colon to anus 
H29.2 Subtotal excision of colon and rectum and creation of colonic pouch NEC 
H29.3 Subtotal excision of colon and creation of colonic pouch and anastomosis of colon to rectum 
H29.4 Subtotal excision of colon and creation of colonic pouch NEC 
H29.8 Subtotal excision of colon, Other specified  
H29.9 Subtotal excision of colon, Unspecified  
H33.1 Abdominoperineal excision of rectum and end colostomy; APR; SCAPER 
H33.2 Proctectomy and anastomosis of colon to anus 
H33.3 Anterior resection of rectum and anastomosis of colon to rectum using staples 
H33.4 Anterior resection of rectum and anastomosis NEC 
H33.5 Hartmann procedure, Rectosigmoidectomy and closure of rectal stump and exteriorisation of bowel 
(CODE COLOSTOMY SEPERATELY) 
H33.6 Anterior resection of rectum and exteriorisation, (CODE COLOSTOMY SEPARATELY) 
H33.7 Perineal resection of rectum HFQ 
H33.8 Anterior Resection of Rectum NEC, Rectosigmoidectomy and anastomosis of colon to rectum Excision of 
rectum, other specified 
H33.9 Rectosigmoidectomy NEC, Excision of rectum, unspecified;  
H34.1 Open excision of lesion of rectum: Open removal of polyp; Yorke Mason 
H40.1 Trans-sphincteric excision of mucosa of rectum 
H40.2 Trans-sphincteric excision of lesion of rectum 
H40.8 Other specified operations on rectum through anal sphincter 
H40.9 Unspecified operations on rectum through anal sphincter 
X14.1 Total exenteration of pelvis 
X14.3 Posterior exenteration of pelvis 
X14.8 Other specified clearance of pelvis 
  
269 
 
Appendix 4 Operation code and name for rectal cancer, England 
OPCS code 
H04.1 Proctocolectomy NEC, Panproctocolectomy and Ileostomy 
H04.2 Panproctocolectomy and anastomosis of ileum to anus and creation of pouch HFQ 
H04.3 Panproctocolectomy and anastomosis of ileum to anus NEC 
H04.8 Other specified total excision of colon and rectum 
H04.9 Panproctocolectomy NEC, Total excision of colon and rectum, unspecified-  
H05.1 Total colectomy and anastomosis of ileum to rectum 
H05.2 Total colectomy and ileostomy and creation of rectal fistula HFQ 
H05.3 Total colectomy and ileostomy NEC 
H05.8 Total excision of colon, other specified 
H05.9 Total excision of colon, Unspecified 
H06.1 Extended right hemicolectomy and end to end anastomosis 
H06.2 Extended right hemicolectomy and anastomosis of ileum to colon 
H06.3 Extended right hemicolectomy and anastomosis NEC 
H06.4 Extended right hemicolectomy and ileostomy HFQ 
H06.9 Extended excision of Right hemicolon, unspecified, excision of Right colon and surrounding tissue 
H07.1 Right hemicolectomy and end to end anastomosis of ileum to colon, Ileocaecal resection 
H07.2 Right hemicolectomy and side to side anastomosis of ileum to transverse colon,  
H07.3 Right hemicolectomy and anastomosis NEC  
H07.4 Right hemicolectomy and ileostomy HFQ 
H07.8 Other specified other excision of right hemicolon 
H07.9 Other excision of right hemicolon, unspecified; Right hemicolectomy NEC 
H08.1 Transverse colectomy and end to end anastomosis 
H08.3 Transverse colectomy and anastomosis NEC 
H08.4 Transverse colectomy and ileostomy HFQ 
H08.5 Transverse colectomy and exteriorisation of bowel NEC (CODE COLOSTOMY SPERATELY) 
H08.8 Other specified excision of transverse colon 
H09.1 Left hemicolectomy and end to end anastomosis of colon to rectum 
H09.2 Left hemicolectomy and end to end anastomosis of colon to colon 
H09.3 Left hemicolectomy and anastomosis NEC 
H09.4 Left hemicolectomy and ileostomy HFQ 
H09.5 Left hemicolectomy and exteriorisation of bowel NEC (CODE COLOSTOMY SEPERATELY) 
H09.8 Excision of left hemicolon, Other specified 
H09.9 Left hemicolectomy NEC, Excision of left hemicolon, Unspecified 
H10.1 Sigmoid colectomy and end to end anastomosis of ileum to rectum 
H10.2 Sigmoid colectomy and anastomosis of colon to rectum 
H10.3 Sigmoid colectomy and anastomosis NEC 
H10.4 Sigmoid colectomy and ileostomy HFQ 
H10.5 Sigmoid colectomy and exteriorisation of bowel NEC 
H10.8 Other specified excision of sigmoid colon 
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Appendix 4 continued (Operation code and name for rectal cancer, England) 
H10.9 Unspecified excision of sigmoid colon 
H11.1 Colectomy and end to end anastomosis of colon to colon NEC 
H11.2 Colectomy and side to side anastomosis of ileum to colon NEC 
H11.3 Colectomy and anastomosis NEC 
H11.4 Colectomy and ileostomy NEC 
H11.5 Colectomy and exteriorisation of bowel (CODE COLOSTOMY SEPERATELY) 
H11.8 Other excision of colon, other specified 
H11.9 Hemicolectomy NEC; Colectomy NEC, Other excision of colon, unspecified;  
H29.1 Subtotal excision of colon and rectum and creation of colonic pouch and anastomosis of colon to anus 
H29.2 Subtotal excision of colon and rectum and creation of colonic pouch NEC 
H29.3 Subtotal excision of colon and creation of colonic pouch and anastomosis of colon to rectum 
H29.4 Subtotal excision of colon and creation of colonic pouch NEC 
H29.8 Subtotal excision of colon, Other specified  
H29.9 Subtotal excision of colon, Unspecified  
H33.1 Abdominoperineal excision of rectum and end colostomy; APR; SCAPER 
H33.2 Proctectomy and anastomosis of colon to anus 
H33.3 Anterior resection of rectum and anastomosis of colon to rectum using staples 
H33.4 Anterior resection of rectum and anastomosis NEC 
H33.5 Hartmann procedure, Rectosigmoidectomy and closure of rectal stump and exteriorisation of bowel 
(CODE COLOSTOMY SEPERATELY) 
H33.6 Anterior resection of rectum and exteriorisation, (CODE COLOSTOMY SEPARATELY) 
H33.7 Perineal resection of rectum HFQ 
H33.8 Anterior Resection of Rectum NEC, Rectosigmoidectomy and anastomosis of colon to rectum Excision of 
rectum, other specified 
H33.9 Rectosigmoidectomy NEC, Excision of rectum, unspecified;  
H34.1 Open excision of lesion of rectum: Open removal of polyp; Yorke Mason 
H34.2 Open cauterisation of lesion of rectum, Diathermy 
H34.5 Open destruction of lesion of rectum NEC 
H34.8 Open removal of lesion of rectum, other specified 
H40.1 Trans-sphincteric excision of mucosa of rectum 
H40.2 Trans-sphincteric excision of lesion of rectum 
H40.3 Trans-sphincteric destruction of lesion of rectum 
H40.8 Other specified operations on rectum through anal sphincter 
H40.9 Unspecified operations on rectum through anal sphincter 
X14.1 Total exenteration of pelvis 
X14.2 Anterior exenteration of pelvis 
X14.3 Posterior exenteration of pelvis 
X14.8 Other specified clearance of pelvis 
X14.9 Clearance of pelvis, unspecified 
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Appendix 5 List of chronic and acute comorbidities 
Chronic comorbidities Count Acute comorbidities Count 
Chronic heart failure 1 Chronic heart failure 1 
Dementia 1 Dementia 1 
Chronic pulmonary disease 1 Chronic pulmonary disease 1 
Connective tissue disease 1 Connective tissue disease 1 
Diabetes mellitus with end organ 
complication 
1 
Diabetes mellitus with end organ 
complication 
1 
Hemiplegia 1 Hemiplegia 1 
Chronic renal disease, moderate to 
severe  
1 
Chronic renal disease, moderate to 
severe  
1 
Liver disease, moderate to severe  1 Liver disease, moderate to severe  1 
HIV (Human Immunodeficiency Virus) 
infection 
1 
HIV (Human Immunodeficiency Virus) 
infection 
1 
Malignancy (not colorectal cancer) 1 Myocardial infarction 1  
 Peripheral vascular disease 1  
 Cerebrovascular disease 1  
 Peptic ulcer disease 1  
 Malignancy (not colorectal cancer) 1 
Chronic comorbidities were defined as the medical conditions that were recorded 0.5–5 years before diagnosis of 
colorectal cancer. 
Acute comorbidities were defined as the medical conditions that were recorded for the first time 0–0.5 years before 
diagnosis of colorectal cancer. 
In England, both chronic and acute comorbidities were used. In Japan, only acute comorbidities were used.  
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Appendix 6 Operation code and name for colorectal cancer, Japan 
K7191 Colectomy (partial) 
K7192 Colectomy (hemicolectomy) 
K719-21 Laparoscopic colectomy (partial or hemicolectomy) 
K719-22 Laparoscopic colectomy (total or subtotal) 
K7193 Colectomy (total, subtotal resection or operation for malignancy) 
K719-3 Laparoscopic colectomy for malignancy 
K719-5 Total colectomy and proctectomy with anastomosis of pouch and anal canal 
K720 Resection of colon tumour by laparotomy (including cecum tumour 
resection) 
K7391 Transanal resection of rectal tumour (including polyp resection) 
K7393 Resection of rectal tumour (laparotomy or transanal) 
K7401 Proctectomy 
K7402 Low anterior resection 
K7403 Proctectomy, resection of rectum (super low anterior resection) (transanal 
anastomosis of colonic pouch and anal canal) 
K7404 Proctectomy, resection of rectum 
K740-21 Laparoscopic proctectomy 
K740-22 Laparoscopic low anterior resection 
K740-23 Laparoscopic resection of rectum 
K645 Total exenteration of pelvis 
  
273 
 
Appendix 7 Distribution of imputed variables, England 
Colon cancer SES  
1 (affluent) 2 3 4 5 (deprived) 
Stage (%) 
     
I 13.7 12.7 13.0 12.2 12.2 
II 27.1 27.6 26.6 25.9 26.4 
III 25.4 25.5 24.8 24.8 25.0 
IV 33.8 34.2 35.6 37.0 36.4 
Histology (%) 
     
Adenocarcinoma 97.9 97.9 97.9 97.8 97.5 
asc, scc 0.3 0.4 0.4 0.4 0.4 
Non-epithelial tumours 1.7 1.7 1.7 1.8 2.1 
Tumour grade (%) 
     
Well/moderately differentiated 79.4 79.6 78.9 79.8 79.7 
Poorly/undifferentiated 20.6 20.4 21.1 20.2 20.3 
Emergency presentation (%) 
     
No 75.3 73.5 72.6 70.2 66.6 
Yes 24.7 26.5 27.4 29.8 33.4 
 
Rectal cancer SES  
1 (affluent) 2 3 4 5 (deprived) 
Stage (%) 
    
  
I 23.9 22.3 22.7 21.0 20.1 
II 20.7 20.6 20.3 21.1 19.8 
III 29.4 29.9 29.7 29.1 29.6 
IV 26.0 27.1 27.3 28.8 30.5 
Histology (%) 
    
  
Adenocarcinoma 97.5 97.8 97.2 97.1 96.4 
asc, scc 1.1 1.2 1.4 1.5 1.5 
Non-epithelial tumours 1.4 1.1 1.3 1.5 2.1 
Tumour grade (%) 
    
  
Well/moderately differentiated 86.6 87.0 85.7 85.9 86.1 
Poorly/undifferentiated 13.4 13.0 14.3 14.1 13.9 
Emergency presentation (%) 
    
  
No 90.1 89.0 87.8 86.3 82.9 
Yes 9.9 11.0 12.2 13.7 17.1 
Abbreviations: asc, adenosquamous cell carcinoma; scc, squamous cell carcinoma; SES, socioeconomic status.  
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Appendix 8 Distribution of time to treatment (days from diagnosis to major surgery) in rectal 
cancer patients, England 
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Appendix 9 Distribution of imputed variables, Japan 
 
SES  
1 (affluent) 2 3 4 5 (deprived) 
Stage (%) 
     
No metastasis 76.9 77.7 68.6 79.4 79.1 
Metastasis 23.1 22.3 31.4 20.6 21.0 
Number of comorbidities (%) 
     
0 80.7 77.0 69.5 73.7 69.1 
1+ 19.3 23.0 30.5 26.3 30.9 
Brinkman index (%) 
     
0 64.6 61.5 58.6 67.9 64.8 
>0 35.4 38.5 41.4 32.1 35.3 
Modified ADL (%) 
     
Completely independent 54.3 59.6 40.8 46.5 51.7 
Need support 45.7 40.4 59.2 53.5 48.3 
Abbreviations: ADL, activities of daily living; SES, socioeconomic status. 
